Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 1A PHASE 2 ,RANDOMIZED , DOUBLE -BLIND, PLACEBO- CONTROLLED STUDY 
TO INVESTI GATE THE EFFICACY, S AFETY AND TOLERABILITY OF 
PONSEGROMAB IN PATIENTS WITH CANCER ,CACHEXIA, AND ELEVATED 
CONCENTRATIONS OF GD F-15, FOLLOWED BY AN OPTIONAL OPEN- LABEL 
TREATMENT PERIOD (PROACC -1)
Study Intervention Number : PF-06946860
Study Intervention Name: ponsegromab
USIND Number: 139674
EudraCT /CTIS Number: 2022- 003016- 87
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number: NA
Protocol Number: C3651003
Phase: 2
Sponsor Legal Address: Pfizer I nc.
66 Hudson Boulevard East
New York, NY 10001
Brief Title: A Phase 2 Study  of the Efficacy  and Safet y of Ponsegromab in Patients with 
Cancer, Cachexia and Elevated GDF -15. (PROACC - 1)
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or reviewing these document s, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by applicable law ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 2Document History
Document Version Date
Amendment 2 24May 2023
Amendment 1 27October 2022
Original protocol 17 June 2022
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and IRBs/ECs and any  protocol administrative change 
letter(s). 
Protocol Amendment Summary of Changes Table
Amendment 2 ( 24May 2023)
Overall Rationale for the Amendment: The overall rationale for this amendment is to 
incorporate PK substudy, changes to eligibility criteria, and other clarifications. 
Description of Change Brief Rationale Section # and Name
Substantial Modification(s)
Incorporated PK substudy 
designAdditional PK/PD 
samples included for a 
subset of participants 
in response to 
regulatory  request.1.1. Sy nopsis, 1.2 Schema, 1.3 
Schedule of Activities, 3. 
Objectives, Endpoints and 
Estimands, 4.1 Overall Design, 
4.2 Scientific Rationale for 
Study  Design, 8.1 
Administrative Procedures , 
8.1.3 Additional Visits for PK 
substudy , 8.1.4 Home Health 
Visits, 9.5 Sample Size 
Determination
Removed eGFR requirement Ponsegromab is not 
excreted b y the 
kidney . Insufficient 
rationale to support 
eGFR requirement.1.1. Sy nopsis; 5.2. Exclusion 
Criteria (# 11)
Added exclusionary  
medications used for increasing To minimize potential 
for confounding of 
primary  endpoint.6.9.1 Prohibited During the 
Study
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 3Description of Change Brief Rationale Section # and Name
appetit e/body  weight and 
weight loss.
Clarified permitted medications Clarification 6.9.2 Permitted During the 
Study
Removed A ppendix 9 detailing 
France requirementsDecision made to not 
proceed with France Appendix 9. Country  Specifi c
Requirements, 10.9.1 France
Added Appendix 12: list of 
platinum -based chemotherap yAdditional guidance 
since stratification at 
randomization is based 
upon participant being 
on platinum -based 
chemotherap y or not.Appendix 12
: List of Platinum -
based Chemotherap y
Non-substantial Modification(s)
Added Clinical Trials.gov ID 
numberInformation available Title page and Section 1.1 
synopsis
Separated SoA for Part A and 
Part B; removed visit numbersClarification 1.3. Schedule of Activities  
Clarified text regarding SOC 
therap y timing Clarification 1.1. Sy nopsis; 5.1. I nclusion 
Criteria (#2)
Clarified expectations of 
evaluation and timing of 
participation.Clarification 1.1. Sy nopsis; 5.1 I nclusion 
Criteria (#5)
Clarified that participants 
previously  dosed with I P are 
excludedClarification 1.1. Sy nopsis; 5.2. Exclusion 
Criteria (# 9)
Consolidated exclusion criteria 
related to prior concomitant 
medications since information
is covered in section 6.9 prior 
and concomitant therap yClarification 1.1. Sy nopsis; 5.2. Exclusion 
Criteria (# 7) 
Updated to include “result may  
be confirmed b y a single repeat 
test, if necessary ” and “if there 
is liver involvement by  the 
tumor”Clarif ication 1.1. Sy nopsis; 5.2. Exclusion 
Criteria (#1 0)
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 4Description of Change Brief Rationale Section # and Name
Added exclusion criteria #12 to 
clarify  participants cannot 
adhere to a calorie -restricted 
diet with the intention weight 
lossClarification 1.1. Sy nopsis; 5.2. Exclusion 
Criteria (#12)
Added examples for injection 
site combinationsClarification 6.1.1 Administration
Editorial clarifications To provide 
clarification , correct 
typos, and improve 
readabilit y1.1. Sy nopsis; 5.2. Exclusion 
Criteria (#s 1 &4), 2.3.1 Risk 
Assessment, 2.3.3 Overall 
Benefit/Risk Conclusion, 4.1 
Overall Design, 4.2 Scientific 
Rationale ,4.3 Justification for 
Dose, 4.4 End of stud y 
definition, 5.4 Screen Failures, 
6.1.1 Administration, 6.5 Study  
Intervention Compliance, 6.9 
Prior and Concomitant 
Therap y, 7.1 Discontinuation 
of Study  Intervention, 7.3 Lost 
to Follow-up, 8.1.1 Screening 
Visit, 8.1.2 Week 5 Visit, 8.1.4
Home Health Visits, 8.2.2 
Patient Reported Outcomes, 
8.3.3.1 Blood Pressure and 
Pulse Rate, 8.3.4 
Electrocardiograms, 8.3.7 .1
Imaging Safet y Assessment, 
8.4.5.1 Exposure During 
Pregnancy , 8.5 
Pharmacokinetics, 8.7.1 GDF -
15, 9.3.2 Primary  Endpoint 
analysis, 9.3.5 Other Analy ses, 
9.4.1 PK/PD Unblinding Plan
, 
10.4.2 Female Participant 
Reproductive Inclusion Criteria
Updated visit windows for 
PartA and for Part B added 
contraception checks for 
follow up Part A and follow Protocol 
Administrative 
Change Letter dated 
13 Feb 20231.3 Schedule of Activities, 
8.1.5 Transportation, 3. 
Objectives, Endpoints and 
Estimands, 8.4.1. Time Period 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 5Description of Change Brief Rationale Section # and Name
up Part B; added 
transportation allowance to 
footnote ‘a’.
Added section for
transportation.
Updated evaluation of safety  
and tolerability  in Part B to 
also include vital signs and 
ECG abnormalities
Updated the time period for 
activel y eliciting and 
collecting AEs and SAEs.
Updated the serum cy statin 
C (SCy s) test to be 
performed at Screening to 
capture the baseline valueand Frequency  for Collecting 
AE and SAE Information, 10.2 
Appendix 2 Clinical 
Laboratory
Added updated clinical 
informationTo include 
information f rom the 
latest IB update2.2.1 Clinical Overview, 
2.2.1.1 Phase 1b Bod y Weight 
Data, 2.2.1.3 Summary  of 
Pharmacokinetics, 2.2.1.4 
Summary  of GDF -15 response, 
2.2.1.5 I mmunogenicit y,2.3.2 
Benefit Assessment
Protocol t emplate updates P rotocol template 
version 14 April 2023Title page and Appendices
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 6TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ................... 12
1. PROTOCOL  SUMMARY ................................ ................................ ................................ ...13
1.1. Sy nopsis ..................................................................................................................13
1.2. Schema ....................................................................................................................23
1.3. Schedule of Activities .............................................................................................24
2. INTRODUCTION ...............................................................................................................30
2.1. Study  Rationale .......................................................................................................30
2.2. Bac kground .............................................................................................................30
2.2.1. Clinical Overview .......................................................................................31
2.2.1.1. Phase 1b Bod y Weight Data Summary .....................................32
2.2.1.2. Summary  of Safety  Data ...........................................................32
2.2.1.3. Summary  of Pharmacokinetics ..................................................33
2.2.1.4. Summary  of GDF -
15 Response ................................................34
2.2.1.5. I mmunogenicit
y ........................................................................34
2.3. Benefit/Risk Assessment
.........................................................................................34
2.3.1. Risk Assessment
.........................................................................................35
2.3.2. Benefit Assessment .....................................................................................37
2.3.3. Overall Benefit/Risk Conclusion ................................................................37
3. OBJECTI VES, ENDPO INTS, AND ESTIMANDS ...........................................................37
4. STUDY DESIGN .................................................................................................................42
4.1. Overall Design .........................................................................................................42
4.2. Scientific Rationale for Study  Design .....................................................................44
4.2.1. Patient I nput Into Design ................................ ................................ ............ 45
4.2.2. Diversity  of Study  Population ................................ ................................ ....46
4.2.3. Choice of Contraception/Barrier Requirements .........................................47
4.2.4. Collection of Retained Research Samples ................................ .................. 47
4.3. Justification for Dose ..............................................................................................47
4.4. End of Study  Definition ..........................................................................................48
5. STUDY POPUL ATION
................................ ................................ ................................ ......49
5.1. I nclusion Criteria .....................................................................................................49
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 75.2. Exclusion Criteria ....................................................................................................50
5.3. L ifesty le Considerations ..........................................................................................52
5.3.1. Contraception ..............................................................................................52
5.4. Screen Failures ........................................................................................................52
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY .................................53
6.1. Study  Intervention(s) Administered ........................................................................53
6.1.1. Administration ............................................................................................53
6.2. Preparation, Handling, Storage, and Accountability ...............................................54
6.2.1. Preparation and Dispensing ........................................................................55
6.3. Assignment to Study I ntervention ...........................................................................55
6.4. Blinding
...................................................................................................................56
6.4.1. Blinding of Participants ..............................................................................56
6.4.2. Blinding of Site Personnel ..........................................................................56
6.4.3. Blinding of the Sponsor
..............................................................................56
6.4.4. Breaking the Blind ......................................................................................56
6.5. Study  Intervention Compliance ...............................................................................57
6.6. Dose Modification ...................................................................................................57
6.7. Continued Access to Study  Intervention After the End of the Study ......................57
6.8. Treatment of Overdose
............................................................................................57
6.9. Prior and Concomitant Therap y
..............................................................................58
6.9.1. Prohibited During the Study .......................................................................58
6.9.2. Permitted During the Study ........................................................................59
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................59
7.1. Discontinuation of Study  Intervention ....................................................................59
7.1.1. COVID -
19 ..................................................................................................60
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......61
7.2.1. Withdrawal of Consent ................................ ................................ ............... 61
7.3. L ost to Follow -Up...................................................................................................62
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................62
8.1. Administrative Procedures ......................................................................................62
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 88.1.1. Screening Visit ............................................................................................63
8.1.2. Week 5 Visit
...............................................................................................63
8.1.3. Additional Visits for PK Substudy .............................................................64
8.1.4. Home Health Visits .....................................................................................64
8.1.5. Transportation .............................................................................................64
8.2. Efficacy  Assessments ..............................................................................................64
8.2.1. Bod y Weight ...............................................................................................64
8.2.2. Patient Reported Outcomes
........................................................................65
8.2.2.1. Functional Assessment of Anorexia
-Cachexia Therap y 
(FAACT) ...........................................................................................66
8.2.2.2. Patient’s Global Impression of Severit
y (PGI -S) of 
Appetite, Fatigue, and Physical Function ..........................................66
8.2.2.3. Patient’s Global Impression of Change (PGI -C) of 
Appetite, Fatigue, and Physical Function ..........................................66
8.2.2.4. PROMI S –
Fatigue (version 7a)................................................67
8.2.2.5. PROMI S –Physical Function (version 8c)...............................67
8.2.2.6. Cancer -Related Cachexia Sy mptom Diary  2.0.........................67
8.2.2.7. Qualitative Exit Interviews ........................................................67
8.2.2.8. Patient’s Global Impression of Severit
y (PGI -S) of 
Physical Activity  and Walking ..........................................................68
8.2.2.9. Patient’s Global Im pression of Change (PGI -C) of 
Physical Activity  and Walking ..........................................................68
8.2.3. Phy
sical Activity .........................................................................................68
8.2.3.1. Comfort and Wearability  Questionnaire for Digital 
Measures ............................................................................................68
8.3. Safet y Assessments .................................................................................................69
8.3.1. Phy sical Examinations ................................................................................69
8.3.2. Eastern Cooperative Oncology  Group (ECOG) Performance Status
......... 70
8.3.3. Vital Signs ..................................................................................................70
8.3.3.1. Blood Pressure and Pulse Rate ..................................................70
8.3.4. Electrocardiograms
.....................................................................................70
8.3.5. Clinical Safety  Laboratory  Assessments ....................................................70
8.3.6. Pregnancy  Testing ......................................................................................71
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 98.3.7. I maging Assessment -CT Scan ....................................................................71
8.3.7.1. I maging Safet y Assessment ......................................................71
8.3.7.2. I maging Efficacy Assessment ...................................................72
8.4. Adverse Events, Serious Adver se Events, and Other Safet y Reporting .................72
8.4.1. Time Period and Frequency  for Collecting AE and SAE Information .......73
8.4.1.1. Reporting SAEs to Pfizer Safety ...............................................73
8.4.1.2. Recording Nonserious AEs and SAEs on the CRF
...................74
8.4.2. Method of Detecting AEs and SAEs ..........................................................74
8.4.3. Follow -Up of AEs and SAEs ......................................................................74
8.4.4. Regulatory
 Reporting Requirements for SAEs ...........................................74
8.4.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure .....................................................75
8.4.5.1. Exposure During Pregnancy ......................................................75
8.4.5.2. Exposure During Breastfeeding ................................................77
8.4.5.3. Occupational Exposure .............................................................77
8.4.6. Cardiovascular and Death Events ...............................................................77
8.4.7. Disease -Related Events and/or Disease - Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................77
8.4.8. Adverse Events of Special Interest
.............................................................78
8.4.8.1. Lack of Efficacy ........................................................................78
8.4.9. Medical Device Deficiencies ......................................................................78
8.4.10. Medication Errors .....................................................................................78
8.5. Pharmacokinetics ....................................................................................................79
8.6. Genetics ...................................................................................................................80
8.6.1. Specifi
ed Genetics ................................ ................................ ...................... 80
8.6.2. Retained Research Samples for Genetics ...................................................80
8.7. Biomarkers ..............................................................................................................80
8.7.1. GDF -
15 .......................................................................................................80
8.7.2. Circulating Biomarkers ...............................................................................81
8.7.3. Specified Gene Expression (RNA) Research ................................ ............. 81
8.7.4. Specified Protein Research ................................ ................................ ......... 81
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 108.7.5. Specified Metabolomic Research ...............................................................82
8.7.6. Retained Research Samples for Biomarkers ...............................................82
8.8. I mmunogenicit y Assessments .................................................................................82
8.9. Health Economics ...................................................................................................83
9. STATI STICAL CONSI DERATIONS
................................................................................83
9.1. Statistical Hy potheses .............................................................................................83
9.1.1. Estimands ....................................................................................................83
9.1.1.1. Pri mary  Estimand ......................................................................83
9.1.1.2. Secondary  Estimands ................................................................85
9.2. Analy sis Sets ...........................................................................................................86
9.3. Statistical Analy ses................................ ................................ ................................ .87
9.3.1. General Considerations ...............................................................................88
9.3.1.1. Analy ses for Continuous Endpoints ..........................................88
9.3.2. Primary  Endpoint Analy sis.........................................................................89
9.3.3. Secondary  Endpoints Analy sis...................................................................90
9.3.4. Tertiary /Exploratory  Endpoints Analy sis...................................................90
9.3.5. Other Anal yses............................................................................................91
9.4. I nterim Anal yses.....................................................................................................91
9.4.1. PK/PD Unblinding Plan
..............................................................................92
9.5. Sample Size Determination .....................................................................................92
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................94
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............94
10.1.1. Regulatory and Ethical Considerations ....................................................94
10.1.1.1. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................94
10.1.2. Financial Disclosure ................................ ................................ ................. 95
10.1.3. I nformed Consent Process ................................ ................................ ........ 95
10.1.4. Data Protection .........................................................................................96
10.1.5. Committees Structure ...............................................................................97
10.1.5.1. Data Monitoring Committee ...................................................97
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 1110.1.5.2. Executive Steering Committee................................................97
10.1.5.3. Operations Steering Committee
..............................................97
10.1.6. Dissemination of Clinical Study  Data ......................................................97
10.1.7. Data Qualit y Assurance ............................................................................99
10.1.8. Source Documents ..................................................................................100
10.1.9. Study  and Site Start and Closure ............................................................100
10.1.10. Publication Policy .................................................................................101
10.1.11. Sponsor’s Medically  Qualified Individual ................................ ............ 102
10.2. Appendix 2: Clinical Laboratory  Tests ...............................................................103
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting ...................................................................104
10.3.1. Definition of AE .....................................................................................104
10.3.2. Definition of an SAE ..............................................................................105
10.3.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ..........................................................................107
10.3.4. Reporting of SAEs
..................................................................................111
10.4. Appendix 4: Contraceptive and Barrier Guidance ..............................................112
10.4.1. Male Participant Reproductive Inclusion Criteria
..................................112
10.4.2. Female Participant Reproductive Inclusion Criteria ...............................112
10.4.3. Woman of Childbearing Potential ..........................................................112
10.4.4. Contraception Methods ...........................................................................113
10.5. Appendix 5: Genetics
..........................................................................................115
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments .....116
10.7. Appendix 7: Kidney  Safety  Monitoring Guidelines ...........................................118
10.7.1. Laboratory
 Assessment of Change in Kidney  Function and 
Detection of Kidney  Injury ............................................................................118
10.7.2. Age -Specific Kidney  Function Calculation Recommendations .............118
10.7.2.1. Adults (18 Years and Above) -2021 CKD -EPI Equations .....118
10.7.3. Adverse Event Grading for Kidney  Safet y Laboratory  
Abnormalities .................................................................................................118
10.8. Appendix 8: ECG Findings of Potential Clinical Concern ................................ .119
10.9. Appendix 9: Comfort and Wear abilit y Questionnaire ........................................121
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 1210.10. Appendix 10: ECOG Performance Status .........................................................123
10.11. Appendix 11: RECI
ST 1.1 Tumor Assessment Criteria RECI ST 
(Response Evaluation Criteria In Solid Tumors) version 1.1 Guidelines ...............124
10.12. Appendix 12: L ist of Platinum -Based Chemotherapies ....................................129
10.13. Appendix 13: Abbreviations .............................................................................130
10.14. Appendix 14: Protocol Amendment History .....................................................136
11. REFERENCES ................................................................................................................144
LIST OF TABLES
Table 1. Schedule of Activities for Part A Double -Blind .......................................24
Table 2. Schedule of Activities for Participants Enrolled in Optional Part B 
OLT
...........................................................................................................28
Table 3. Summary  of Predicted Stead y State Total ponsegromab Exposures 
and Associated Safet y Margins and Exposure Multiples Following 
Q4W SC Doses .........................................................................................48
Table 4. Summary  of Predicted Stead y State Unbound ponsegromab 
Exposures and Associated Exposure Multiples Following Q4W SC 
Doses .........................................................................................................48
Table 5.
Objective Response Status at each Evaluation .......................................128
Table 6. Objective Response Status at each Evaluation for Patients with Non 
Target Disease Onl y
...............................................................................128
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 131.PROTOCOL SUMMARY 
1.1.Synopsis 
Protocol Title: 
A Phase 2, R andomized, Double -blind , Placebo -controlled Study to Investigate the Efficacy , 
Safety ,and Tolerability  of Ponsegromab in Patients W ith Cancer , Cachexia , and E levated 
Concentrations of GDF -15, Followed b y an Optional Open- Label Treatment Period . 
Brief Title:
A Phase 2 Study  ofthe Efficacy  and Safety  of Ponsegromab in Patients withCancer , 
Cachexia and Eleva
ted GDF -15.(PROACC -1)
Regulatory Agency Identification Number(s):
US IND Number: 139674
[EudraCT /CTIS] Number: 2022- 003016 -87
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
Pediatric Investigational Plan Number : NA
Protocol Number: C3651003
Phase: 2
Rationale :
Patients with advanced cancer and elevated concentrations of GDF -
15frequently  develop 
cachexia which impacts their quality  of life and survival. Inhibiting the activity  of GDF -15 in 
such patients 
may help reverse cachexia and improve the ir quality  of life. This study  will 
evaluate the efficacy , safety ,andtolerability of ponsegromab, an inhibitor of GDF -15,
compared to placebo, in patients with cancer, cachexia, and elevated concentrations of 
GDF -
15. 
This study  is also known as PROACC 
-1, Patient Reported Outcomes and Activity  in 
CanCer.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 14Objectives , Endpoints ,and Estimands :
Part A
Objectives Endpoints Estimands
Prim ary Prim ary Prim ary
To evaluate the effect of 
ponsegromab compared 
with placebo on body 
weight in participants 
with cancer, cachexia, and 
elevated concentration s of 
GDF -15.Change from baseline body 
weight at Week 12.Estimand 1 (similar to 
“hypothetical”) is the difference 
betw een ponsegromab and 
placebo in mean change from 
baseline in body weight at 
Week 12, in participants with 
cancer, cachexia and elevated 
concentrations of GDF -15, 
under the scenario of no 
discontinuation of study 
intervention and without the 
potential confounding effect of 
prohibited procedures , 
prohibited medications or 
participants’ non -compliance 
with dosing.
Secondary Secondary Secondary
To evaluate the effect of 
ponsegromab compared to 
placebo on physical activity and 
gait as measured by wearable 
digital sensors in participants 
with cancer, cachexia, and 
elevated concentrations of 
GDF -15.Change from baseline in each 
of the physical activ ity and 
gait endpoints measured w ith 
remote digital sensors at 
Week12: 
Moderate to 
vigorous 
physical activity time;
Sedentary activity time;
Non sed entary activity 
time;
Total vector magnitude;
Mean activity level during 
M6m in;
Mean gait speed ;
95thpercentile gait speed .Estimand 2 (similar to 
“hypothetical”) is the difference 
betw een ponsegromab and 
placebo in mean change from 
baseline in each of the physical 
activity and gait endpoints at 
Week 12, in participants with 
cancer, cachexia and elevated
concentrations of GDF -15, 
under the scenario of no 
discontinuation of study 
intervention and without the 
potential confounding effect of 
prohibited procedures , 
prohibited medications or 
participants’ non -compliance 
with dosing.
To evaluate the effect of 
ponsegromab compared to 
placebo on the appetite- related 
symptoms as measured by 
FAACT in participants with 
cancer, cachexia, and elevated 
concentrations of GDF -15.Change from baseline in 
FAACT sub -scale scores at 
Week 12 :
FAACT -ACS
;
FAACT -5IASS .Estimand 3 (similar to 
“hypothetical”) is the difference 
betw een ponsegromab and 
placebo in mean change from 
baseline in each FAACT 
sub-scale score at Week 12 , in 
participants with cancer, 
cachexia and elevated 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 15Objectives Endpoints Estimands
concentrations of GDF -15, 
under the scenario of no 
discontinuation of study 
intervention and without the 
potential confounding effect of 
prohibited procedures , 
prohibited medications or 
participants’ non -compliance 
with dosing.
To evaluate the effect of 
ponsegromab compared to 
placebo on anorexia/ap petite 
nausea, vomiting ,and fatigue 
measured by the CRCSD , 
Pfizer -developed instrument, in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Change from baseline score for 
the questions from the CRCSD 
at Week 12 related to:
Anorexia/appetite;
Nausea and vomiting ;
Fatigue.Estimand 4 (similar to 
“hypothetical”) is the difference 
betw een ponsegromab and 
placebo in mean change from 
baseline in each of the 
anorexia/appetite, nausea, 
vomiting,and fatigue questions 
from the CRCSD at Week 12, in 
participants with cancer, 
cachexia and elevated 
concentrations of GDF -15, 
under the scenario of no 
discontinuation of study 
intervention and without the 
potential confounding effect of 
prohibited procedures , 
prohibited medications or 
participants’ non -compliance 
with dosing.
To characterize the safety and 
tolerability of repeated SC
administrations of ponsegromab 
compared to placebo in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Incidence of adverse events,  
safety laboratory tests, vital 
signsand ECG abnormalities *There are no defined estimands 
for the incidence of adverse 
events, safety laboratory tests, 
vital signs and ECG 
abnormalities, and these 
endpoints will be summarized 
using Pfizer data standards as 
applicable .
* Safety, tolerability and survival will also be characterized in Part B once all applicable participants have 
completed Part B of the study. These data will be reported as part of the supplemental CSR.
Overall Design:
This is a Phase 2 , randomized , double -blind, placebo -controlled study  of the efficacy , safety,
andtolerability of three different doses of ponsegromab compared to placebo , administered 
for 12 weeks, in patients with NSCL C, PANC, or CRC who have elevated concentration s of 
GDF -
15 andcachexia . The double -blind period is followed by  an optional open- label (Part 
B) extension period.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 16The Screening visit will occur no more than 28 days and no less than 7 days, prior to 
Randomization. The 7 -day minimum duration between Screening and Randomization visits 
will ensure that the GDF-15 results are available to inform the investigator’s assessment of 
eligibility  and the 7 -day collection of PRO and phy sical activity  data. Following the 
Screening period to confirm eligibility , approximate ly 168 study  participants, who meet the 
entry  criteria, will be randomized to study  intervention (one of 3 dose groups of 
ponsegromab or matching placebo) and will be stratified by  treatment with or without 
platinum -based chemotherap y, which is known to in duce GDF -15 and therefore may  impact 
the response to ponsegromab treatment. The 12 -week double -blind dosing period (Part A) 
will consist of a total of 3 doses administered Q4W SC.
A PK substudy  will be conducted in 
approximately  36 of the approximately  168 participants 
(approximately  9 in each treatment group inPart A). Up to 3 additional PK and PD samples 
(two samples during Part A and one sample during Part B, if relevant), will be collected in 
these participants at timepoints during the study outlined in Section s1.2 schema and 1.3 
SoA.
On completion of Part A, participants will have the opportunity  to enter an optional OL T 
period (Part B) consisting of ponsegromab 400 mg Q4W SC for up to 1 y ear. The 
investigator and participant must decide at the Week 8 visit if they  wish to continue to the 
optional OL T period. 
Participants opting to continue to the optional OLT period will receive their first dose of 
open -label ponsegromab 400 mg at the Week 12 visit, which is the last visit of the 
double -blind portion. Upon completion of the optional OLT period, there will be a follow -up 
visit (Week 72) which is to occur 56 to 63 day s post last dose of study  intervention .
Participants who do not proceed with the optional OLT period are to complete the Week 12 
visit and a follow
-up visit at Week 16. 
Additional follow -up may be conducted for safet y evaluation, at the discretion of the 
investigator.
The optional OLT period will continue as currently planned, unless the following factors 
develop in which case the optional OLT period may be modified:
Upon completion of the double -blind portion, the final anal ysis shows a lack of 
efficacy  for the primary  endpoint and/or inadequ ate safet yand tolerability ;
An alternative method of study  intervention delivery  become available;
Alower dose of ponsegromab is shown to be efficacious; 
The sponsor decides to terminate the study /clinical development program. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 17Participants may  withdraw from the optional OLT period at an y time, for reasons 
such as the following:
The study  participant withdraws consent or dies;
The study  participant experiences an AE attributable to intervention ;
A change in study  participant’s medical condition that,in the investigator’s 
judgment, make s it inappropriate to continue study  participation .
Anindependent oversight committee in the form of an IRC will monitor the safet y, 
efficacy , and tolerability  of the study  participants and the study  conduct . There will 
also be an Executive Steering Committee and an Operation
sSteering Committee. 
Number of Participants:
Approximately  168 participants will be enrolled in the study , of which up to approximately  
36 participants will be enrolled in the PK substudy .
Note:“Enrolled ”means a participant ’s, or their legall y authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process andrandomization to study  intervention .A participant will be considered enrolled if 
the informed consent is not withdrawn prior to participating in an y stud y activity after 
Screening .Potential participants who are screened for the purpose of determining eligibility  
for the stud y, but do not participate in the stud y, are not c onsidered enrolled, unless otherwise 
specified b y the protocol.
Study Population :
Inclusion and exclusion criteria are listed below:
Inclusion Criteria 
Participants must meet the following inclusion criteria to be eligible for enrollment into the 
study :
1.Participants aged ≥18 years (or the minimum age of consent if > 18 in accordance 
with local regulations) at screening who have signed informed consent. 
a.A female participant is eligible to participate if she is not pregnant or 
breastfeeding.
b.Refer to Appendix 4 for reproductive criteria for male ( Section 10.4.1) and female
(Section 10.4.2) participants.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 182.Documented histologic or cytologic active diagnosis of NSCL C, PANC , or CRC and
are currentl y receiving , or have completed, standard of care treatment for this cancer
(which may  include s ystemic therapy ).
3.Cachexia defined b y Fearon criteria of weight loss as(See Section 8.1.1 for details if 
the participant’s bod y weight is unavailable from medical record )
:
BMI <20 kg/m2with involuntary  weight loss of >2% within 6 months prior to 
screening; 
or
Involuntary  weight loss of >5% within 6 months prior to screening irrespective of 
BMI.
4.Serum GDF -15 concentration s of ≥ 1.5 ng/mL (as measured using the Investigational 
Use Onl y Roche Elecs ys GDF -15 assay )10at Screening.
5.Participants who are assessed by  the investigator to have :
an ECOG PS ≤3, 
and;
a life expectancy  of at least 4 months to be able to complete Part A.
6.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures. 
Exclusion Criteria 
Participants with any  of the following characteristics/conditions will be excluded:
1.Current active reversible causes of decreased food intake, as determined by  the 
Investigator. These causes may  include, but are not limited to:
NCI CTCAE Grade 3 or 4 oral mucositis;
NCI CTCAE Grade 3 or 4 GI disorders [nausea, vomiting, diarr hea, and 
constipation];
mechanical obstructions interfering with the participant’s ability to eat.
2.Receiving tube feedings or parenteral nutrition (either total or partial) at the time of 
Screening or Randomization .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 193.Cachexia caused b y other reasons, as det ermined by  the investigator, including, but 
not limited to: 
Severe COPD requiring use of home O2;
NYHA class III-IV heart failure;
AIDS.
4. Undergoing major surgery  (central venous access placement and tumor biopsies are 
not considered major surgery ) within 4 weeks prior to randomization. Patient must 
have recovered from acute effects of surgery  prior to screening. Patient should not 
have plans to undergo major surgical procedures during the stud y.
5.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the risk 
of study  participation or, in the investigator’s judgment, make the participant 
inappropriate for the study .
6.History  of allergic or anaphy lactic reaction to any  therapeutic or diagnostic 
monoclonal antibody  (IgG protein) or molecules made of components of monoclonal 
antibody . 
7.Current use of an y prohibited concomitant medication(s) within 4 weeks prior to first 
dose of study  intervention .Refer to Section 6.9.
8.Concurrent administration ofinvestigational products (including d rug, biologic 
agents, or vaccines) are not permitted within 30 days (or as determined b y the local 
requirement) or 5 half-lives (whichever is longer) of the first dose of study  
intervention through the duration of the study  (including both Part A and B) .Refer to 
Section 6.9.
9.Enrollment and previous ly dosed in a prior 
study  with ponsegromab.
10.History  of severe liver disease or cirrhosis , unrelated to metastatic cancer. Potential 
study  participants with the following liver function test abnormalities will be 
excluded ; result may  be confirmed by  a single repeat test, if necessary : 
Total bilirubin ≥1.5 × ULN (except for Gilbert’s syndrome) 
AST >3 × ULN (AST > 5X ULN if there is liver involvement by  the tumor) 
ALT >3 × ULN (ALT >5X ULN if there is liver involvement by  the tumor) 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 20Alkaline phosphatase >3 x ULN (Alkaline phosphatase > 5X ULN if there is liver 
involvement by  the tumor and /orin case of bone metastases , or if considered 
related to prior surgery  e.g. pancreaticoduodenectomy ).
11.Renal disease requiring dialy sis.
12.Current adherence to a calorie -restricted diet with the intention of weight loss.
13.Investigator site staff or Pfizer employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  the investigator, and their respective family  
members. 
Study Arms and Duration :
Following a 2 8-day screening pe riod to confirm eligibility , study  participants who meet the 
entry  criteria will be randomized to study  inter vention (one of 3 dose groups of ponsegromab 
or placebo). The 12 -week double -blind dosing period (Part A) will consist of a total of 3 SC 
doses, ad ministered Q4W. On completion of Part A, participants will have the opportunity  to 
enter an optional open -label treatment period (Part B) consisting of ponsegromab 
400mgQ4W SC for up to 1 y ear. 
Study Intervention(s)
Intervention Name ponsegromab ponsegromab ponsegromab placebo
Arm  Nam e
(group of 
participants 
receiving a specific 
treatm ent or no 
treatm ent)ponsegromab 
Double -Blind 
Treatment 100 mgponsegromab 
Double -Blind 
Treatment 200 mgponsegromab 
Double -Blind 
Treatment 4 00 mgplacebo 
Double -Blind 
Treatment
Dose Level 100mgQ4W 200mgQ4W 400mgQ4W placebo Q4W
Unit Dose Strength(s) 100 mg/ mL 100 mg/ mL 100 mg/ mL placebo
Route of 
AdministrationSC SC SC SC
Use experimental experimental experimental placebo -
active -comparator
IMP or NIMP/AxMP IMP IMP IMP IMP
Statistical Methods :
The sample size in the ponsegromab and placebo arms is based on the primary  efficacy  
endpoint, mean change from baseline in body  weight at Week 12. Approximately  
168randomized participants are proposed ,to ensure completion of approximately  
120participants, assuming a discontinuation rate of approximately  30%. 
120completing
participants, in a 1:1 :1:1ratio, plus 39 participants from a n informative meta -analy tic 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 21predictive prior (based on historical results from internal and external studies, robustified by  
the inclusion of a weakly  informative component to handle any  possible prior -data conflict)
gives acceptable Operating Characteristics in that the probability  of achieving statistical 
significance (at the 5% significance level, using a 1 -sided t- test), for a true difference 
between ponsegromab and placebo of 2.7kg, is approximately  80% (with a conservative 
standard deviation of 4.9 kg ). 
The primary  estimand will be the population level estimate of the difference between 
ponsegromab and placebo i n the mean change from baseline in body  weight at W eek12,
under the scenario of no discontinuation of study  intervention and without the potential 
confounding effect of prohibited procedures
, prohibited medications or participants’ 
non-compliance with dosing. Data collected after a participant has discontinued study  
intervention , has undergone a prohibited procedure
, received prohibited medications, or has 
inadequate compliance will be censored and treate d as missing data.
The primary  endpoint analy sis will be a Bay esian E maxmodel applied to results from an 
MMRM analy sis. Change from baseline inbody  weight will be first anal y z edusing an 
MMRM model fitted to all post -treatment dosing timepoints up to Week 12 (ie,Weeks 4, 8,
and 12) . The primary  analy sis will include all participants randoml y assigned to study  
intervention and who take at least 1 dose of stud y intervention. The MMRM model will 
include participant as a random term, and baseline, time (a s a factor), baseline -by-time 
interaction, treatment and treatment -by-time interaction as fixed terms in the model.
Additional terms for type of therapy  [ie,platinum or not] and type of cancer will be fitted in 
the model. An unstructured covariance matrix will be fitted to the repeated times within 
subject, and the Kenward Roger approximation will be used for estimating degrees of 
freedom. No adjustments will be made for multiplicity .A Bay esian E maxmodel will then be 
fitted to the L smeans and S esfrom Week 12 only .The posterior medians and 90% credible 
intervals will be reported for each randomized dose (including placebo) and their differences 
relative to placebo. 
Secondary  endpoints of phy sical activity  and gait , FAACT sub -scales and questions from the 
CRCSD ,will be analy zed using an MMRM model with similar estimands to the primary  
estimand. Safet y and tolerability data will be summarized descriptivel y through appropriate 
data tabulation, descriptive statistics, categorical summaries, and graphical presentations, as 
appropriate, in accordance with Pfizer Data Standards.
Ethical Considerations :
Considering all available clinical and nonclinical data, the benefit -risk profile of 
ponsegromab i s favorable and supports continued clinical development in patients with 
cancer and cachexia. 
More detailed information about the known and expected benefits and risks and reasonabl y 
expected adverse events of pon segromab may  be found in the IB, which is theSRSD for this 
study .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 22Taking into account the measures to minimize risk to study  participants, the potential risks 
identified in association with ponsegromab are justified by  the anticipated benefits that may  
be afforded to participants with cancer and cachexia.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022 )
TMF Doc ID: 164.01
Page 231.2.Schema
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 302.INTRODUCTION
Ponsegromab is an inhibitor of GDF -15 that is currently  being investigated in participants 
with cancer, cachexia, and elevated concentrations of GDF -15. P onsegromab is also being 
investigated in patients with heart failure and elevated concentration
sof GDF -15. 
2.1.Study Rationale 
Patients with cancer suffer considerable morbidity  related to both tumor progression and the 
side effects of therapies targeting t he underly ing malignancy . As cancers progress, patients 
frequentl y develop cachexia, a loss of weight due to the catabolism of muscle and fat 
tissue.1,2The progressive worsening of cachexia impacts a cancer patient’s quality  of life and 
contributes to poo r survival.
The purpose of the study  is to evaluate the efficacy , safet yand tolerability of ponsegromab 
compared to placebo in the treatment of patients with cancer, cachexia, and elevated 
concentrations of GDF
-15.
This study  is also known as PROACC -1, Patient Reported Outcomes and Activity  in CanCer.
2.2.Background 
At the present time, treatments for cancer related cachexia are limited. Pharmacologic 
interventions associated with improvements in appetite improvement or body  weight gain 
include progesterone analogues and corticosteroids.1The ASCO, in its 2020 Management of 
Cachexia Guidelines , stated that there is no recommended pharmacologic standa rd of care 
for patients with cancer associated cachexia.2
One of the biomarkers associated with cancer cachexia is the cy tokine GDF -
15.3GDF -15, 
also known as MIC -1, is a member of the TGF bsuperfamil y. In healthy individuals the 
major source of circulating GDF -15 is believed to be the liver, although it is also expressed 
by the kidney s, lung and adipose tissue.4GDF -15 is secreted b y tumor cells a nd is associated 
with cachexia in cancer patients.5,6,7
In addition, published clinical data and internal animal model data suggest that 
administration of platinum therap y can induce increases in serum GDF -15 concentrations . 
Clinical literature and internal animal model data8also suggest that the nausea, emesis and 
anorexia observed with platinum therapy  may  be mediated, at least in part, by  
platinum -induced elevations in GDF -15. 
Therefore, it is hy pothesized that cachexia in many  types of cancer, including NSCL C, 
PANC , and CRC, is largely mediated via GDF -15 and that suppression of GDF -15 in these 
patients may  lead to improvement in serious aspects of cachexia such as anorexia leading to 
unintended weight loss, fatigue and impaired mobility . Furthermore, given the observations 
of GDF -15 elevation with platinum therapy , patients receiving standard of care antitumor
treatment that includes sy stemic platinum -based therapy , may  be a specific population that 
could potentially  gather additional- benefit from GDF -15 inhibition.8
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 31Ponsegromab is an anti-GDF -15 mAb that is currently  being investigated in study  
participants with cancer who have elevated concentrations of GDF -
15and cachexia. The 
objective of this clinical study  is to determine if ponsegromab administered at three different 
doses every  4-weeks over 12 -weeks can reduce the study  participants’ cachexia related 
symptom burden and improve their qualit y of life compared to placebo during 12 -weeks of 
treatment.
A summary  of relevant, currentl y available data on ponsegromab is provided in this protocol. 
Additi onal detail, and further information for this compound, may  be found in the IB , 
including its phy sical, chemical, pharmaceutical properties and formulation, non -clinical 
studies, and its known effects in humans. 
2.2.1. Clinical Overview
To date, the safet y of po nsegromab has been assessed in 2 completed Phase 1 clinical studies 
in healthy  adult volunteers (C3651001 and C3651002) and in 2 completed Phase 1b studies 
in patients with elevated serum GDF- 15 levels and cancer cachexia (C3651009) or cancer 
anorexia (C36 51010). A total of 80 participants were exposed to this at least one dose of 
ponsegromab across these studies. A summary  of the completed studies is presented in the 
table below. 
Completed Clinical Studies with Ponsegromab
Study 
IdentifierStudy Design 
and Type of 
ControlDosing Regimen, 
Form ulation, DoseNumber of 
Participants 
RandomizedPopulation Treatm ent 
Duration 
C3651001 Phase 1, 
double- blind, 
randomized, 
sponsor -open, 
placebo 
controlled, 
single 
ascending 
dose study.Ponsegromab or 
placebo. 
Subcutaneously 
administered 
solution
Dose: 
0.1, 0.3, 1, 3, 10, 
30, 100 and 300 mgTotal: 63
47ponsegromaba, 
16placeboEight sequential 
cohorts of 
healthy adult 
participants. Single dose 
C3651002 Phase 1, 
double- blind,
randomized, 
sponsor -open, 
placebo 
controlled, 
single dose 
study.Ponsegromab or 
placebo. 
Subcutaneously 
administered 
solution
Dose: 100 mgTotal: 8
6ponsegromab, 
2placeboOne cohort of 
healthy adult 
Japanese 
participants. Single dose 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 32Completed Clinical Studies with Ponsegromab
Study 
IdentifierStudy Design 
and Type of 
ControlDosing Regimen, 
Form ulation, DoseNumber of 
Participants 
RandomizedPopulation Treatm ent 
Duration 
C3651009 Phase 1b, 
open -label 
multiple dose 
studyPonsegromab
Subcutaneously 
administered 
solution
Dose: 200 mg Q3WTotal: 11
10 ponsegromabbParticipants 
with cancer, 
cachexia, and 
serum GDF -15 
levels ≥ 1500 
pg/ml.12 w eeks
C3651010 Phase 1b, 
double- blind, 
randomized, 
placebo 
controlled 
followed by 
open -label 
extensionPonsegromab or 
placebo
Subcutaneously 
administered 
solution
Dose: 200 mg Q3WTotal: 18
Double -blind 
period
12 ponsegromab
6 placebo
Open -label 
period:
14 ponsegromabcParticipants 
with cancer, 
anorexia, and 
serum GDF -15 
levels ≥ 1500 
pg/ml.6 weeks 
followed by 
18 w eek 
open label 
extension.
a.N=6 per dose except for the 300 mg dose group where N=5.
b.1 participant randomized and not dosed.
c.Of these 14, 5 received placebo and 9 received ponsegromab during the preceding double -blind period.
More detailed information for the completed studies may  be found in the ponsegromab IB, 
which is the SRSD for this study . 
2.2.1.1. Phase 1 b Body Weight Data Summary
While the primary  objective of Phase 1b C3651009 study  was to evaluate the safet y, 
tolerability , PK/PD, and immunogenicit y of ponsegromab 200 mg Q3W (through 12 weeks/5 
doses) in cancer patients with cachexia, change of body  weight from baseline was also 
evaluated, as a signal of clinical efficacy . Mean increases from baseline in body  weight were 
observ ed at all time points during the 12 -week treatment period and 12- week follow -up
period.  The mean ( SD) body  weight increase from baseline was 4.46 (4.75) kg at Week 1 2, 
with a mean (SD) percent increase from baseline of 5.81 (5.87
).
Body weight data are not presented for C3651010 study  given that this study  was terminated 
for non -safet y reasons , with less than 50% of originally  planned number of participants 
enrolled, precluding meaningful evaluation for changes in bod y weight.
2.2.1.2. Summary of Safety Data
In the single arm, open -label, Phase 1b C3651009 study  of pati ents with cancer, cachexia, 
and elevated GDF- 15 levels, there were 92 TEAEs reported for 10 participants dosed with 
ponsegromab 200 mg Q3 W SC.  None of the seTEAEs were attributed to study  intervent ion
by the investigator or sponsor . Of these non -treatment related TEA E s, most were mild or 
moderate ;5 were serious, of which onewas fatal due to neoplasm progression during the 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 33follow -up period (131 day s after randomization). No deaths occurred during the treatment 
period. 
In the Phase 1B study  C3651010 study  in patients with cancer ,anorexia and elevated GDF -15 
levels, there were 58 TEAEs (including 8 SAEs) across 18 participant s. Only  1 TEAE 
(myalgia) was considered treatment-related b y the investigator. The incidence and severit y of 
TEAEs were similar between the two treatment arms. I n the double -blind treatment phase 
there were 3 deaths: one in a participant receiving placebo due to a cardiac arrest and 2 in the 
ponsegromab 200 mg Q3W treatment arm, one due to respiratory  failure and one due to acute 
myocardial infarction. During the open label extension there were 3 deaths attributed due to 
disease progression. None of these d eaths were considered treatment related.
2.2.1.3. Summary of Pharmacokinetics
Following single dose administration of ponsegromab to healthy  non-Japanese participants, 
SC absorption of unbound ponsegromab for the 3 to 300 mg dose groups occurred with 
median T maxranging from 2.25 to 7.00 day s. In general, over the 10 to 300 mg dose range, 
increases in geometric mean unbound C maxin serum were approximately  dose -proportional 
and increases in unbound AUC lastand AUC infin serum appeared to be greater than dose -
proport ional. The geometric mean CL/F appeared to decrease with increasing dose, and mean 
terminal t ½increased with increasing dose, ranging from 3.52 to 11.1 day s across the 10 to 
300 mg dose groups.
Following single doses of SC ponsegromab in healthy  participa nts, absorption of total 
ponsegromab occurred with median T maxranging from 6.00 to 14.0 day s across the 1 to 300 
mg dose groups. In general, increases in geometric mean total C max, AUC last, and AUC inf  in 
serum appeared to be less than dose -proportional o ver the 10 to 100 mg dose range, while 
increases in exposure from 100 to 300 mg doses were largel y dose proportional. The mean 
terminal t ½values increased from 20.1 days for the 10 mg group to 30.9 day s for the 300 mg 
group. The long terminal t½of total ponsegromab in serum is driven primarily  by the half -life 
of bound ponsegromab (ponsegromab -GDF -15 complex), as the unbound ponsegromab 
terminal t ½ values observed over the same dose ranges were much shorter. Unbound 
ponsegromab (not total ponsegr omab) is the active moiety  that accounts for pharmacological 
activity  of the drug.
At a single 100 mg SC dose, the geometric mean unbound ponsegromab Cmax, AUC last, and 
AUC infin Japanese participants were approximately 50%, 70%, and 71% higher, 
respective ly, than those observed in non
-Japanese participants. Similarly , the geometric mean 
total C max, AUC last, AUC infin Japanese participants were approximately  48%, 65%, and 66% 
higher, respectivel y.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 342.2.1.4. Summary of GDF -15 R esponse
In stud y C3651001, following sin gle SC administration of 1 to 300 mg doses of 
ponsegromab to health y non-Japanese adults, the median duration of serum unbound GDF - 15 
suppression (defined as last time post -dose with unbound GDF -15 concentration reported as 
below LLOQ which was 42.4 pg/mL) increased with increasing dose of ponsegromab, 
ranging from 0.17 day  for the 1 mg dose group to 75.61 day s for the 300 mg dose group. 
There was generall y no change from baseline in measures of unbound GDF -15 in 
participants treated with placebo, ponsegrom ab 0.1 and 0.3 mg groups. Following a single 
SC administration of ponsegromab 100 mg in healthy  Japanese adult participants in study  
C3651002, serum unbound GDF -15 concentrations were suppressed to below the LLOQ 
starting on Day  1, with the median duration of suppression of 40.49 days, ranging from 9.00-
88.07 day s in individual participants.
In stud y C3651009, following SC administration of ponsegromab at 200 mg Q3W through 
Week 12 (Day  85) in participants with cancer, cachexia and elevated serum GDF -15 
concentrations, median unbound GDF -15 concentrations were suppressed from the baseline 
concentration of 2269 pg/mL  to below the LLOQ at all visits between Day  1 and Week 15 
(Day  106). 
2.2.1.5. Immunogenicity
Based on the available ADA/Na b data from the Phase 1 C3651001 and C3651002 studies 
conducted in healthy
 participants (n=53), none of the 53 participants had pre -existing ADA at 
baseline and the overall incidence of treatment-induced ADA was 9.43% (5/53 participants). 
Nab was observed in 1 participant across the 2 studies. Overall, there was no apparent effect 
of ADA observed on the PK, PD andsafety profile of ponsegromab. 
In C3651009 and C3651010 studies, following SC administration of ponsegromab at 200 mg 
Q3W through 12 and 24 weeks, respectivel y, in part icipants with cancer, cachexia or 
anorexia, and elevated serum GDF -15 concentrations, the incidence of treatment -induced 
ADA was very  low with overall incidence of treatment- induced ADA of 0 and 9.1% (1/11), 
respectivel y, and no incidence of N ab was observed in either stud y. 
2.3.Benefit/Risk Assessment
Based on theavailable clinical data described in the IB, no safet y concerns have been 
identified in the four clinical trials completed to date. 
More detailed information about the known and expected bene fits and risks and reasonabl y 
expected AEs of ponsegromab may be found in the IBwhich is the SRSD for this study .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 352.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) ponsegrom ab
SC injection site reactions and hypersensitivity 
reactions . Although there w ere no injection site reactions or 
delayed hypersensitivity reactions observed in the 
completed clinical studies, as with all injectable 
mAbs, there is the potential for injection site 
reactions or delayed hypersensitivity reactions.The follow ing exclusion criteria is added: 
History of allergic or anaphylactic reaction to 
any therapeutic or diagnostic monoclonal 
antibody (IgG protein) or molecul es made of 
components of monoclonal antibody. 
Additionally, i njection site reactions will be 
monitored, and injection sites rotated. 
Use of a placebo arm. Use of a placebo arm represents a risk of lack of 
benefit for those not receiving active therapy. As 
there are no data on efficacy yet, this risk cannot be 
assessed. Participants will continue to receive standard 
of care throughout the study for their 
underlying cancer. The study has been 
designed w ith, a 3active : 1placebo 
randomization ratio, in order to increase 
participants’ chances of receiving active 
therapy.
Study Procedure
Challenges in collecting the requisite amount of 
blood required.Participants may be anemic or have a concomitant 
condition that makes it difficult to collect requisite 
volume of bio -samples. Effort to streamline bio sample collection in 
the SoA and reduce volume collected w here 
feasible.
Additional CT scans . Participants may undergo up to tw o additional CT 
scans beyond standard of care, thereby increasing 
exposure to radiation.Participants will not be required to undergo 
additional CT scans if they had a SOC CT 
scan within 3 w eeks prior to the Screening 
visit, betw een Weeks 10 -12 or w ithin 7 days 
after the Week 12 visit.
Use of ECG patches . Mild skin reactions /irritations attributed to use of 
ECG patches were observed in completed studies 
with ponsegromab.Sites will be reminded to clean and dry the 
study pa rticipant ’sskin before attaching the 
ECG electrodes ; And after removing the 
electrodes , clean the study participant’s skin 
with soap and water.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 36Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Other
The COVID- 19 pandemic may pose risks to study 
participation .Participants may have increased risk of 
SARS -CoV- 2 infection by undergoing a study 
procedure at a study facility .Sites will follow local guidelines to minimize 
risk of SARS -CoV -2 infection at a study 
facility. Non-dosing visits may be conducted 
by a qualified site staff member /phlebotomist
at the participant’s home, in order to reduce 
the risk of exposure at the site. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 372.3.2. Benefit Assessment
Clinical data on any potential benefit of ponsegromab inpatients with cancer, cachexia, and 
elevated 
serum GDF -15 concentrations, are limited to observations from the single arm, 
open -label, Phase 1b C3651009 study  of ponsegromab 200 mg Q3W . Mean increases from 
baseline in body  weight were observed at all time points during the 12 -week treatment period 
and 12- week follow -up period. In addition, median serum unbound GDF -15 concentrations 
were suppressed in these participants from elevated baseline concentration sto below the 
lower level of quantification at all visits from Day 1 through week 15, with last dose of 
ponsegromab 200 mg Q3W at 12 weeks (see Section 2.2.1.4). Similar suppression of serum 
unbound GDF -15 concentrations was observed throughout treatment with ponsegromab in 
patients with cancer, anorexia, and elev
ated serum GDF -15 concentrations enrolled in the 
Phase 1b C3651010 study . No safet y concerns were identified in the 80 participants who 
received at least one dose of ponsegromab across four clinical trials completed to date.
Based upon these clinical data and nonclinical data, it is hy pothesized that dosing with 
ponsegromab may improve participants appetite and support maintenance of body  weight in 
participants enrolled in this study . More detailed information about the known and expected 
benefits and risks and reasonably expected adverse events of ponsegromab may be found in 
the IB, which is the SRSD for this study .
It is estimated that 50 %-80%9of patients with advanced malignant ca ncer suffer with 
cachexia which results in worse outcomes. Therefore, the development of ponsegromab for 
the treatment of cachexia may  satisfy  an area of high unmet need.
2.3.3. Overall Benefit /Risk Conclusion
This study  is designed primarily  to assess efficac y, safet y, tolerabilit y, pharmacokinetics and 
pharmacod ynamics of ponsegromab in participants with cancer who have cachexia and 
elevated concentrations of GDF -15. 
Considering all available clinical and nonclinical data, the benefit -risk profile of 
ponsegroma bis favorable and supports continued clinical development in patients with 
cancer ,cachexia and elevated serum GDF -15 concentrations . 
3.OBJECTIVES, ENDPOINT S, AND ESTIMANDS
Part A
Objectives Endpoints Estimands
Prim ary Prim ary Prim ary
To evaluate the effect of 
ponsegromab  compared w ith 
placebo on body weight in 
participants with cancer, Change from baseline 
body weight at Week 
12.Estimand 1 (similar to 
“hypothetical”) is the 
difference between 
ponsegromab and 
placebo in mean change 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 38Objectives Endpoints Estimands
cachexia, and elevated 
concentrations of GDF -15.from baseline in body 
weight at Week 12, in 
participants with cancer, 
cachexia and elevated 
concentrations of GDF -
15, under the scenario 
of no discontinuation of 
study intervention and 
without the potential 
confounding effect of 
prohibited procedures , 
prohibited medications
or participants’ 
non
-compliance with 
dosing.
Secondary Secondary Secondary
To evaluate the effect of 
ponsegromab compared to 
placebo on physical activity 
and gait as measured by 
wearable digital sensors in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Change from baseline 
in physical activity 
and gait endpoints 
measured w ith remote 
digital sensors at 
Week 12.
Moderate to 
vigorous 
physical activity time;
Sedentary activity 
time;
Non sedentary activity 
time;
Total vector 
magnitude ;
Mean activity level 
during M6m in;
Mean gait speed ;
95thpercentile gait 
speed .Estimand 2 (similar to 
“hypothetical”) is the 
difference between 
ponsegromab and 
placebo in mean change 
from baseline in each of 
the physical activity and 
gait endpoints at 
Week 12, in participants 
with cancer, cachexia 
and elevated
concentrations of 
GDF -15, under the 
scenario of no 
discontinuation of study 
intervention and without 
the potential 
confounding effect of 
prohibited procedures , 
prohibited medications
or participants’ 
non
-compliance with 
dosing.
To evaluate the effect of 
ponsegromab compared to 
placebo on the appetite- related 
symptoms as measured by 
FAACT in participants with 
cancer, cachexia, and elevated 
concentrations of GDF -15.Change from baseline 
in FAACT sub -scale 
scores at Week 12 :
FAACT -ACS;
FAACT -5IASS .Estimand 3 (similar to 
“hypothetical”) is the 
difference between 
ponsegromab and 
placebo in mean change 
from baseline in each 
FAACT sub -scale score 
at Week 12 , in 
participants with cancer, 
cachexia and elevated 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 39Objectives Endpoints Estimands
concentrations of GDF -
15, under the scenario 
of no discontinuation of 
study intervention and 
without the potential 
confounding effect of 
prohibited procedures , 
prohibited medications
or participants’ 
non
-compliance with 
dosing.
To evaluate the effect of 
ponsegromab compared to 
placebo on anorexia/appetite 
nausea, vomiting ,and fatigue 
measured by the CRCSD , 
Pfizer -developed instrument, in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Change from baseline 
score forthe questions 
from the CRCSD at 
Week12 related to:
Anorexia/appetite;
Nausea and vomiting ;
Fatigue.Estimand 4 (similar to 
“hypothetical”) is the 
difference between 
ponsegromab and 
placebo in mean change 
from baseline in each of 
the anorexia/appetite, 
nausea, vomiting ,and 
fatigue quest ions from 
the CRCSD at Week 12, 
in participants with 
cancer, cachexia and 
elevated concentrations 
of GDF -15, under the 
scenario of no 
discontinuation of study 
intervention and without 
the potential 
confounding effect of 
prohibited procedures , 
prohibited me dications
or participants’ 
non
-compliance with 
dosing.
To characterize the safety and 
tolerability of repeated SC 
administrations of 
ponsegromab compared to 
placebo in participants with
cancer, cachexia, and elevated 
concentrations of GDF -15.Incidence of adverse 
events, safety 
laboratory tests, vital 
signs and ECG 
abnormalities. *There are no defined 
estimands for the 
incidence of adverse 
events, safety laboratory 
tests, vital signs, and 
ECG abnormalities, and 
these endpoints will be 
summarized using 
Pfizer data standards as 
applicable.
Tertiary/Exploratory Tertiary/Exploratory Tertiary/Exploratory
To evaluate the effect of 
ponsegromab compared to Change from baseline 
in additional physical Not Applicable.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 40Objectives Endpoints Estimands
placebo on physical activity 
and gait as measured by 
wearable digital sensors in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.activity and gait 
endpoints measured 
with remote digital 
sensors at Week 12.
To evaluate the effect of 
ponsegromab compared to 
placebo on HRQoL as 
measured by FAACT in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Change from baseline 
in additional FAACT 
total and sub-scale 
scores at Week 12 .Not Appli cable.
To evaluate PK of 
ponsegromab following 
repeated SC administration to 
participants with cancer 
cachexia and elevated 
concentrations of GDF -15.Serum unbound and 
total concentrations of 
ponsegromab on Day 
1, Week 4, 5, 8, 10, 
12, and 16, plus Week 
9and 11 in PK 
substudy onlyNot Applicable.
To evaluate the effect of 
repeated SC administration of 
ponsegromab on circulating 
GDF -15 concentrations in 
participants with cancer 
cachexia, and elevated 
concentrations of GDF -15.Serum unbound and 
total concentrations of 
GDF -15 on Day 1, 
Week 4, 5, 8, 10, 12, 
and 16, plus Week 9 
and 11 in PK substudy 
onlyNot Applicable.
To evaluate the 
immunogenicity profile of 
ponsegromab following 
repeated SC administration in 
participants wit h cancer 
cachexia, and elevated 
concentrations of GDF -15.Incidence of ADA a nd 
NAb.Not Applicable.
To evaluate the effect of 
ponsegromab compared to 
placebo on Patient -Reported 
Outcomes Version 
PROMIS -Fatigue 
questionnaire in participants 
with cancer, cachexia, and 
elevated concentrations of 
GDF -15.Change from baseline 
score for 
PROMIS -Fatigue at 
Week 12.Not Applicable.
To evaluate the effect of 
ponsegromab compared to 
placebo on PROMIS Physical 
Function -Short Form 8c in Change from baseline 
score for 
PROMIS -Physical 
Function at Week 12.Not Applicable.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 41Objectives Endpoints Estimands
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.
To evaluate the effect of 
ponsegromab compared to 
placebo on PGI -S and PGI -C in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Change from baseline 
PGI- S at w eek 12;
PGI- C at Week 12.Not Applicable.
To evaluate the effect of 
ponsegromab compared to 
placebo on tumor burden and 
tumor status in participants 
with cancer, cachexia, and 
elevated concentrations of 
GDF -15.Tumor status 
according to RECIST 
1.1 guidelines using 
CT scan at Week 12.Not Applicable.
To evaluate the effect of 
ponsegromab compared to 
placebo on body composition 
as measured by CT scan in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Change from baseline 
in LSMI derived from
CT scan sat Week 12.
Percent change from 
baseline in s keletal 
muscle and adipose 
tissue measures 
derived from CT scans
at We ek12.Not applicable
To evaluate the effect of 
ponsegromab compared to 
placebo on albumin and 
pre-albumin levels in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Change from baseline 
albumin and pre -
albumin levels at 
Week 12.Not Applicable.
To evaluate the effect of 
ponsegromab compared to 
placebo on survival in 
participants with cancer, 
cachexia, and elevated 
concentrations of GDF -15.Survival status at end 
of Part A.*Not Applicable.
* Safety, tolerability and survival will also be characterized in Part B once all applicable participants have 
completed Part B of the study. These data will be reported as part of the supplemental CSR.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 42Part B
In addition, the following objectives will be evaluated using data from Part B, as data permit:
Objectives Endpoints Estimands
Tertiary/Exploratory Tertiary/Exploratory Tertiary/Exploratory
To evaluate the effect of ponsegromab 
on body weight in participants w ith 
cancer, cachexia, and elevated 
concentrations of GDF -15.Change from baseline body 
weight , in Part B of the 
study .Not Applicable
.
To characterize the safety and 
tolerability of repeated SC 
administrations of ponsegromab in 
participants with cancer cachexia, and 
elevated concentrations of GDF -15, 
during the open -label treatment 
period.Incidence of adverse events , 
safety laboratory tests, vital 
signs and ECG 
abnormalities, in Part B of 
the study.Not Applicable
.
To evaluate the PK of ponsegromab 
following repeated SC administration
in participants with cancer cachexia,
and elevated concentrations of 
GDF -15, during the open -label 
treatment period.Serum unbound and total 
concentrations of 
ponsegromab at Weeks16, 
24, 36, 48 ,64, and 72plus 
flexib le PK timepoint in PK 
substudy .Not Applicable .
To evalu atethe effect of repeated SC 
administration of ponsegromab on 
circulating GDF -15 concentrations in 
participants with cancer cachexia, and 
elevated concentrations of GDF -15, 
during the open -label treatment 
period.Serum unbound and total 
concentrations of GDF -15at 
Weeks 16, 24, 36, 48 , 64, 
and 72, plus flexible P D
timepoint in PK substudy . Not Applicable
.
To assess the immunogenicity of 
ponsegromab following repeated SC 
administration in participants with 
cancer cachexia, and elevated 
concentrations of GDF -15, during the 
open -label treatment period.Incidence of ADA and N
ab.Not Applicable.
4.STUDY DESIGN
4.1.Overall Design
This is a Phase 2, randomized, double blind, placebo- controlled study  of the efficacy , safet y, 
and tolerability of three different doses of ponsegromab compared to matchin g placebo in 
patients with NSCL C, CRC ,or PAN C, receiving sta ndard of care (which may  includ e
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 43systemic therapy ), who have elevated levels of GDF -15 and cachexia. The double -blind 
period is followed b y an optional open -label extension period.
The Screening visit will occur no more than 28 days and no less than 7 days, prior to 
Randomization. The 7 -day minimum duration between Screening and Randomization visits 
will ensure that the G DF-15 results are available to inform the investigator’s assessment of 
eligibility  and the 7 -day collection of PRO and phy sical activity  data. Following the 
Screening period to confirm eligibility , approximately  168 study  participants, who meet the 
entry  criteria, will be randomized to study intervention (one of 3 dose groups of 
ponsegromab or matching placebo) and will be stratified by  treatment with or without 
platinum -based chemotherap y (see Appendix 12),which is known to induce GDF -15 and 
therefore may  impact the response to ponsegromab treatment. The 12
-week double -blind 
dosing period (Part A) will consist of a total of 3 doses administered Q4W SC.
A PK substudy  will be conducted in approximately  36 of the approximatel y 168 participants
(approximately  9 in each treatment group in Part A ). Up to 3 additional PKand PDsamples 
(two samples during Part A and one sample during Part B, if relevant), willbe collected in 
these participants at timepoints during the stud y outlined in Section s1.2 schema and 1.3 
SoA.
On completion of Part A, participants will have the opportunity  to enter an optional OLT 
perio d (Part B) consisting of ponsegromab 400 mg Q4W S C for up to 1 y ear. The 
investigator and participant must decide at the Week 8visit if they  wish to continue to the 
optional OL T period. 
Participants opting to continue to the OL T period will receive their first dose of open -label 
ponsegromab 400 mg at t he Week 12 visit, which is the last visit of the double -blind portion. 
Upon completion of the OLT period, there will be a follow
-up visit (Week 72) which is to 
occur 56 to 63 day s post last dose of study  intervention.
Participants who do not proceed with t he optional OL Tperiod are to complete the Week 12 
visit and a follow -up visit at Week 16. 
Additional follow -up may be conducted for safet y evaluation, at the discretion of the 
investigator.
The optional OLT period will continue as currently planned, unle ss the following factors 
develop in which case the open -label extension may be modified:
Upon completion of the double -blind portion, the final anal ysis shows a lack of 
efficacy  for the primary  endpoint and/or inadequate safet y and tolerability ;
A
n alternative method of study  intervention delivery  become available;
Alower dose of ponsegromab is shown to be efficacious; 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 44The sponsor decides to terminate the study /clinical development program. 
Participants may  withdraw from the optional OLT period at any time, for reasons 
such as the following:
The study  participant with draws consent or dies;
The study  participant experiences an AE attributable to study  intervention .
A change in stud y participant’s medical condition that, in the investigator’s 
judgmen t, makes it inappropriate to continue study  participation.
An independent oversight committee in the form of an IRC will monitor the safet y, efficacy
, 
and tolerability  of the study  participants and the study  conduct. There wi ll also be an 
Executive Steerin g Committee and an Operation Steering Committee .
Study  design aspects have been informed by  feedback obtained during the conduct of the 
ponsegromab Phase 1b studies to enhance recruitment, reduce participant dropout and reduce 
the likelihood of missing da ta.
4.2.Scientific Rationale for Study Design
The purpose of this stud y is to evaluate the efficacy, safet y, and tolerability  of ponsegromab, 
an inhibitor of GDF -15, compared to placebo, in patients with cancer, cachexia, and elevated 
concentrations of GDF- 15.
Elevated concentrations of circulating GDF- 15 have been reported in literature5,6,7in patients 
experiencing weight loss with a variet y of tumor types and a greater magnitude of ele vation 
was associated with worse survival. Biospecimens from healthy  adults10(n=739) and patients 
with cancer (from both external commercial biorepositories and an internal study ) were 
analyzed for GDF -15 concentrations. The cancer sample set contained 399NSCL C, 
116 pancreatic cancer, and 157 colorectal cancer patients. Analysis of both the cancer and 
healthy  sample sets using the Roche Elecs ys assay,10confirmed literature reported elevations 
in GDF -15concentrations in NSCL C, PANC , and CRC patients in comparison to healthy  
subjects (approximately  4-fold, 5- fold, and 4 -fold, respectivel y). An ad -hoc anal ysis of 
samples from NSCL C patients from an internal Pfizer study  demonstrated that higher 
GDF -15 concentrations were associated with a reduction in body  weight. These data were 
also used to determine the GDF -15 inclusion criteria for this st udyto be the 95thpercentile of 
GDF -15 concentrations reported in these healthy  subjects ( ≥1.5 ng/mL). 
In addition, published clinical data and internal animal model data suggest that 
administration of platinum therap y can induce increases in serum GDF -15 concentrations. 
Clinical literature and internal animal8model data also suggest that the nausea, emesis and 
anorexia observed with platinum therapy  may  be mediated, at least in part, by  platinum
induced- elevations in GDF -15. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 45Therefore, it is hy pothesized that cachexia in many  types of cancer, including NSCL C, 
PANC and CRC, is largely  mediated via GDF -15 and that suppression of GDF- 15 in these 
patients may  lead to improvement in serious aspects of cachexia such as anorexia leading to 
unintended weight loss, fatigue and impaired mobility . Furthermore, given the observations 
of GDF -15 elevation with platinum therapy ,patients receiving standard of care anti -tumor 
treatment that includes sy stemic platinum -based therap y, ma y be a specific population that 
could potentially  gather additional benefit from GDF -15 inhibition. Therefore, randomization 
will be stratified by  presence/absence of background platinum therapy  due to this association 
of platinum and GDF -15 levels.
The primary  endpoint is the change in body  weight from baseline. The study  will also assess 
secondary  and exploratory  endpoints including physical activity , safet y, fatigue, appetite , 
immunogenicit y, PK and PD.
Patient safet y will be monitored primarily  via clinical laboratory  tests, vital signs, ECG and 
adverse event monitoring . To supplement the standard clinical safet y laboratory tests 
assessed at this s tage of development, albumin and pre
-albumin will be included as measures 
of nutritional status. Additionally ,CT scans will be performed for evaluation of tumor 
burden by the investigator and measurement of the skel etal muscle are aand adipose tissue 
areaat the 3rdlumbar vertebral level by a central imaging laboratory .
Assessment of the impact of ponsegromab on other aspects of cachexia, such as anorexia, 
nausea, vomiting and fatigue, will be studied. These will be measured through the use of 
ePRO instruments administered to patients at home and during clinic visits. 
Another characteristic of cachexia is a decline in performance status with impairment in the 
patients’ ability  to carry  out desired activities. Assessment of the potential impact of 
ponsegromab on activity  measures (eg, gait speed, activity  time) via wearable digital sensors 
will be included in this study  to better understand the effects of PF- 06946860 on patient s’
physical function. 
Sparse unbound and total ponsegromab and GDF -15 concentrat ions will be measured in this 
study  to (1) characterize ponsegromab  PK in this population; (2) assess the range of baseline 
GDF -15 values and variability  in this population; (3) characterize the dose/ exposure -GDF -15 
response after ponsegromab treatment inthis population, and (4) evaluate GDF -15 
suppression effect on body  weight response . Participants enrolled in the PK substu dy will 
have additional PK and PD assessment sto enhance PK/PD characterization. As ponsegromab 
is a monoclonal antibody, immunogenicit y samples will be collected for the determination of 
ADA and NAb.
4.2.1. Patient 
Input Into Design
Previously  patients and caregivers were interviewed in order to better understand what 
symptoms are most bu
rdensome to patients and what might impact their decision to 
participate in a clinical study . All patients had cancer (prostate, non- small cell lung, 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 46colorectal or pancreatic cancer) and had experienced significant unintentional weight loss 
and other s ymptoms of cachexia. 
Patients and caregivers also provided input on the study  design which triggered incorporation 
of options to potentially  enhance patient participation and retention, and highlighted the 
following additional considerations which are anticip ated to be of value to patients: 
Decision to maintain a dosing frequency  that aligns with SOC treatment visits .
Option for home/tele -visits with phy sician or in -person phy sician appointments 
where feasible.
Confirmed the importance to patients of including the option to receive open -label 
treatment following double -blind period.
Patients emphasized the significance of having their overall experiences with the 
study  treatment heard b y the Sponsor. This led to the incorporation of phone 
interviews in order to facilitate a more holistic assessment. 
Highlighted the value of appropriate training, including to home HCPs, on 
important aspects of the disease and the potential social and ps ychological impact. 
4.2.2. Diversity of Study Population
Reasonable attem pts will be made to enroll participants that are representative of the patient 
population that will be treated with ponsegromab in clinical practice. The team will follow 
best practices for diverse study  population enrollment and retention. The following s trategies 
may be explored in support of diverse recruitment efforts:
Inclusion of diversity  questions into the Feasibility  Survey  and Pre -Trial 
Assessment to identify  sites with access to diverse patient populations .
Discussion with investigator sites ahe ad of selection to assess preparedness, 
mitigation strategies for reaching diversit y goals, and active inclusion .
Encouragement of investigator sites to complete the Investigator Site Recruitment 
Plan.
Provide investigator sites with site kit materials des igned for use with diverse 
patient populations.
Implement as needed targeted digital outreach to diverse patient groups .
Have proactive discussions with investigator sites throughout the enrollment 
period to assess and reevaluate site specific strategies as needed to best position 
each site for the most diverse representation enrollment outcomes .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 47Monitor diverse enrollment to identify  potential opportunities to include diverse 
populations.
4.2.3. Choice of Contraception/Barrier Requirements 
Studies to evaluate the developmental toxicity  of ponsegromab have not been conducted. 
However, based upon the calculated safet y margins, no contraception methods are required 
for male participants, and the use of a highl y effective method of contraception is required 
for fem ale participants (see Appendix 4 ).
4.2.4. Collection of Retained Research Samples
Retained Research Samples will be collected and stored for further anal yses which may , for 
example, provide greater understanding of th e study  intervention.
4.3.Justification for Dose
In the part A of this study , ponsegromab will be administered with 100, 200, or 
400mgQ4W SC for a total of 3 doses .The proposed doses were determined based on all 
relevant information obtained from nonclinical safety  studies andclinical data (including 
safet y, tolerabilit y, PK and PD )available . These clinical data included data from 2 completed 
studies in healthy  participants (C3651001 and C3651002, see IB), clinical data (including 
safet y, tolerabilit y, PK, and PD )from the 
phase 1 bstudy in cancer cachexia patients
(C3651009), and the expected duration of GDF -15 suppression, defined as the time it 
suppress GDF -15 to below the median observed in healthy  subjects 
(0.71 ng/mL).
The median baseline GDF- 15 in NSCL C, PANC , and CRC patients are expected to be 
approximately  3.02, 3.32, and 3.50 ng/mL, respectively , and the 95thpercentile are expected 
to be 8.69, 9.35, and 13.4 ng/mL, respectivel y.It is assumed that the composition of the 
cancer t ypes will be similar to that observed in study  C3651009, which is 4:4:3 for NSCL C, 
CRC
, and PANC , respectively. Based on preliminary  population PK/PD simulations, the 
proposed 100 mg Q4W SC dose is expected to suppress the unbo und GDF -15 concentration 
in ~64%, and ~28% of the assumed cancer cachexia patients for 2, and 4 weeks, respectivel y. 
The proposed 200 mg Q4W SC dose is expected to suppress the unbound GDF -15 
concentration in ~92%, and ~72% of the cancer cachexia patients for 2, and 4 weeks, 
respectivel y. The proposed high dose of 400 mg Q4W SC dose is expected to suppress the 
unbound GDF -15 concentration in >90% of 
the cancer cachexia patients for 4 weeks.
Based on these preliminary  PK/PD simulations, the predicted steady state total ponsegromab 
Cmax, AUC tau, and C avg, following 100, 200, and 400 mg Q4W SC doses , along with the 
corresponding safet y margins calculated using exposure data from the 6 -month toxicology  
study  in monkey s (SeeIB), and exposure multiples calculated using total exposure data 
following a single 300 mg SC dose to health y participants in study C3651001 are 
summarized in Table 3. The corresponding steady  state unbound ponsegromab exposures and 
exposure multiples calculated using unbound exposure data from study  C3651001, are 
summarized in Table 4.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 48Table 3. Summary of Predicted Steady State Total ponsegromab Exposures and 
Associated Safety Margins and Exposure Multiples Following Q4W SC
Doses
Dose
(mg, Q4W SC )Cmax
(µg/mL)AUC tau
(µg•day/m L)Cavg
(µg/mL)Safety MarginaExposure Multipleb
Cmax Cavg Cmax AUC tau
100 16.4 413 14.8 57 53 0.85 0.54
200 29.5 739 26.4 32 30 1.5 0.96
400 52.8 1302 46.5 18 17 2.7 1.7
a. Based on the predicted steady state total C maxand C avgfollowing Q4W SC doses of ponsegromab at 100, 200, and 
400mgrelative to the NOAEL total Cmax(934 µg/mL) and C avg(786 µg /mL) observed in the 6 -
month toxicology 
study in monkey (IB).
b. Based on the predicted steady state total C maxand AUC taufollowing Q4W SC doses of ponsegromab at 100, 200, 
and 400 mg relative to the total Cmax(19.2 µg /mL) , and AUC inf ( 766 µg•day /mL) observed following the 300 mg 
single SC dose from C3651001.
Table 4.Summary of Predicted Steady State Unbound ponsegromab Exposures 
and Associated Exposure Multiples Following Q4W SC Doses 
Dose 
(mg, Q4W SC)Cmax
(µg/mL)AUC tau
(µg•day/m L)Cavg
(µg/mL)Exposure Multiplea
Cmax AUC tau
100 3.14 51.9 1.85 0.15 0.08
200 11.5 238 8.50 0.55 0.38
400 32.1 726 25.9 1.5 1.1
a. Based on the predicted steady state unbound C maxand AUC taufollowing Q4WSCdoses of ponsegromab at 100, 
200, and 400 mg relative to the unbound C max(20.9 µg /mL)and AUC inf(632 µg•day /mL) observed following the 
300 mg single dose from study C3651001.
Given thesafety  margins, the observed safet y data in healthy  participants from studies 
C3651001 and C3651002, with up to ponsegromab 300 mg SC single doses , and the
observed safet y data in participants with cancer, cachexia or anorexia, and ele vated serum 
GDF -15 concentrations from studies C3651009 and C3651010 ,with repeated doses of
ponsegromab 200 mg SC Q3W , the proposed 100, 200, and 400 mg Q4W SC doses are 
expected to have an acceptable safet y and tolerability  profile. 
Upon completion of Part A, participants will have the opportunity  to enter an optional 
open -label treatment period (Part B) and receive the high dose of 400 mg Q4W SC as a 
no-regret approach until a lower efficacious dose is identified either at the interim anal ysis or 
the end of Part A.
4.4.End of Study Definition
The end of the stud y is defined as the date of the last v isit of the last participant in the study  
globall y.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 49A participant is considered to have completed the study  if they  have either completed Part A 
(including follow -up), or has completed Part A and has entered, and completed, the OL T
extension Part B, as des cribed in the SoA .
The PCD is the date of the last visit for Part A (Week 12,) for the last participant.
5.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate 
participant s are enrolled , including 
participants across diverse and representative racial and ethnic backgrounds. If a 
prescreening tool is utilized for stud y recruitment purposes, it will include collection of 
information that reflects the enrollment of a diverse participant pop ulation including, where 
permitted under local regulations, age, sex, race, and ethnicity . The following eligibility  
criteria are designed to select participant s for whom participation in the study  is considered 
appropriate. All relevant medical and nonmed ical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptio ns, 
is not permitted .
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1. P articipants aged ≥18 years (or the minimum age of consent if>18 in accordance 
with local regulations) at Screening who have signed informed consent . 
a.A female participant is eligible to participate if she is not pregnant or 
breastfeeding.
b.Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female 
(Section 10.4.2) participants.
Disease Characteristics:
2.Documented histologic or cy
tologic active diagnosis of NSCL C, PANC , or CRC and 
are currentl yreceivin g,or have completed ,SOC treatment for this cancer (which may  
include sy stemic therapy).
3.Cachexia defined b y Fearon criteria of weight loss as(See Section 8.1.1 for details if 
the partic ipant’s bod y weight is unavailable from medical record )
:
BMI <20 kg/m2with involuntary  weight loss of >2% within 6 months prior to 
Screening; 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 50or
involuntary  weight loss of >5% within 6 months prior to screening irrespective of 
BMI .
4.Serum GDF -15 concentration s of ≥1.5 ng/mL (as measured using the Investigational 
Use Onl y Roche Elecs ys GDF 15 assay )10at Screening.
5.Participants who are assessed by  the investigator to have:
an ECOG PS ≤3, and,
alife expectan cy of at least 4 months to be able to complete PartA.
Other Inclusion Criteria :
6.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, lifesty le considerations, and other study  procedures .
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Current active reversible causes of decreased food intake, as determined by  the 
Investigat or. These causes may  include, but are not limited to:
NCI CTCAE Grade 3 or 4 oral mucositis;
NCI CTCAE Grade 3 or 4 GI disorders (nausea, vomiting, diarrhea, and 
constipation);
Mechanical obstructions interfering with the participant’s ability  to eat. 
2.Receiving tube feedings or parenteral nutrition (either total or partial) at the time of 
Screening or Randomization .
3.Cachexia caused b y other reasons, as determined by the investigator, including, but 
not limited to: 
Severe COPD requiring use of home O2;
NYHA class III-IV heart failure;
AIDS.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 514. Undergoing major surgery  (central venous access placement and tumor biopsies are 
not considered major surgery ) within 4 weeks prior to randomization. Patient must 
have recovered from acute effects of surgery  prior to Screening. Patient should not 
have plans to undergo major surgical procedures during the stud y.
5.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  that may  increase the risk 
of study  participation or , in the investig ator’s judgment ,make the participant 
inappropriate for the study .
6.History  of allergic or anaphy lactic reaction to any  therapeutic or diagnostic 
monoclonal antibody  (IgG protein) or molecules made of components of monoclonal 
antibody . 
Prior/ Concurrent Therapy :
7.Current use of an y prohibited concomitant medication(s) within 4 weeks prior to first 
dose of study  intervention . Refer to Section 6.9.
Prior/Concurrent Clinical Study Experience:
8.Concurrent administration of investigational products (including drug, biologic 
agents, or vaccines) are not permitted withi n 30 days (or as determined b y the local 
requirement) or 5 half-lives (whichever is longer) of the first dose of study  
intervention . Refer to Section 6.9.
9.Enrollment and previously  dosed in a prior 
study  with ponsegromab.
Diagnostic Assessments:
10.History  of severe liver disease or cirrhosis ,unrelated to metastatic cancer .Potential 
study  participants with the following liver function test abnormalities will also be 
excluded; result may  be confirmed by  a single repeat test, if necessary : 
Total bilirubin ≥1.5 × ULN (except for Gilbert’s sy
ndrome) 
AST >3 × ULN (AST > 5X ULN if there is liver involvement by  the tumor) 
ALT >3 × ULN (ALT >5X ULN if there is liver involvement by  the tumor) 
Alkaline phosphatase >3 x ULN (Alkaline phosphatase >5X ULN if there is liver 
involvement by  the tumor and /or in case of bone metastases , or if considered 
related to prior surgery  e.g. pancreaticoduodenectomy ).
11.Renal disease requiring dialy sis. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 52Other Exclusion Criteria:
12.Current adherence to a calorie -restricted diet with the intention weight loss.
13.Investigator site staff directly  involved in the conduct of the study  and their family  
members, site staff otherwise supervised b y the investigator, and sponsor and sponsor 
delegate employ ees directly  involved in the conduct of the study  and their family  
members.
5.3.Lifestyle Considerations
5.3.1. Contraception 
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
from the permitted list of contraception methods (see Appendix 4 ,Section 10.4.4) and will 
confirm that the participant has been instructed in its consistent and correct use. At time 
points indicated in the SoA, the investigator or de signee will inform the participant of the 
need to use highly  effective contraception consistently  and correctly  and document the 
conversation and the participant’s affirmation in the participant’s chart .
Participants need to 
affirm their consistent and correct use of at least 1 of the selected methods of contraception,
considering that their risk for pregnancy  may  have changed since the last visit . 
In addition, the investigator or designee will instruct the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol-specified method, including if the participant will n o longer use abstinence 
as the selected contraception method, or if pregnancy is known or suspected in the participant 
or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subs equently enrolled in the study . A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minima l 
information includes demograph y, screen failure details, and an y SAE.
Individuals who qualify  for this study  but are not randomized for administrative reasons, may  
be rescreened. Individuals who do not meet the criteria for participation in this study  (screen 
failure) may  be rescreened once with sponsor notification if, in the judgement of the 
investigator, the reason for initial ineligibility  is considered to be resolved, or there has been 
a change in eligibility  status. 
For individuals who are rescreened for any  reason, all screening procedures must be 
repeated, unless discussed with, and agreed by ,theSponsor in advance, and the participant 
assigned a new SSID.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 536.STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY
Study  interventions are all prespecified investigational interventions, marketed products , 
placebo and medical devices, and other interventions (eg, surgical and behavioral) intended 
to be administered to the study participants during the study  conduct. 
For the purposes of this protocol, study  intervention refers to ponsegromab (PF-06946860, 
IMP) and placebo (IMP) .
6.1.Study Intervention(s) Administered
Intervention Name ponsegromab (PF- 06946860) placebo
Arm  Nam e
(group of participants receiving 
a specific treatm ent or no 
treatm ent)ponsegromab Double -Blind Treatment placebo Double- Blind 
Treatment 
Type biologic placebo
Unit Dose Strength(s) 100 mg/mL placebo
Dosage Level(s) 100 mg, 200 mg, and 400 mg Q4W Matching placebo Q4W
Route of Adm inistration SC SC
Use experimental experimental
IMP or NIMP/AxMP IMP IMP 
Sourcing provided centrally by the sponsor provided centrally by the 
sponsor
Packaging and Labeling Study intervention will be provided in 
6-mL glass vial with a 1 mL withdraw 
volume.  Each vial will be labeled as 
required per country requirement.Study intervention will be 
provided in 6 -mL glass vial 
with a 1 mL withdraw  volum e. 
Each vial will be labeled as 
required per country 
requirement.
Current/Former Name(s) or 
Alias(es)ponsegromab placebo 
6.1.1. Administration
Each dose of investigational product must be administered by  appropriatel y qualified health 
care personnel in a clinic setting. During the double blind portion (Part A) of the study , 
investigational product will be administered at a dose of 100 mg , 200 mg , 400 mg,or 
matching placebo Q4W SC for a total of 3 doses. On completion of Part A, participants will 
have the opportunit y to enter an optional OLT period (Part B) consisting of ponsegromab 
400mg Q4W SC for up to 1 y ear.For participants who are receivin g standard of care (which 
may include sy stemic therapy ), premedication is permitted consistent with institutional 
guidelines, and, may  include an antihistamine, anti-inflammatory agent, or pain reliever.  In 
such cases, ponse gromab is to be administered first, followed by  any required 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 54premedications. If the standard of care s ystemic antineoplastic treatment is to be 
administered on the same day  of dosing with study intervention (ponsegromab or matching 
placebo in Part A or ponsegroma bin Part B), where feasible, the study  intervention will be 
administered prior to the standard of care treatment. 
Study  intervention will be administered in a divided dose requiring 2 separate SC injections 
given in rapid succession every  4 weeks. The pe rmitted injection sites are the abdomen, 
upper arm (right or left) and the thigh (right or left). The following combination of injection 
sites are provided as examples:
Two injections in abdomen (each injection should be administered into a different 
quadrant and separated by  at least 3 cm)
One injection into each upper arm
One injection into each thigh
One injection in the arm (right or left) and one injection in the leg (right or left) or
One injection in arm or leg (left or right) and one in the abdom en. 
The injections can be rotated with each administration for participant comfort. If participants 
are receiving other, non -study  intervention injectable agents, those interventions should be 
administered in a quadrant different from where the study  intervention was administered. 
Additionally , areas with scarring, redness, tattoos, or other visible marks should be avoided.
Refer to the IP manual for additional detail s regarding the preparation, 
injection site 
administration, handling , storage and accounta bility .
6.2.Preparation , Handling , Storage , and Accountability
1.The investigator or designee must confirm that 
appropriate conditions 
(eg,temperature) have been maintained during transit for all study  intervention s
received and an y discrepancies are reported and resolved before use of the study  
intervention. 
2.Only  participants enrolled in the study  may  receive study  intervention and only  
authorized site staff may  supply , prepare, and/ or administer study  intervention . 
3.All study  intervention smust be stored in a secure, environmentally  controlled, and 
monitored (manual or automated recording ) area in accordance with the labeled 
storage conditions with access limited to the investigator and authorized site staff. At 
a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperatures since previousl y documented upon 
return to business.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 554. A ny excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with actions taken. The site should activel y 
pursue options for returning the stud y intervention to labeled storage conditions, as 
soon as possible. Once an excursion is identified, the study  intervention must be 
quarantined and not used until Pfizer provides permission to use the study  
intervention. Specific details regarding the excursion definition and information to
report for each excursion will be provided to the site in the I P Manual .
5.Any storage conditions stated in the SRSD will be superseded by  the storage 
conditions stated on the label.
6.Study  interventions should be stored in their original containers.
7.The investigator, institution, head of the medical institution (where applicable), or 
authorized site staff is responsible for study  intervention accountability , 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final 
disposition records) , such as the IPAL or sponsor -approved equivalent . All study  
intervention swill be accounted for using a study  intervention accountability  
form/record. 
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P Manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional pol icy, and any  special instructions 
provided b y Pfizer.
9.Upon identification of a product complaint, notify the sponsor w ithin 1 business day  
of discovery  as described in the I P
Manual .
6.2.1. Preparation and Dispensing
See the IP manual for instructions on how to prepare the stud y intervention for 
administration. Study  intervention should be prepared and dispensed by  an appropriatel y 
qualified and experienced member of the stud y staff (eg, ph ysician, nurse, phy sician’s 
assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as allowed by  
local, state, and institutional guidance. A second staff member will verify  the dispensing. 
6.3.Assignment to Study Intervention
All participants will be centrally  assigned to randomized study  intervention using a central 
randomization list. Allocation of participants to treatment groups will proceed through the 
use of an IRT s ystem. The site personnel (study  coordinator or specified designee) will be 
required to enter or select information including but not limited to the user’s I D and 
password, the protocol number, and the participant number. The site personnel will then be 
provided with a randomization number corresponding to the assigned treatment group , and 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 56DU or container number (s)when study  intervention is being supplied via the I RT s ystem. 
The I RT sy stem will provide a confirmation report containing the participant number, 
randomization number, and DU or container number assi gned. The confirmation report must 
be stored in the site’s files. 
Study  intervention will be dispensed at the stud y visits summarized in the SoA. 
The study -specific I RT reference manual and I PM will provide the contact information and 
further details on the use of the I RT sy stem.
6.4.Blinding
This is a double -blind study with blinding of ponsegromab versus placebo for each dose 
level .
6.4.1. Blinding of Participants
Participants will be blinded to their assigned stud y intervention.
6.4.2. Blinding of Site Personnel
Investigators and other site staff will be blinded to participants’ assigned study  intervention. 
In the event of a Qualit y Assurance audit, the auditor(s) will be allowed access to unblinded 
study  intervention records at the site(s) to v erify  that randomization/dispensing has been done 
accuratel y.
6.4.3. Blinding of the Sponsor
Sponsor staff will be blinded to participants’ assigned study  intervention, except for sponsor 
staff involved in the assignment or distribution of study  intervention.
6.4.4. Breaking the Blind 
The I RT will be programmed with blind -breaking instructions. I n case of an emergency , the 
investigator has the sole responsibility  for determining if unblinding of a participant’s 
treatment assignment is warranted. Participant safety must alway s be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every  effort to contact the study medical monitor prior to 
unblinding a participant’s treatment assignm ent unless this could delay  further management 
of the participant. If a participant’s treatment assignment is unblinded, the sponsor must be 
notified within 24 hours after breaking the blind. The date and reason that the blind was 
broken must be recorded in the source documentation and CR F.
The study -specific I RT reference manual and I PMwill provide the contact information and 
further details on the use of the I RT sy stem.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 576.5. Study Intervention Compliance
The study  intervention will be administered to particip ants directly  by an appropriatel y 
qualified individual. The date and time of each dose administered will be recorded in the 
source documents and recorded in the CRF. The dose of study  intervention and study  
participant identification will be confirmed at t he time of dosing b y designated healthcare 
personnel if the study intervention is administered at the participant’s home or a member of 
the study  site staff other than the person administering the study  intervention if the study  
intervention is administere d at the clinic. 
Deviation(s) from the protocol- specified dosage regimen should be recorded in the CRF .In 
exceptional circumstances and with agreement from the Sponsor, the study  intervention may  
be administered outside of the window for a given dosing v isit; in such circumstances, the 
rationale should be recorded in the CRF. 
A record of the number of the study  intervention (ponsegromab or placebo vials) 
administered to each participant must be maintained and reconciled with study  intervention
and compliance records. Intervention start and stop dates, including dates for intervention 
delay s and/or missed doses, will also be recorded in the CRF.
6.6.Dose Modification 
There is no dose modification of study intervention anticipated for a given partic ipant in this 
study .
6.7.Continued Access 
toStudy Intervention A fter the End of the Study
The study  design includes an optional open -label treatment period for up to 1 y ear(Part B) as 
described in Section 4.1. An expanded access program may be available after the open label 
treatment period.
6.8.Treatment of Overdose
Given the allowed visit window, an overdose will be defined as more than 2 doses of 
ponsegromab 400 mg administered in a period of 4weeks , eg,any dose of ponsegromab 
greater than 900 mg within a 4 -week period will be considered an overdose.
There is no specific treatment for an overdose.
In the event of an overdose, the investigator/treating ph ysician should:
1.Contact the study medical monitor within 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities as 
medically  appropriate for at least 5 half -lives or 28 calendar day s after the overdose 
of ponsegromab (whichever is longer). The duration of monitoring required will be 
provided b y the sponsor.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 583.Document the quantit y of the excess dose as well as the duration of the ove rdose in 
the CRF.
4. Overdose is reportable to Pfizer Safety  only when associated with an SAE .
5.Obtain a blood sample for PK anal ysis within 5-7days from the date of the last dose 
of study  intervention if requested by  the 
study  medical monitor (determined on a 
case-by-case basis). 
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the study  medical monitor as needed based on the clinical evaluation of the 
participant. 
6.9.Prior and Concomitant Therapy
Details on all concomitant treatment (including antitumor treatments and steroid usage )will 
be determined from participant and/or medical records, at each visit from Screening until the 
end of study  visit and will be recorded on the CRF .Investigators should specify  reasons for 
modifications to or discontinuations of prescribed antitumor treatments. At the S creening 
visit and each clinic visit , details of previous and current treatment with a platinum -based
therap y
will be determined from participant and/ or medical records . The information will be 
recorded on the CRF at each visit . Specificall y at the Screening visit, current treatment with 
or without platinum -based chemotherap y will be utilized for stratif ication of study  
participants who meet the entry  criteria at the Randomization visit. ( seeAppendix 12)
6.9.1. Prohibited During the Study
Initiation of new treatment with sy stemic glucocorticoids within the 4 weeks prior 
to the first dose of study  intervention through Week 16
; Stable (ie, no significant 
change to dosage or frequency  of administration in prior 4 weeks) steroid therap y 
eg, dexamethasone as part of pre- medication or daily  oral prednisone is 
permissible. I nitiation of steroid therapy  following randomization (eg ,  for 
management of immune -
related AEs that occur as a consequence of 
immunotherapy ) may  be permitted following discussion with Sponsor
Concurrent administration of anamorelin hydrochloride isnot permitted within 
30days prior to first dose of study  interve ntion through Week 16.
Concurrent administration ofmegestrol acetate, olanzapine, cannabinoids , or 
mirtazapine, if prescribed for purpose of increasing appetite/body  weight , are not 
permitted within 30 day s prior to first dose of study  intervention throug h Week 
16. Use of these medications on a short -term, as required basis, for management 
of sy mptoms (eg ,chemotherap y-induced nausea and vomiting) is permitted.
Concurrent administration of a GLP -1 receptor agonist -based therap y (eg,
semaglutide, liraglutide, tirzepatide), if prescribed specificall y to promote weight 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 59loss, is not permitted within 30 day s prior to first dose of study  intervention 
through Week 16. Use of such therapies for indication of diabetes mellitus is 
permitted.
Investigational produc ts (including drug, biologic agents, or vaccines) are not 
permitted within 30 day s (or as determined by  the local requirement) or 
5half-lives (whichever is longer) of the first dose of study  intervention through 
the duration of the stud y (including both P art A and B).
6.9.2. Permitted During the Study
Hormonal contraceptives that meet the requirements of this study  are allowed to 
be used in participants who are WOCBP (see Appendix 4 ).
All standard of care (which may  include s ystemic therapy )including required 
premedications (see Section 6.1.1).
Background biologics are permitte d as indicated by  the label (not contra -indicated 
for combination with an investigational mAb).
Participants in this study  will be allowed to be on concomitant medications that have been 
prescribed according to their label and monitored as per local standard of care. 
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study
 intervention may include the following :
Progression of underl ying disease such that t he investigator no longer considers 
participation appropriate, or of potential benefit to the participant.
Hospitalization that in the opinion of the investigator would render continued 
participation unfeasible.
If a participant experiences Grade 3 AEs jud ged by the Investigator as related to 
randomized study  intervention, the study  intervention will be temporarily  
discontinued until the treatment -
related AE s return to Grade 2 (or less). If the 
treatment -related AEs return to Grade 2 (or less) or resolve wi thin 4 weeks, 
continuation of dosing with study  intervention may  be considered. If these A Es do 
not return to Grade 2 (or less) within 4 weeks, and after discussion with the 
sponsor, the participant will be permanentl y discontinued from the study 
intervent ion. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 60If a participant experiences Grade 4 A Es judged by  the Investigator as related to 
randomized study  intervention, the participant will be permanently  discontinued 
from the study  intervention .
Severe allergic reaction to study  intervention.
Intent to become pregnant or pregnancy  confirmed by  b-hCG testing.
Drug -induced l iver injury  as described in Section 10.6, Appendix 6.
Note that discontinuation of study  intervention does not represent withdrawal from the stud y.
If study  intervention is permanentl y
discontinued, the participant should remain in the study  
to be evaluated for follow up .All cases of 
planned or potential discontinuation of study  
intervention should be discussed with Sponsor before classify ing a subject as ‘Discontinued 
from Study  Intervention’ and completing an Early Termination visit .See the SoA for data to 
be collected at the time of discontinuation of study intervention and follow -up for an y further 
evaluations that need to be completed.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt of stud y intervention or also from study  procedures, posttreatment study  follow -up, 
and/or future collection of additional information. Follow -Up:
Participants will undergo review of concomitant treatments, vital signs, and assessment for 
resolution of an y treatment -related AEs through approximately  56 day s following 
discontinuation of study  interventio n. Participants continuing to experience AEs at this point 
following discontinuation of treatment will continue to be followed at least every  4weeks 
until resolution or determination, in the clinical judgment of the investigator, that no further 
improveme nt is expected. If the unresolved AE is considered b y the investigator as possibly 
related to or associated with ADA formation, the participant will be asked to return for drug 
concentration and ADA blood sampling at up to 3 -month intervals, until the last follow -up of 
the AE.
7.1.1. COVID -
19
If a participant has COVID -19 during the study , this should be reported as an AE or SAE (as 
appropriate) and appropriate medical intervention provided. Study  treatment should continue 
unless the investigator/treating ph ysician is concerned about the safet y of the participant, in 
which case temporary  or permanent discontinuation may  be required. 
It is recommended that the investigator discuss temporary  or permanent discontinuation of 
study  intervention with the study  medical monitor. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 617.2. Participant Discontinu ation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at theirown request . Reasons for 
discontinuation from the study  include the following :
Participant r efused further follow-up;
Lost to follow -up;
Death;
Study  terminated by  sponsor.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted
.See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and f or any  further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely  withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.
If a participant withdraws from the study , they may request destruction of any  remaining 
samples taken and not tested
,andthe investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the pa rticipant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use an y data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with them or persons previously  authorized by  the participant to provide this information. 
Participant s should notify  the investigator in writing of the decision to withdraw consent 
from future follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by  the investi gator, as to whether the withdrawal is only  from 
further receipt of study  intervention or also from study  procedures and/or posttreatment study  
follow -up, and entered on the appropriate CRF page. In the event that vital status (whether 
the participant is alive or dead) is being measured, publicly  available information should be 
used to determine vital status only  as appropriately  directed in accordance with local law.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 627.3.Lost to Fol low-Up 
To prevent participants being lost to follow- up, their contact details, including next of kin 
contacts should be collected initially, if permit ted, and updated regularl y by the site staff or 
representative. The Investigator should educate the participant on the importance of contact 
with the I nvestigator throughout the study . Repeated attempts will be made to locate and 
obtain pertinent medical information for participants who are potentiall y lost to follow up.
If a participant fails to return to the clinic for /attend a required study  visit the site must 
attempt to contact the participant and reschedule the missed visit as soon as possible , counsel 
the participant on the importance of maintaining the assigned visit schedule ,and ascertain 
whether the participant wishes to and/or should continue in the study .
Where permissible b ylocal regulations , the ICD will include language to grant the option to 
employ  patient locator agencies to assist in obtaining updated contact information or 
ascertainment of vital status of lost participants using publicl y available source.
A participant will be classified as lost to follow up only  if they  havefailed to return for the 
required stud y visits and 
their visitstatus remains unknown despite multiple attempts to 
contact them via telephone, fax, email, certified letter or through patient locato r agencies (if 
allowed b y local regulation s).These contact attempts should be documented in the 
participant’s medical record. The participant will then be considere dlost to follow -up and 
discontinuation of study  will be documented in source data and CRF as the date of last 
contact .
8.STUDY ASSESSMENTS AND PROCEDURES
8.1.Administrative Procedures
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing any  study -specific procedures.
Study  proced ures and their timing are summarized in the SoA.Protocol waivers or 
exemptions are not allowed.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study  conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligi bility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the investigator that make it unfeasible to perform the 
test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 63well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manne r.
Safety /laboratory /anal yte results that have been collected for the purposes of this study  and 
could unblind the study  will not be reported to investigative sites or other blinded personnel 
until the study  has been unblinded.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for each part of the study  is estimated as follows for 
individual participant s:
Part A , where participants arenot enrolled in the PK substudy = 145 m L
Part A , where participants are enrolled in thePKsubstudy  = 165 mL
Optional Part B, where participants are not enrolled in the PK substudy  = 125 m L
Optional Part B. where participants are enrolled in the PK substudy  = 135 mL
The actual collection times of blood sampling may change. Additional blood samples may  be 
taken for safet y assessments at times specified b y Pfizer, provided the total volume t aken 
during the stud y does not exceed 550 mL during any  period of 56 consecutive day s.In 
addition, if a participant has an unplanned site visit for any  reason (chemotherap y, radiology, 
other doctor appointment s, etc.), collect an unplanned PK and GDF-15 sample during this 
visit, if feasible, provided the total volume taken during the stud y does not exceed 550 mL 
during an y period of 56 consecutive day s.
8.1.1. Screening Visit
The Screening visit will occur no more than 28 days and no less than 7 days, prior to 
Randomization. The 7 -day minimum duration between Screening and Randomization visits 
will ensure that the GDF- 15 results and the 7- day collection of PRO and phy sical activity  
data are available to inform the investigator’s assessment of eligibility .
At the S creening visit only, t he evaluation of the Fearon Criteria eligibility  criteria is to be 
assessed using the participant’s body  weight from their medical record.  I f the participant’s 
body  weight is unavailable from medical record, the partic ipant’s weight is to be captured 
utilizing question 1 of the PG -SGA questionnaire .11
8.1.2. Week 5 Visit
The Week 5 visit is considered a n optional visit to collect PK and GDF -15 sample sas well as 
measurement of weight and SAE/AE monitoring based upon participant avai lability . It will 
not be considered a protocol deviation if the participant is unable to make this visit .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 648.1.3. Additional Visits for PK Substudy
Participants enrolled in the PK substudy  will have an additional visit ,as per SoA ,atWeek 9 
and Week 11 in Part A , and one flexible visit i n Part B that can occur 1, 2 or 3 weeks 
following an y dose after or including the W eek 20 dose. The purpose of these additional PK 
visits is to obtain blood sample sfor PK and PD assessment .  These visits may be performed 
at the participant’s home rather than at the study  site if feasible and permitted by  country , 
study  site, and participant.
8.1.4. Home Health Visits
A home health care service /phlebotomist may beutilized to facilitate the Week 5 , Week 9 
(PK substudy  only), Week 10,and Week 11 (PK substudy  only)visits . Home health visits 
include a healthcare provider conducting an in -person study  visit at the participant’s location, 
rather than an in -person study  visit at the site. The following may  be performed during a 
home heal th visit (see the SoA):
PKand PDsample collection .
Note: Bod y weight does not need to be obtained if the visit is conducted offsite.
8.1.5. Transportation
Transportation to and from the study  site may  be provided for stud y participants for Part A 
visits, as permitted by  the country , study  site and participant.
8.2.Efficacy Assessments
8.2.1. Body Weight
Bodyweight will be measured in duplicate as indicated in the SoA. The second weight 
measurement should be obtained at least 1-2 minutes apart from the first measurement. 
Weight will be recor dedusing a calibrated scale (with the same scale used if possible for the 
duration of the study )
report ingweight in kg, and accuracy to the nearest 0.1 kg; ie, the 
device must be able to distinguish a difference between 68.4 kg versus 68.3 kg. The scale 
must be placed on a stable, flat surface. Body weight does not need to be obtained if the visit 
is conducted offsite.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 65Weight measurements should be taken under the following conditions, whe re feasible:
After void of urine;
After removal of shoes, socks, bulky  layers of clothing and jackets so that only  
light clothing remains; 
While remaining still during the measurement.
8.2.2. Patient Reported Outcomes
Patient Reported Outcom e 
(PRO) Measure Frequency Completion 
locationNumber of 
QuestionsCompletion 
Time
FAACT Baseline, Week 4, Week 8, 
Week 12 or EDPart AAt clinic 39 ~15 minutes
PGI-S of appetite , fatigue ,and 
physical functionBaseline, Week 4, Week 8, 
Week 12 or EDPart AAt clinic 3
PGI-C of appetite , fatigue ,and 
physical functionWeek 4, Week 8, Week 12 or ED
Part AAt clinic 3
PROMIS -Fatigue 7a (“Past 7 days” 
recall version)Baseline, Week 4, Week 8, 
Week 12 or ED Part AAt clinic 7
PROMIS -Physical Function 8c 
(norecall version)Baseline, Week 4, Week 8, 
Week 12 or EDPart AAt clinic 8
Cancer -Related Cachexia Symptom 
Diary 2.0
(appetite, fatigue, nausea, and 
vomiting)Daily including the Screening 
period (minimum of 
7consecutive days) to Week 12
or ED Part AAt home 4 ~2 minutes
Qualitative Exit Interview Week 12 or EDPart A Via phone N/A Up to 60
minutes
PGI- S of physical activity and 
walkingAt the end of the 7 -day 
consecutive monitoring 
period /wearing the digital 
sensors for Screening (at home) , 
Week 8 (approximately Day 63 
at home ), Week 10 
(approximately Day 77 at home ), 
at Week 12 ( approximately Day 
85at the clinic ) or ED Part AAt home/in 
clinic2 ~2 minutes
PGI-C of physical activity and 
walkingAt the end of the 7 -day 
consecutive monitoring period
forWeek 8 (approximately Day 
63 at home ), Week 10 
(approximately Day 7 7 at home ) 
and at Week 12 (approximately 
Day 85at the clinic ), or ED 
Part AAt home/in 
clinic2 ~2 minutes
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 66All PRO assessments , with the exception of the E xit Qualitative I nterview, are implemented 
using a sponsor -provided ePRO device and completed b y study participants at home 
(handheld device), or at the clinic (tablet), as per the SoA. 
Every  effort should be made to have the study  participant complete all PRO assessments as 
per the SoA . Site -based PRO assessments should be completed by  the participant at the 
beginning of the visit before an y medical procedures or i nteractions with the medical staff (as 
much as practicall y possible) take place.
Additional details are provided in the ePRO/eCOA User Manual
8.2.2.1. Functional Assessment of Anorexia- Cachexia Therapy (FAACT)
TheFAACT combines the FACT- G core instrument and ACS . 
FACT -G is a summated score of 27 items pertaining to phy sical well -being (7 items), 
emotional well-being (6 items), functional well- being (7 items), and social well being 
(7items) in the past 7 day s. Each of the items uses a 5- point (0 to 4) scale. ACS i s a 12 item 
summated scale containing items specific to patients’ perceptions of appetite and weight, also 
using the 5 point scale. Adding the 12 ACS items to the FACT- G produces the 39 item 
FAACT . Higher scores are associated with a higher health- related quality  of life. For 
additional details regarding scoring refer to FACIT User’s Manual.
8.2.2.2. Patient’s Global Impression of Severity (PGI -S)of Appetite , Fatigue ,and 
Physical Function
The PGI -S consists of 3questions that ask the study  participants to evaluat e the severity  of 
their appetite loss
, fatigue ,and ph ysical function over the past 7 day s,on a 5 -point verbal 
response scale that ranges from “None” to “Very severe”.
The PGI -S is recommended by  FDA for use as an anchor measure to generate an appropriate 
threshold that represents meaningful within individual change in the target patient 
population.
8.2.2.3. Patient’s Global Impression of Change (PGI- C)of Appetite , Fatigue ,and 
Physical Function
The PGI -C consists of 3 questions that ask the study  parti cipants to rate the overall change in 
their level of appetite
, fatigue ,and ph ysical function since they  started taking the study  
intervention on a 5-point verbal rating scale that ranges from “Much better” to “Much 
worse”. 
The PGI -C is recommended by  FDA for use as an anchor measure to generate an appropriate 
threshold that represents meaningful within -individual change in the target patient 
population.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 678.2.2.4. PROMIS –Fatigue (version 7a)
The PROMI S Fatigue 7a is a self -reported measure that assesses a range of symptoms in the 
past 7 days from mild subjective feelings of tiredness to an overwhelming, debilitating, and 
sustained sense of exhaustion that likely  decreases one’s ability  to execute daily  activities 
and function normall y in family  or social roles.
Theshort form 7A consists of 7 items that study  participants will rate from 1: “Never” to 5: 
“Alway s”. A global raw score ranging from 7 to 35 is calculated and can be translated into a 
T score (Mean = 50, standard deviation (SD) = 10) using the applicable s core conversion 
table provided in the PROMI S User’s Manual.
8.2.2.5. PROMIS –Physical Function (version 8c)
The PROMI S Phy sical Function short form 8C is a self -reported 8 item measure that assesses 
capability  rather than actual performance of phy sical activities. It includes the functioning of 
one’s upper extremities (dexterity) and lower extremities (walking and mobility ), as well as 
instrumental activities of daily  living. A single Phy sical Function capability  score is obtained 
from a short form. A global raw sc ore ranging from 8 to 40 is calculated and can be 
translated into a T score (Mean = 50, SD = 10) using the applicable score conversion table 
provided in the PROMIS User’s Manual.
8.2.2.6. Cancer -Related Cachexia Symptom Diary 2.0
The CRCSD is a daily , self -reported questionnaire that measures severit y of sy mptoms 
related to cancer cachexia: appetite, nausea, vomiting, and fatigue. It was developed based on 
qualitative research with patients as well as review of literature and other existing relevant 
measures. The me asure consists of 4 questions that ask study  participants to rate the severit y 
of their s ymptoms over the past 24 hours on an 11 point NRS.
8.2.2.7. Qualitative Exit Interviews
Qualitative exit interviews with a selected group of English -speaking participants (up to 40) 
at selected sites will be conducted b y telephone at the end of Part A, as indicated in the SoA. 
The interviews will be conducted b y trained moderators, that are not part of study  site staff, 
will be audio recorded and transcribed, and are anticipated to be approximately  60minutes in 
duration. 
The transcripts and interviewer field notes will be used to examine changes in sy mptoms and 
impacts experienced over the period of stud y duration, to describe treatment experience, and 
the importance of an y improvement reported b y the study  participants. Following the 
analysis of the qualitative data, a summary  report that describes the stud y objectives , 
methods, participants, and results of the qualitative interviews will be reported separatel y 
from the CSR.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 688.2.2.8. Patient’s Global Impression of Severity (PGI -S) of Physical Activity and 
Walking
The PGI -S of phy sical activity  and walking consists of 2 questions that ask the study  
participants to evaluate the severit y of limitations of physical activit y and walking over the 
past 7 day s, on a 5- point verbal response scale that ranges from “None” to “Very  severe”. 
The PGI -S is to be administered at the end of the 7- day monito ring period for Screening
(+1) (at home) , Week 8 (approximately  Day 63 +1 at home ), Week 10 ( approximately  
Day77 +1 at home ), and at the Week 12 visit (approximately  Day 85at the clinic ) .
8.2.2.9. Patient’s Global Impression of Change (PGI- C) of Physical Activity and 
Walking 
The PGI -C of phy sical activity  and walking consists of 2 questions that ask the study  
participants to rate the overall change in their level of physical activit y and walking since 
they started taking the study  intervention on a 5 -point verbal rating scale that ranges from 
“Much better” to “Much worse”. The PGI -C is to be administered at the end of the 7- day 
monitoring period for Week 8 (approximately  Day 63 +1 at home ), Week 10 
(approximately  Day 77 +1 at home) and at the W eek 12 visit (approximately  Day 85at the 
clinic ).
8.2.3. Phys ical Activity
Monitoring of ph ysical activity andgait via accelerometry  (wearable digital sensors) will be 
conducted in participants during the following 3 periods : Screening (with a target of at least 
1consecutive week of monitoring prior to first dose of IP), Week 8 (from Week 8 to W eek9)
and from Week 10 to Week 12 . The digital sensors will be worn continuously  for one week 
during Screening and Week 8; and will be worn continuously  for two weeks between
Week 10 and Week 12.
Placement of the sensors: one sensor will be placed on the lumbar region and one sensor will 
be placed on the non -dominant wrist. Participants will be asked to we ar the sensor on the 
wrist continuously (approximately  24/day ; can remove for short periods of time as needed). 
thesensor worn on the lumbar only  needs to be worn while a wakeduring the monitoring
periods .
The participant is able to remove the activity  monitor s for charging or other activities without 
it being considered a protocol deviation. Please refer to the activit y monitoring manual for 
detailed instructions.
8.2.3.1. Comfort and Wearability Questionnaire for Digital Measures
To measure comfort and wearability  of the wearable digital sensors, the participant will be 
asked to complete a Comfort and Wearabili ty Questionnaire at Week 12or at Earl y 
discontinuation visit. Data will be captured on the CRF. See Appendix 9 .
The Digital Sensors technical training guide will be provided separatel y.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 698.3.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled safet y 
measurements may  be obtained at any  time during the study  to assess any  perceived safety  
issues.
Although not observed so far with ponsegromab, injection site reactions and delay ed 
hypersensitivity  reactions are theoretically possible in response to injected monoclonal 
antibodies. Participants should be monitored after receiving injections for clinical signs of 
systemic immune reactions, and any  such reactions assessed and reported as part of standard 
safet y/AE monitoring, inc luding adverse events that are manifestations of injection site 
reactions. Additional assessments may be conducted at investigator discretion and/or until 
any symptoms resolve. If deemed appropriate b y the investigator, a consultation with a 
dermatologist may be performed. Documentation of a reaction may  include items such as 
investigator notes, photographs, dermatologist report and/or clinic notes. As part of the safet y 
analysis, any  cases of potential anaphy laxis will be assessed b y the sponsor against th e 
Sampson criteria .12
8.3.1. Physical Examinations
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regulation.
A full phy sical examination will include, at a minimum, head , ears, ey es, nose, mouth, skin, 
heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. Height and weight will also be measured and recorded . Height will be 
measured at Screening only , in cm and accuracy  to the nearest 0.1 cm.Body  weight will be 
measured in duplicate at each visit, in kg, and accuracy  to the nearest 0.1 kg. Please refer to 
Section
8.2.1 for additional details regarding collection of body  weight.
An abbreviated ph ysical examination will be focused on general appearance, the respiratory  
and cardiovascular s ystems, and subject -reported sy mptoms.
Physical examination s (full and abbreviated) will be conducted as detailed in the SoA, 
however full exams may  be performed for findings during previous exam, new/open AEs, or 
at investigator discretion. 
All phy sical exams (full and a bbreviated) will include an assessment for ascites and/or 
edema. In addition, a scites and/or edema will be captured as an AE on the AE CRF.
Investigators should pay  special attention to clinical signs related to previous serious 
illnesses.
Physical examin
ation findings collected during the study  will be considered source data and 
will not be required to be reported , unless otherwise noted. Any  untoward phy sical 
examination findings that are identified during the active collection period and meet the 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 70definition of an AE or SAE (Appendix 3 ) must be reported according to the processes in 
Sections 8.4.1 to 8.4.3 .
8.3.2. Eastern Cooperative Oncology Group (ECOG) Performance Status
The assessment of 
ECOG performance status may  be conducted by  a phy sician, trained 
physician's assistant, or nurse practitioner as acceptable according to local regulation. See 
Appendix 10.
8.3.3. Vital Signs
Any untoward vital sign findings t
hat are identified during the active collection period and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Sections 8.4.1 to 8.4.3.
8.3.3.1. Blood Pressu re and Pulse Rate
B
Pand PRmeasurements will be assessed with a completely  automated device. Manual 
techniques will be used only  if an automated device is not available.
Single BP and PRmeasurements should be preceded by  at least 5 minutes of rest with the 
participant in a supine position, in a quiet setting without distractions (eg, television, cell 
phones) and the results recorded in the CRF .
Vital signs will be taken before collection for laboratory tests, if feasible, but it would not be 
considered a protocol deviation ifcollected after laboratory  tests.  .
8.3.4. Electrocardiograms
A single s tandard 12-l ead ECGs utilizing limb leads (with a 10-second rhy thm strip) should 
be collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the 
HRand measures PR interval , QT interval , QTc F,and QRS 
complex .At all visits, a single standard 12 -lead ECG will be collected.
If the site does not have an ECG machine that performs automated calculations, the 
investigator is permitted to calculate the standard intervals.
ECG values of potential clinical concern are listed in Appendix 8.
8.3.5. Clinical Safety Laboratory Assessments
All laboratory  samples are to be sent to the central lab.
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the S
oAfor 
the timing and frequency. All protocol -required laboratory  assessments, as defined in 
Appendix 2, must be conducted in accordance with the laboratory  manual and the SoA.
Unscheduled clinical laboratory  measurements may  be obtained at any time during the study 
to assess an y perceived safet y issues
.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 71The investigator must review the laboratory  report, document this review, and record any  
clinically  significant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  test findings are those thatare not associated with 
the underl ying disease, unless judged by  the investigator to be more severe than expected for 
the participant's condition.
All laboratory  tests with values considered clinically  significant and abnormal during 
participation in the study  or within up to the time of the final planned follow- up visit after the 
last dose of study  intervention should be repeated until the values return to normal or 
baseline or are no longer considered clinically  significant by  the investigator or study  
medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investi gator, the etiology  should be identified and the sponsor notified.
See Appendix 6 for suggested actions and follow -up assessments in the event of potential 
DILI .
See Appendix 7 for instructions for laboratory  testing to monitor kidney  function and 
reporting laboratory  test abnormalities.
8.3.6. Pregnancy Testing 
A serum pregnancy  test is only required at Screening and will be sent to the central lab . 
Following 
Screening , pregnancy  tests may be urine or serum tests, andmust have a 
sensitivity  of at least 25 mIU/mL. Pregnancy  tests will be performed in WOCBP at the times 
listed in the SoA. Following a negative pregnancy test result at Screening, appropriate 
contra ception must be commenced and a second negative pregnancy  test result will be 
required at the baseline visit prior tothe participant ’sreceiving the study  intervention .
Pregnancy  tests will also be done whenever 1 menstrual cy cle is missed during the acti ve 
treatment period (or when potential pregnancy is otherwise suspected) and at the end of the 
study . Pregnancy  tests may  also be repeated if requested by  IRBs/ECs or if required b y local 
regulations. For urine samples collected after the screening visit, the urine sample should be 
tested at the site facility  and results are to be confirmed negative and recorded in the 
database. Pregnancy  test results must be reviewed and confirmed as negative in order to 
continue dosing with study intervention .
8.3.7. Imaging Ass essment -CT Scan
8.3.7.1. Imaging Safety Assessment
CT scans will be acquired during the study  to monitor the tumor burden. All CT scans will 
need to include chest, abdomen, and pelvis to be acceptable for this study .
If SOC CT scan with chest , abdomen, and pelvis was performed within 3 weeks prior to the 
Screening the visit , then a CT scan at S creening is not needed. If a SOC CT scan is being 
performed at the Week 12 visit, between Weeks 10 -12 or within 7 day s after the Week 12 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 72visit as part of SOC, then an additio nal CT scan is not needed. Similarly , if SOC CT scan is  
performed 2 weeks prior or 7 day s after the E Dvisit, then an additional CT scan is not 
needed.
Monitoring of the tumor burden will be performed by  the site following standard 
RECI ST1.1 criteria (ou tlined in Appendix 11). The RECIST 1.1 categorization is to be 
entered in the CRF after each scan.
All follow up testing and final diagnosis will be left to the discretion of the medical 
professionals at the site or those with an existing phy sician participant relationship. The PI  
will be responsible for reporting an y AEs identified from incidental findings as described in 
the AE reporting section. 
8.3.7.2. Imaging Efficacy Assessment
CT scans are to include the chest, abdomen and pelvis . All CT scans will be collected for the 
RECI ST assessment by the study  site. The CT scans will then need to be submitted to a 
central imaging vendor for the measurement of body  compos ition. Thecentral imaging 
assessments will be performed solely  for the analysis of the skeletal muscle area and adipose 
tissue areas at the 3rdlumbar vertebral level. Additional exploratory body  composition 
measurements may be performed , but may  not be reported in the CSR .The analysesfrom the 
central review of the CT scans for bod y composition will not be shared with the site or study  
participant . The c entral imaging laboratory  will not be performing a clinical assessment of 
the images and no incidental findings will be shared with the principal investigator, site staff 
or participant. All medical reviews of CT scan images will be the sole responsibility  of the 
site staff.
Instructions for central image upload will be provided in a separ ate manual. I n addition to 
submitting all CT scans to a central repository , sites will still be required to save a ll 
participants’ radiologic images for source verification and for potential questions. 
8.4.Adverse Events ,Serious Adverse Events , and Other Saf ety Reporting
The definitions of an AE andanSAE can be found in Appendix 3 .
AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or, when appropriate, b y a caregiver, sur rogate, or the participant's legall y 
authorized representative), or they  may  arise from clinical findings of the i nvestigator or 
other healthcare providers (clinical signs, test results, etc).
The investigator and an y qualified designees are responsible fo r detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  intervention (see Section 7.1). 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 73During the active collection period as described in Section 8.4.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.4.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before undergoing an y stud y-related procedure and/or receiving study  
intervention , through and including a minimum of the time of the final planned follow -up 
visit,except as indicated below ,after the last administration of the study  intervention .
Follow -up by  the investigator continues throughout the active collection period and until the 
AE or SAE or its sequelae resolve or stabilize at a level acceptable to the investigator.
When a clinically  important AE remains ongoing at the end of the active collection period, 
follow -up by  the invest igator continues until the AE or SAE or its sequelae resolve or 
stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently discontinues or temporaril y discontinues study intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE safter the 
participant has concluded study  participation. However, if the investigator learns of an y SAE, 
including a death, at an y time after a participant has completed the study , and they consider 
the event to be reasonably related to the stud y interven
tion, the investigator must promptly  
report the SAE to Pfizer using the CT SAE Report Form .
8.4.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.4.1 are reported to Pfizer Safety  on the CT SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24hours of it s
being available.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 748.4.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant d uring the active collection period , 
which 
begins after obtaining informed consent as described in Section 8.4.1 , will be recorded 
on the AE section of the CRF.
The investigator is to reco rd on the CRF all directly
 observed and all spontaneously  reported 
AEs and SAEs reported by  the participant.
As part of ongoing safet y reviews conducted b y the sponsor, an y nonserious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE. To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.4.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when det ecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.4.3. Follow -Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follo w each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is provided in Appendix 3 .
8.4.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 75sponsor will co mply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRB s/ECs, and investigators.
Investigator safety  reports must be prepared for SUSAR saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives SUSAR sor other specific safety information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD (s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.4.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person n ot enrolled in the study as a participant 
receives unplanned direct contact with or exposure to the study  intervention. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed . An 
environmental exp osure may include EDP, EDB , and occupational exposure.
Any such exposure s to the study  interventio nunder study  are reportable to Pfizer Safety  
within 24 hours of investigator awarene ss.
8.4.5.1. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be pregnant while receiving or after discontinuing 
study  intervention .
A male participant who is receiving or has discontinued study  intervention 
inseminates a female partner .
A female 
nonparticipant is found to be pregnant while being exposed or having 
been exposed to study  intervention because of environmental exposure. Below are 
examples of environmental EDP : 
A female family  member or healthcare provider reports th at she is pregnant after 
having been exposed to the study  intervention by  eg, skin contact .
A male famil y member or healthcare provider who has been exposed to the study  
intervention by  eg, skin contact then inseminates his female partner prior to or 
aroun d the time of conception .
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 76should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must 
report this information to Pfizer Safety  on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of w hether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until at least 
5terminal half -lives after the last dose (ie,at least 8 weeks) .
If EDP occurs in the setting of environmental exposure, the investigator must 
report information to Pfizer Safet y using the CT SAE Report Form and EDP 
Supplemental Form. Since the exposure information does not pertain to the 
participant enrolled in the stu dy, the information is not recorded on a CRF; 
however, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspect ion (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
Pfizer Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion should be 
reported as an SAE ;
Neonatal deaths that occur within 1 month of birth should be reported, without 
regard to causalit y, as SAEs. In addition, infant deaths after 1 month should be 
reported as SAEs when the investigator assesses the infant death as related or 
possibly  related to exposure to the study  intervention. 
Additional information regarding the EDP m
ay be requested by  the sponsor. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 77Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.5.2. Exposure Dur ing Breastfeeding
An EDB occurs if:
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  intervention .
A female nonparticipant is found to be breastfeeding while being exposed or 
having been exposed to study  inter vention (ie, environmental exposure). An 
example of environmental EDB is a female family  member or healthcare provider 
who reports that she is breastfeeding after having been exposed to the study 
intervention byinhalation, or skin contact.
The investigator must report EDB to Pfizer Safety  within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using the CT SAE Report Form. When EDB occurs in the setting of environmental e xposure, 
the exposure information does not pertain to the participant enrolled in the study , so the 
information is not recorded on a CRF. However, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
An EDB report is not created when a Pfizer drug specificall y approved for use in 
breastfeeding women (eg, vitamins) is administered in accord ance with authorized use. 
However, if the infant experiences an SAE associated with such a drug, the SAE is reported 
together with the EDB.
8.4.5.3. Occupational Exposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 
24
hours of the investigator’s awareness using the CT SAE Report Form, regardless of 
whether there is an associated SAE. Since the informat ionabout the occupational exposure
does not pertain to a participant enrolled in the study , the information is not recorded on a 
CRF; however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .
8.4.6. Cardiovascular and Death Events
Not applicabl e.
8.4.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 788.4.8. Adverse Events of Special Interest
All AESI s must be reported as an AE or SAE following the procedures described in 
Sections 8.4.1 through An AESI is to be recorded as an AE or SAE on the CRF . In addition, 
an AESI that is also an SAE must be reported using the CT  SAE Report Form.
8.4.8.1. Lack of Efficacy
The investigator must report signs, s ymptoms, and/or clinical sequelae resulting from lack of 
efficacy . Lack of efficacy  or failure of expected pharmacological action is reportable to 
Pfizer Safety  only if associated with an SAE . 
8.4.9. Medical Device Deficiencies
Not applicable .
8.4.10. Medication Errors
Medication errors may  result from the administration or consumption of the 
study  
intervention by the wrong participant , or at the wrong time, or at the wrong dosage strength.
Medication errors are recorded and reported as follows:
Recorded on the 
Medication Error Page 
of the CRFRecorded on the 
Adverse Event Page 
of the CRFReported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours of 
Awareness
All (regardless of whether 
associated with an AE)Any AE or SAE associated 
with the medication errorOnly  if associated with an 
SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that 
do or do not involve the study participant .
Such medication errors occurring to a stud y partici pant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 79Medication errors should be reported to Pfizer Safety  within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.5.Pharmacokinetics 
Blood samples of approximately  4mL, to provide a minimum of 1.5 mL serum, will be 
collected for measurement of serum unbound and total concentrat ions of ponsegromab as 
specified in the SoA. The PK sample collection at the Week 5 visit is considered a n optional
sample and i t will not be considered a protocol deviation if the participant is unable to make 
this visit. In addition, if a participant has an u nplanned site visit for any reason, 
(chemotherap y, radiology, other doctor appointments, etc), a PK sample may  be collected, if 
feasible , provided the total volume taken during the study  does not exceed 550 mL during 
any period of 56 consecutive day s .
The actual times may  change, but the number of samples will remain the same. Collection of 
samples within the protocol -allowed visit window, as defined in SoA or noted above will not 
be captured as a pr otocol deviation, as long as the exact time of the collection is noted on the 
source document and the CRF.
Samples will be used to evaluate the PK of ponsegromab. Samples collected for anal yses of 
ponsegromab serum concentrations may  also be used to evalua te safet y or efficacy  aspects 
related to concerns arising during or after the study, for metabolite identification and/or 
evaluation of the bioanalytical method, or for other internal exploratory  purposes.
Genetic anal yses will not be performed on these se rum samples unless consent for this was 
included in the informed consent. Participant confidentiality  will be maintained.
Samples collected for measurement of serum concentrations of ponsegromab (unbound and 
total) will be anal yzed using a validated analy tical method(s) in compliance with applicable 
SOPs. 
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity . Any  deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has b een compromised.
Drug concentration information that may  unblind the study  will not be reported to 
investigator sites or blinded personnel until the study  has been unblinded.
Any changes in the timing or addition of time points for any  planned stud y assess ments must 
be documented and approved by  the relevant study  team member and then archived in the 
sponsor and site study  files, but will not constitute a protocol amendment. The I RB/EC will 
be informed of an y safety issues that require alteration of the saf ety monitoring scheme or 
amendment of the ICD.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 80If the sample is unable to be collected during F/U part A and F/U part B , it will not be 
considered a protocol deviation.
8.6.Genetics
8.6.1. Specified Genetics
Specified g enetic anal yses are not evaluated in this study .
8.6.2. Retained Research Samples for Genetics
A 2-mLblood sample optimized for DNA isolation Prep D1.5 will be collected according to 
the 
SoA, as local regulations and I RBs/ECs allow.
Retained Research Samples may be used for research related to the study  intervention (s)and 
cancer cachexia .Genes and other anal ytes (eg ,proteins, RNA, nondrug metabolites) may  be 
studied using the 
retained samples. 
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in the laboratory  manual.
8.7.Biomarkers
Collection of samples for biomarker research is also part of this study , see Section 8.7.6. 
8.7.1.
GDF-15
Blood samples of approximately  6 mL, to provide a minimum of 2 mL  serum, will be 
collected for measurement of serum concentrat ions of total and unbound GDF -15 at time 
points specified in the SoA. The GDF - 15 sample collection at the Week 5 visit is considered 
an optional sample. It will not be considered a protocol deviation if the participant is unable 
to make th isvisit. In addition, if a participant has an unplanned site visit for any  reason, 
(chemotherap y, radiology, other doctor appointments, etc.), a GDF -15 sample may be 
collected, if feasible , provided the total volume taken during the study  does not exceed 
550mL during an y period of 56 consecutive day s.
At the S creening visit, twoGDF - 15 samples will be collected (6-mL for each) . One GDF - 15 
(Roche) sample will be analy zed using the IUO Roche Elecs ys GDF -15 assay , for 
determination of enrollment eligi bility . In addition, this sample may  be used to help support 
development of a potential companion diagnostic test for ponsegromab. This screening assay  
will be validated in a CLIA accredited central laboratory . The 
second Screening GDF -15 
(Pfizer) sample, as well as the GDF -15 samples collected at the other time points specified in 
the SoA , will be anal yzed for unbound and total GDF -15 using validated Pfizer assay s in 
compliance with applicable SOPs.
Instructions for the collection an d handling of biological samples will be provided in the 
laboratory  manual or by  the sponsor. The actual date and time (24 -hour clock time) of each 
sample will be recorded. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 81The actual times may  change, but the number of samples will remain the same. Colle ction of 
samples within the protocol -allowed visit window, as defined in the SoA or above will not be 
captured as a protocol deviation, as long as the exact time of the collection is noted on the 
source document and the CRF.
Sample wi ll be used to evaluate the PD of ponsegromab. Samples collected for PD anal yses 
may also be used to evaluate safety  or efficacy  aspects related to concerns arising during or 
after the stud y, and/or evaluation of bioanal ytical methods, or for other internal exploratory  
purposes.
The PD samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity . Any  deviations from the PD sample 
handling procedure (eg, sample collection and processing steps, interim storage, or shipping 
conditions), including any actions taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may  make a determination as to whether sample 
integrit y has been compromised. 
GDF -15 concent ration information that may  unblind the study  will not be reported to 
investigator sites or blinded personnel until the study  hasbeen unblinded.
Any changes in the timing or addition of time points for any  planned stud y assessments must 
be documented and approved by  the relevant study  team member and then archived in the 
sponsor and site study  files, but will not constitute a protocol amendment. The I RB/EC will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme or 
amen dment of the ICD.
If the sample is unable to be collected during F/U part A and F/U part B, it will not be 
considered a protocol deviation.
8.7.2. Circulating Biomarkers
Albumin and pre -albumin will be assessed as a biomarker for nutritional status . A serum
sample of approximately  6 mL  will be collected for measurement of albumin and pre-
albumi n as specified in the SoA.
Laboratory /anal yte results 
for albumin and pre-albumin collected from baseline through EOT 
of Part A , that could unbl ind the study  will not be reported to investigator sites or other 
blinded personnel until the study  has been unblinded.
8.7.3. Specified Gene Expression (RNA) Research 
Specified gene expression (RNA) research is not included in this study .
8.7.4. Specified Protein Rese arch 
Specified protein research is not included in this study .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 828.7.5. Specified Metabolomic Research 
Specified metabolomic research is not included in this study .
8.7.6. Retained Research Samples for Biomarkers
These Retained Research Samples will be collected in this study according to the SoA:
A 2-mL whole blood (Prep B 1.5 optimized for plasma) .
A 2-mL whole blood (Prep B 2.5 optimized for serum) .
Retained Research Samples will be collected as local regulations and IRB/ECs allow 
according to the SoA .
Retained Research Samples may be used for research related to the study  intervention (s)and 
cancer cachexia. Genes and other anal ytes (eg ,proteins, RNA, nondrug metabolites) may  be 
studied using the 
retained samples. 
See Appendix 5 for information regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in the laboratory  manual.
8.8.Immunogenicity Assessments
Blood samples of approximately  4mL, to provide a minimum of 1.5 mL serum, will be 
collected for determination of ADA and NAb as specified in the SoA. 
Instructions for the collection and handling of biological samples will be pro vided in the 
laboratory  manual or by  the sponsor. The actual date and time (24 -hour clock time) of each 
sample will be recorded. 
Samples collected for determination of ADA and NAb may  also be used for additional 
characterization of the immune response and /or evaluation of the bioanaly tical method, or for 
other internal exploratory purposes. These data will be used for internal exploratory  
purposes.
Genetic anal yses will not be performed on these serum samples unless consent for this was 
included in the inf ormed consent. Participant confidentiality will be maintained.
Samples will be analy zed using a validated anal ytical method in compliance with applicable 
SOPs. Samples determined to be positive for ADA may be further characterized for NAb, if 
feasible.
The immunogenicit y samples must be processed and shipped as indicated in the instructions 
provided to the investigator site to maintain sample integrity . Any deviations from the 
immunogenicit y sample handling procedure (eg, sample collection and processing steps, 
interim storage, or shipping conditions), including any  actions taken, must be documented 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 83and reported to the sponsor. On a case -by-case basis, the sponsor may  make a determination 
as to whether sample integrit y has been compromised.
Immunogenicit yinformation that would unblind the study  will not be reported to investigator 
sites or blinded personnel until the study  has been unblinded.
Any changes in the timing or addition of time points for any  planned stud y assessments must 
be documented and appr oved by  the relevant study  team member and then archived in the 
sponsor and site study  files, but will not constitute a protocol amendment. The I RB/EC will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme or 
amendment of the ICD.
If the sample is unable to be collected during F/U Part A and F/U P art B, it will not be 
considered a protocol deviation.
8.9.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in the SAP, which will be maintained by  the sponsor. 
The SAP may  modify  what is outlined in the protocol where appropriate; however, an y major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.
9.1.Statistical Hypotheses
The null hy pothesis of no difference between ponsegromab and pl acebo will be tested for 
each primary  and selected secondary  and tertiary  endpoints. The alternative hy pothesis is that 
ponsegromab is superior to placebo.
9.1.1. Estimands
9.1.1.1. Primary Estimand
Estimand related to the body weight primary  objective:
Estimand 1 (simila r to “hy pothetical”) is intended to provide a population level estimate of 
the treatment effect on the change from baseline in body  weight for ponsegromab compared 
with placebo in all evaluable participants under the scenario of no discontinuation of study
intervention and without the potential confounding effect of prohibited procedures , 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 84prohibited medications or participants’ non -compliance with dosing (ie, using the Censored 
analysis set, as defined in Section 9.2).
Population: Participants with cancer, cachexia, and elevated concentrations of 
GDF -15.
Endpoint: Change from baseline in body  weight at Week 12.
Intercurrent Events:
a.Discontinuation of stud y intervention: Data collected after a participant has 
discontinued study  intervention will be censored and treated as missing data.
b.
Prohibited procedures: Data collected after a participant has undergone prohibited 
procedures, that would modulate the primar y endpoint will be censored and 
treated as missing data. Any  procedures will be reviewed prior to database lock to 
determine which would be classed as “prohibited” for this estimand.
c.Prohibited medications :Data collected after a participant has received prohibited 
medications, that would modulate the primary  endpoint, will be censored and 
treated as missing data. The list of concomitant medications will be reviewed 
prior to database lock to determine which would be classed as “prohibited” for 
this estima nd.
d.Inadequate compliance: Data collected after a participant has missed a dose will 
be censored and treated as missing data
. 
Missing data due to censoring, stud y withdrawal or other reasons, are assumed to 
be missing at random in the anal ysis.
Population -level summary: Difference in mean change from baseline bod y weight at 
Week 12 between ponsegromab and placebo.
Alternative estimands (eg ,one similar to “treatment policy ”, using a complete anal ysis set 
where all observations post -discontinuatio n, prohibited procedure , prohibited medications or 
inadequate compliance, will be included) for the primary  objective may  be used in order to 
examine the robustness of the results and will be detailed in the SAP.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 859.1.1.2. Secondary Estimands
Estimand related to the physical activity and gait secondary  objective:
Estimand 2 will be similar to Estimand 1, except for the following:
Endpoint: Change from baseline in each of the ph ysical activity and gait endpoints at 
Week 12:
Moderate to vigorous phy sical activity time;
Sedentary activity  time;
Non sedentary  activity  time ;
Total vector magnitude ; 
Mean activit y level during M 6min ;
Mean gait speed;
95thpercentile gait speed .
Population -level summary: Difference in mean change from baseline for the physical 
activity  and gait endpoints at Week 12 between ponsegromab and placebo.
Estimand related to the appetite -related symptoms as measured by FAACT secondary  
objective:
Estimand 3 will be similar to Estimand 1, except for the following:
Endpoint: Change from baseline in eachFAACT sub -scale score at Week 12:
FAACT -ACS;
FAACT -5IASS.
Population -level summary: Difference in mean change from baseline for the FAACT 
sub-scale scores at Week 12 between ponsegromab and placebo .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 86Estimand related to the anorexia/appetite , nausea, vomiting and fatigue measured b y the 
CRCSD secondary objective:
Estimand 4 will be similar to Estimand 1, except for the following:
Endpoint: Change from baseline score for each of the questions from the CRCSD at 
Week 12:
Anorexia/appetite
;
Nausea and vomiting;
Fatigue . 
Population -level summary: Difference in mean change from baseline in each of the 
questions from the CRCSD at Week 12 between ponsegromab and placebo.
Estimands related to the safety and tolerability secondary objective:
There are no def ined estimands for the incidence of adverse events, safet y laboratory  tests, 
vital signs and ECG abnormalities, and these endpoints will be summarized using Pfizer data 
standards as applicable.
Estimands related to tertiary/exploratory objectives:
Tertiary /exploratory  endpoints may  be anal yzed using similar estimands or anal yzed in a 
descriptive manner without reference to an estimand. Other supporting estimands may be 
used for some of the primary  and secondary  endpoints as a means to examine the robustness
of results, compare to available literature and/or be used for future stud y planning as needed.
Details of these estimands and anal yses will be presented in the SAP.
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined:
Participant Analysis Set Description
Enrolled "Enrolled" means a participant's, or their legall y authorized
representative’s, agreement to participate in a clinical study  
following completion of the informed consent process and 
randomization to study  intervention . A participant will be 
considered enrolled if the informed consent is not withdrawn 
prior to participating in any  study  activity  after S creening .
Potential participants who are screened for the purpose of 
determining eligibility  for the study , but do not participate in 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 87Participant Analysis Set Description
the study , are not considered enrolled, unless otherwise 
specified b y the protocol.
Evaluable All participants randomly  assign ed to study  intervention and 
who take at least 1dose of study  intervention .Participants 
will be anal yzed according to the randomized intervention.
Safety analysis set All participants randomly  assigned to study  intervention and 
who take at least 1 dose of study  intervention .Participants 
will be anal yzed according to the study  intervention they 
actuall y received.
Defined A nalysis Set Description
Censored All evaluable participants. For participants who discontinue 
study  intervention , or receive a prohibited procedure or 
prohibited medication , all observations post -discontinuation , 
or post -procedure, will be censored and treated as missing 
data. For participants who miss a dose, all observations 
post-
missed dose will be censored and treated as missing 
data. 
PK All participants randomly  assigned to study  interventio n and 
who take at least 1 dose of ponsegromab and in whom at least 
1PK concentration value is reported.
PD All participants randomly  assigned to study  intervention and 
who take at least 1 dose of study  intervention and in whom at 
least 1 PD (GDF -15) concentration value is reported.
Immunogenicit y All participants randomly  assigned to study  intervention and 
who take at least 1 dose of ponsegromab and in whom at least 
1ADA result is reported. 
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data.
This section is a summary of the planned statistical analy ses of the primary  and seconda ry 
endpoints.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 889.3.1. General C onsiderations
Part A and Part B of the study  will be presented separately . For objectives relating to Part A 
of the study , each treatment arm will be reported separately  through the 12 -week 
double -blind treatment period only  (includi ng follow -up for any  participants not continuing 
onto Part B of the stud y).
9.3.1.1. Analyses for Continuous Endpoints
MMRM Model
The MMRM model will include participant as a random term, and baseline, time (as a 
factor), baseline -by-time interaction, treatment and treatment -by-time interaction as fixed 
terms in the model. An unstructured covariance matrix will be fitted to the repeated times 
within subject (other covariance matrices will be considered if necessary ), and the Kenward 
Roger approximation will be used for estimating degrees of freedom. Additional terms may  
be fitted in the model (eg, ty pe of therap y [ie,platinum or not], ty pe of cancer), as 
appropriate.
Bayesian Emax Model
The Bay esian four -parameter Emax model will use dose as a continuous variable. T he model 
structure will take the form: 
   =   +    ∗        
                 
E0is the placebo response, dose is the randomized dose (placebo dose = 0), E maxis the 
maximum effect, ED 50is the dose producing 50% of the maximum effect and Hillis the 
slope parameter. The model will utilize a Bay esian methodology  approach.
The default prior distributions for the Hillparameter and the ED 50 are based on a meta -
analysis of clinical dose respo nse data13,14,15and are listed below. These default distributions 
will be updated if the meta -data, and their anal ysis, are updated before the completion of the 
current stud y.
Parameter Prior
log(ED 50) log(P 50) + t(Mean=0, SD=1.73, df=5)
log(Hill) t(Mean = 0, SD =0.85, df=5)
The correlation between these two parameters is currentl y -0.45 based on the anal ysis of the 
meta -data, which also would be updated if the historical anal ysis is updated.
The predicted ED 50for the compound ( P50),and prior distributions for the placebo response 
(E0), the difference in response ( difTarget ) between the highest dose (400 mg) and placebo, 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 89and the residual standard deviation ( sigma) will be specified for the analy sis endpoint. Note 
that E maxis derived from other parameters and is thus not explicitly  supplied. 
9.3.2. Primary Endpoint Analysis
The primary  endpoint analy sis will be a Bay esian E maxmodel applied to results from an 
MMRM analy sis. 
Change from baseline in body  weight at Week 12 will first be anal yzed using Estimand 1 and 
an MMRM model (as per Section 9.3.1.1). The MMRM model will be fitted to the change 
from baseline at all post- treatment dosing timepoints up to Week 12 (ie,Weeks 4, 8, and 12)
using the Censored anal ysis set. Additional terms for type of therap y [ie,platinum or not] and 
type of cancer will be fitted in the model. Least squares means (and 90% CIs) and mean 
differences versus placebo (and 90% CIs and p -values) will be provided. 
A Bay esian E maxmodel will then be fitted to the Week 12 L Smeans and SEs from the 
MMRM analy sis. The predicted ED 50for the compound ( P50)is currentl y ~150 mgQ4W 
dose, based on latest data for the compound (this may  be updated as new data become 
available). Prior distributions for the placebo response ( E0), the difference in response 
(difTarget ) between the highest do se (400 mg) and placebo, and the residual standard 
deviation ( sigma
) are: 
E0: An informative meta -analy tic predictive16,17prior , based on historical results from 
internal and external studies, robustified by  the inclusion of a weakly  informative 
component to handle any  possible prior -data conflict, will be used for the placebo 
change from baseline at Week 12 . This will be approximated by  a t-distribution with a 
mean of -0.58 kg, an SD of 1.8 4kg and 3 degrees of freedom. If additional relevant 
data become available during the study , a sensitivity analy sis may  be performed by  
incorporating the new data, using the same approach as above. F urther d etails on the 
prior derivation will be given in the statistical analy sisplan (SAP).
difTarget : A vague t - distribution will be used for the 400 mg placebo -corrected 
change from baseline at Week 12 with a mean of 0 , aSDequal to 10 times the 
predicted standard deviation 
(ie, 49 kg) and 5 degrees of freedom .
sigma: A uniform prior will be used, with a range we are confident will include the 
population value. A lower bound of 0.49 kg and an upper bound of 49 kg will be 
used.
The posterior medians and 90% credible intervals (5th and 95th percentiles of the relevant 
posterior distribution) will be reported for each randomized dose (including placebo) and 
their differences relative to placebo. If the E maxmodel cannot be fitted to the data, or the data 
do not support a dose- response , the model may  be simplified, or the anal ysis may  not be 
performed and the primary  results for the study  will be based on the MMRM results at 
Week 12. More details on how this will be assess edwill be described in the SAP. No 
adjustments will be made for multiplicity .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 909.3.3. Secondary Endpoints Analysis
Endpoint Statistical Analysis Methods
Change from baseline in each of the physical activity 
and gait endpoints at Week 12:
Moderate to vigorous physical activity time;
Sedentary activity time;
Non sedentary activity time;
Total vector magnitude;
Mean activity level during M6min;
Mean gait speed ;
95thpercentile gait speed .Change from baseline in physical activity and gait 
endpoints will be analyzed separately using 
Estimand 2 and an MMRM model (as per
Section 9.3.1.1 ). The MMRM model will be fitted to 
the change from baseline at all post -treatment 
timepoints up to We ek 12 using the Censored 
analysis set.
Least squares means (and 90% CIs) and mean 
differences versus placebo (and 90% CIs and p 
values) will be provided. No adjustments will be 
made for multiplicity.
Change from baseline in each of the FAACT 
sub-scale scores at Week 12 :
FAACT -ACS;
FAACT -5IASS .Change from baseline in FAACT sub -scale scores 
will be analyzed separately using Estimand 3 and an 
MMRM model (as per Section 9.3.1.1 ). The MMRM 
model will be fitted to the change from baseline at all 
post-treatment timepoints up to Week 12 using the 
Censored analysis set.
Least squares means (and 90% CIs) and mean 
differen ces versus placebo (and 90% CIs and 
pvalues) will be provided. No adjustments will be 
made for multiplicity.
Change from baseline for each of the questions from 
the CRCSD at Week 12: 
Anorexia/appetite;
Nausea and vomiting;
Fatigue.Change from baseline in questions from the CRCSD
will be analyzed separately using Estimand 4 and an 
MMRM model (as per Section 9.3.1.1 ). The MMRM 
model will be fitted to the change from baseline 
weekly averages at all post -treatm ent timepoints up 
to Week 12 using the Censored analysis set.
Least squares means (and 90% CIs) and mean 
differences versus placebo (and 90% CIs and 
pvalues) will be provided. No adjustments will be 
made for multiplicity.
Incidence of adverse events, safety laboratory tests, 
vital signs and ECG abnormalities .All safety analyses will be performed on the safety 
population. The safety data will be summarized in 
accordance w ith Pfizer Data Standards. All safety 
data w ill be summarized descriptively through 
appropriate data tabulation, descriptive statistics, 
categorical summaries, and graphical presentations, 
as appropriate.
Part B safety data will be reported once all 
applicable participants have completed Part B of the 
study . More details will be provided in the SAP.
9.3.4. Tertiary/Exploratory Endpoints Analysis
The anal ysis of exploratory  endpoints will be detailed in the SAP.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 919.3.5. Other Analyses 
Selected data collected at Screening may  be reported. These data may  include demographic 
data, concomitant medications, GDF -15 concentration s, height, weight, BMI ,and ECOG PS. 
In addition, a subset of medical history  data will be reported; this may  includ e typeand stage 
of cancer, where feasible. Other data collected at Screening that are used for 
inclusion/exclusion criteria, such as laboratory  data, will be considered source data, and will 
not be required to be reported, unless otherwise noted.
As permi tted by  data, and determined by  the sponsor, the PK/PD relationship between serum 
ponsegromab concentration and the effect on primary , secondary  and/or tertiary  endpoints 
may be explored using a population PK/PD approach. The population PK/PD analy sis, if 
conducted, will be reported in a separate report.
Up to 40 e xit interviews will be conducted by  telephone at Week 12 or early  discontinuation. 
Interviews will be conducted b
y trained moderators and are anticipated to be approximately 
60minutes in duration. Using the transcripts and interviewer field notes, dominant trends 
will be identified in each interview and compared across all the interviews to describe the 
participant experience with a focus on the themes or patterns in the way  the treatment 
experience is described, and the importance of any  improvements reported. Following the 
analysis, a comprehensive summary  report that fully  describes the study  objectives, methods, 
participants and results of the qualitative interviews will be prepared and reporte d separatel y 
from the CSR.
Pharmacogenomic or biomarker data from Retained Research Samples may be collected 
during or after the trial and retained for future analy
ses; the results of such anal yses are not 
planned to be included in the CSR. 
CT scans will be collected , retained, analyzed for tumor burden, skeletal muscle, adipose 
tissue, and may be used for additional research related to the study  intervention(s) and cancer 
cachexia . The results of such additional research analy ses may not be included in th e CSR.
9.4.Interim 
Analyses
Interim anal yses may  be performed to assess efficacy  and/ or safet y after at least 
approximately  25% of the planned participant s, ie,approximately  30participant s, complete 
their study  participation through Week 12of the study .Interim anal ysis results may  be used 
for decisions regarding stopping for futility , stopping for early  success, conducting a sample 
size re-estimation ,or adapting the study  after the interim anal ysis.Participants may  be 
discontinued from the study  interv ention/ study as a result of the interim analy sis, as 
described in Section 7. 
Before an y interim anal ysis is performed , the details of the objectives, decision criteria ,
dissemination plan ,and method of maintaining the study  blind (if applicable) as per Pfizer’s 
SOPs will be documented and approved in a n IRC charter . In addition, the anal ysis details 
will be documented and approved in theSAP.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 92Following completion of Part A (PCD), the data will be analyzed and reported in the main 
CSR. The results for Part B will be reported separately  at the end of Part B.
9.4.1. PK/PD Unblinding Plan 
If needed, a PK/PD unblinding plan will be developed to safeguard the study  blind for 
members of the stud y team. These procedures will be in accordance with applicable Pfizer 
SOPs for rele asing randomization codes and breaking the study  blind. Under this plan, a 
limited number of individuals, not on the study  team, will be unblinded, with the purpose of 
composing PK/PD and/or immunogenicit y analysis sets and conducting PK/PD analysis that 
will not be made available to the study  team until after database lock.  
9.5.Sample Size Determination
A sufficient number of participants will be screened to achieve a total of approximately  
168participants, with 42 participants randoml y assigned to ponsegr omab 100, 200 or 400 mg 
and placebo in approximately  a 1:1:1:1 ratio. This is expected to ensure completion through 
Week12 of the study  of approximately  120 completing participants (30 in each of 
ponsegromab 100, 200 or 400 mg and placebo), assuming a dis continuation rate of 
approximately  30% (if this rate is higher, or there is a high rate of non- compliance, more 
participants may  be randomized to ensure the required number of complet ingparticipants). 
The sample size in the ponsegromab and placebo arms i s based on the primary  efficacy  
endpoint, mean change from baseline in body  weight at Week 12. An informative 
meta -analytic predictive prior, 
based on historical results from internal and external studies, 
robustified by  the inclusion of a weakly  informative component to handle any  possible 
prior -data conflict, will be used for the placebo response and is expected to equate toan
effective sample sizeof39placebo partic ipants. Further d etails on the prior derivation will be 
given in the statistical analy sisplan SAP.
120completing participants, in a 1:1:1:1 ratio, plus 39 participants from the placebo prior, 
gives acceptable Operating Characteristics in that:
The probability  of achieving statistical significance (at the 5% significance level, 
using a 1 -sided t-test), for a true difference between ponsegromab and placebo of 
2.7kg, is approximately  80%.
An observed difference between ponsegromab and placebo of 1.8 kg is e xpected 
to achieve statistical significance (at the 5% significance level, using a 1 -sided t-
test).
A conservative estimate of the standard deviation, for the change from baseline in body  
weight at 12 weeks of 4.9 has been used. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 93The sample size determination has been performed using pairwise comparisons. This is 
considered to be a conservative approach since the primary  anal ysis will utilize a Bay esian 
Emaxdose-response model, which would be anticipated to best describe the dose -response in 
the presence o f an effective compound .15
Evaluable participants are defined as in Section 9.2. Participants who withdraw from the 
study  will not be replaced.
Of the approximately  168 planned randomized participants, up to approximately  36are 
planned to be randomized (
to ponsegromab 100, 200 or 400 mg and placebo in 
approximately  a 1:1:1:1 ratio) into the additional PK sub study . This sample size has been 
chosen empirically  to provide sufficient data to adequatel y characteri ze ponsegromab PK and 
GDF -15 effect and PK/PD relationship in cancer patients with cachexia and elevated 
concentrations of GDF -15.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 9410. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the followin g:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines ;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  the sponsor ,submitted to an I RB/EC 
by the investigator, and reviewed and approved by  the IRB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and any substantial amendments to the prot ocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the st udy to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures;
Providing oversight o f the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies, European Medical Device Regulation 2017/745 for 
clinical device research, and all other applicable local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Brea ches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investi gator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study  
intervention , Pfizer should be informed immediately . 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 95In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measure s 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investig ators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or the investigator’s representative will explain the nature of t he study , 
including the risks and benefits, to the participant or their legall y authorized representative
and answer all questions regarding the stud y.The participant or their legally  authorized 
representative should be given sufficient time and opportuni ty to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative (if allowed by  local regulations) will be required to sign a 
statement of informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, privacy  and data protection requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each participan tor their legall y authorized representative is 
fully  informed about the nature and objectives of the study , the sharing of data related to the 
study , and possible risks associated with participation, including the risks associated with the 
processing of t he participant’s personal data. 
The participant or their legall y authorized representative must be informed that their personal 
study -related data will be used by  the sponsor in accordance with local data protection law. 
The level of disclosure must also be explained to the participant or their legally  authorized 
representative .
The participant or their legall y authorized representative must be informed that their medical 
records may  be examined by  Clinical Qualit y Assurance auditors or other authorized 
personnel appointed b y the sponsor, b y appropriate I RB/EC members, and by  inspectors 
from regulatory  authorities.
The investigator further must ensure that each study  participant or their legally  authorized 
representative is fully  informed about their right to access and correct their personal data and 
to withdraw consent for the processing of 
their personal data.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 96The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the dat e on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the IC D.
Participants or their legally  authorized representative must be reconsented to the most current 
version of the IRB/EC -approved ICD(s) during their participation in the study as required per 
local regu
lations.
A cop y of the IC D(s) must be provided to the participant or their legall y authorized 
representative (if allowed by  local regulations) .
Participants who are rescreened are required to sign a new IC D.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic and/or paper 
form and will be password protected or secured in a locked room to ensure that only  
authorized study  staff have access. The study  site will implement appropriate technical and 
organizational measures t o ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach
notifications as required by  law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant-specific code. The study  site will 
maintain a conf idential list of participant s who participated in the study, linking each 
participant ’s numerical code to their actual identity and medical record ID. In case of data 
transfer, the sponsor will protect the confidentiality of participant s’ personal data consistent 
with the c linical study agreement and applicable privacy  laws.
Information technology  systems used to collect, process, and store study -related data are 
secured b y technical and organizational securit y measures designed to protect such data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.
The sponsor maintains SOPs on how to respond in the event of unauthorized access, use, or 
disclosure of sponsor information or sy stems.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 9710.1.5. Committees Structure
10.1.5.1. Data Monitoring Com mittee 
This study  will use an IRC. The I RC is independent of the study  team and includes only 
internal members. The IRC charter describe s the role of the IRC in more detail.
The I RC will be responsible for ongoing monitoring of the efficacy  and safety  of participants 
in the study  according to the charter. The IRC will conduct an initial review of the unblinded 
safet y data once the first 20 randomized participants have safet y data through at least 
6weeks after randomization. Thereafter, the IRC will review safety  data approximately  every  
3months to ascertain whether there is a ponsegromab -related safety  concern by  evaluating 
treatment emergent AEs, including those related to study  intervention , using the NCI  CTCAE 
grading s ystem, and b y reviewing the AEs in both the active treatment arms and placebo. The 
IRC will also review data collected on the administration of anti -cancer therapy , to ascertain 
if there is an imbalance in the rates of discontinuation of anti -cancer therapies across the
treatment arms. The IRC will issue periodic recommendations to the study  team, based on its 
periodic review of the unblinded study  data. Such recommendations may  include 
modification to or discontinuation of a study  treatment arm or termination of the stu dy. The 
recommendations made by  the IRC will be forwarded to the appropriate authorized Pfizer 
personnel for revie wandfinal decision. Pfizer will communicate such decisions, which may  
include summaries of aggregate anal yses of endpoint events and of safe ty data that are not 
endpoints, to regulatory  authorities andinvestigators, as appropriate. 
10.1.5.2. Executive Steering Committee
The Executive Steering Committee will be responsible for reviewing the protocol and 
may 
make suggestions on protocol design and amend ments. This committee will with work 
jointly  with the Operation sSteering Committee to provide guidance regarding identified 
issues with study  conduct
.They  will also lead authorship and provide oversight of study  
publications in collaboration with the sponsor. The charter describes the role of the Executive 
Steering Committee in more detail.
10.1.5.3.
Operations Steering Committee
The Operation s Steering Committee comprise dof medical representatives from each country
or region, Pfizer clinical colleagues and Pfizer operations colleagues, will oversee 
recruitment, retention, and quality  issues within the country or region. This committee will 
work jointly  with the Executive Steering Committee to ensure that identified issues are 
effectivel y addressed at each participating site. The charter describes the role of the 
Operations Steering Committee in more detail.
10.1.6. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  result s through posting the 
results of studies on www .clinicaltrials.gov (ClinicalT rials.gov), the EudraCT /CTI S, and/or 
www .pfizer .com, and other public registries and websites in accordance with applicable local 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 98laws/regulations. In addition, Pfizer reports stu dy results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or th e country  in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study is conducted. These r esults are 
submitted for posting in accordance with the format and timelines set forth by  US law.
EudraCT /CTI S
Pfizer posts clinical trial r esults on EudraCT /CTI Sfor Pfizer -sponsored interventional studies 
in accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts CSR synopses and plain- language study  results summaries on www .pfizer .com 
for Pfizer -sponsored interventional studies at the same time the corresponding study  results 
areposted to 
www.clinicaltrials.gov. CSR sy nopses will have personally  identif iable 
information anon ymized.
Documents within marketing applications
Pfizer complies with applicable local laws/regulations to publish clinical documents included 
in marketing applications. Clinical documents include summary  documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally  identifiable information anony mized.
Data sharing
Pfizer provides researchers secure access to participant -level data or full CSRs for the 
purposes of “ bona -fide scientific research ” that contribute sto the scientific understanding of 
the disease, target, or compound class. Pfizer will make data from these trials available 
18months after study  completion. Participant -level data will be anon ymized in accordance 
with applicable privacy  laws and regulations. CSRs will have perso nally identifiable 
information anon ymized.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analy ses.Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 9910.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted t o the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
Guidance on completion of CRFs will be provided in theCRF Completion Requirements 
document .
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access b y unauthorized third parties.
QTL s are predefined parameters that are monitored during the study . Important deviations 
from the QTLs and any remedial actions taken will be summarized in the CSR.
The investigator must permit study -related monitoring, audits, IRB/EC review, and
regulatory  agency  inspections and provide direct access to source records and documents.
This verification may  also occur after study  completion. I t is important that the 
investigator(s) and their relevant personnel are available during the monitoring vis its and 
possible audits or inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study -critical data items and 
processes (eg, risk- based initiatives in operations and quality  such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and 
monitoring plan maintained and utilized by  the sponsor or designee.
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 100The investigator(s) will notify thesponsor or its agents immediately  of any regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant ’s medical records. The investigator will promptly  
provide copies of the inspecti on findings to the sponsor or its agent. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source document s are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must b e 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what co nstitutes a source document and its origin can be found in the 
Source 
Document Locator , which is maintained by  the sponsor.
Description of the use of the computerized sy stem is documented in the data management 
plan, which is maintained by  the sponsor.
The investigator must maintain accurate documentation (source record
) that supports the 
information entered in the CRF.
The sponsor or designee will perform monitoring to confirm that data entered into the CRF 
by authorized site personnel are accurate, com plete, and verifiable from source documents; 
that the safet y and rights of participants are being protected; and that the study is being 
conducted in accordance with the currentl y approved protocol and an y other study  
agreements, I CH GCP guidelines, and al l applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date of the first participant’s first visit.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reaso n at the sole discretion of the sponsor , including (but not limited to) 
regulatory  authorit y decision, change in opinion of the I RB/EC, or change in benefit -risk 
assessment .Study  sites will be closed upon study completion. A study  site is considered 
close d when all required documents and study  supplies have been collected and a study -site 
closure visit has been performed.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 101The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
or designee/ CRO if requested to do so by  the responsible I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor ’s procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  the investigator;
Discontinuation of further study  intervention development .
If the stud y is prematu rely terminated or suspended, the sponsor shall promptly  inform the 
investigators, the E Cs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirement s. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol ,the contract will control as to termination rights.
10.1.10. Publication Policy
For multicenter trials, the primary  publication will be a joint publication developed b y the 
investigator and Pfizer reporting the primary  endpoint(s) of the study  covering all s tudy sites. 
The investigator agrees to refer to the primary  publication in any  subsequent publications. 
Pfizer will not provide any financial compensation for the investigator’s participation in the 
preparation of the primary congress abstract, poster, pre sentation, or primary  manuscript for 
the study .
Investigators are free to publish individual center results that they  deem to be clinically  
meaningful after publication of the overall results of the study  or 12 months after primary  
completion date or stud ycompletion at all sites, whichever occurs first, subject to the other 
requirements described in this section.
The investigator will provide Pfizer an opportunity  to review any  proposed publication or 
any other t ype of disclosure of the stud y results (coll ectively , “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to Pfizer 30 days before 
submission. If an y patent action is required to protect intellectual propert y rights, the 
investigator agrees to delay  the disc losure for a period not to exceed an additional 60 days 
upon request from Pfizer. This allows Pfizer to protect proprietary  information and to provide 
comments, and the investigator will, on request, remove an y previousl y undisclosed 
confidential information before disclosure, except for any  study -intervention or  
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 102Pfizer -related information necessary  for the appropriate scientific presentation or 
understanding of the study  results. For joint publications, should there be disagreement 
regarding interpretatio n and/or presentation of specific anal ysis results, resolution of, and 
responsibility  for, such disagreements will be the collective responsibility  of all authors of 
the publication.
For all publications relating to the stud y, the investigator and Pfizer will comply with 
recognized ethical standards concerning publications and authorship, including those 
established by  the International Committee of Medical Journal Editors. The investi gator will 
disclose an y relationship with Pfizer and any relevant potential conflicts of interest, including 
any financial or personal relationship with Pfizer, in any  publications. All authors will have 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication .
10.1.11. Sponsor’s 
Medically Qualified Individual 
The contact information for the sponsor ’s MQI for the study  is documented in the study  
contact list located in the supporting stud y docume ntation/study  portal or other electronic 
system . 
To facilitate access to their investigator and the sponsor’s MQI for study -related medical 
questions or problems from non -study  healthcare professionals, participants are provided 
with an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol 
and study  intervention identifiers, (b) participant’s study  identification number, (c) site 
emergency  phone number active 24 hours/day , 7days per week, and (d) Pfizer C all C enter 
number.
TheECC is intended to augment, not replace, the established communication pathway s 
between the participant and their investigator andsite staff, and between the investigator and 
sponsor study  team. The ECC is only to be used by  healthcare professionals not involved in 
the research stud y, as a means of reaching the investigator or site staff related to the care of a 
participant. The Pfizer Call Center number is to be used when the investigator and site staff 
are unav ailable . The Pfizer Call Center number is not for use by  the participant directl y; if a 
participant calls that number directly , they will be directed back to the investigator site.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 10310.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may  be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  the clinical laboratory ,or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Hem atology Chemi stry Other
Hem oglobin
Hem atocrit
RBC count
Platelet count
WBC countUrea and creatinine, 
SCys(at Screening only)
Sodium
Potassium
AST, ALT
Total bilirubin
Alkaline phosphatase
Total protein
Glucose (non-fasting)At Screening only:
FSHa
Per SoA or as needed:
Pregnancy test ( b-hCG or urine 
test)b
For potential DILI:
AST/ALT 
T bili, direct and indirect bili 
Total bile acids, GGT 
Total protein, albumin 
CK 
PT, INR 
Acetaminophen/paracetamol or 
protein adduct levels 
Hepatitis serology (even if screening 
negative) 
For potential DICI/DIKI: 
Creatinine (Scr) 
CystatinC (Scys) 
eGFR (Scr only and combined Scr+Scys) 
Spot (dipstick) UACR
a.For confirmation of postmenopausal status only.
b.Serum b-hCG will be collected at Screening for female participants of childbearing potential. Local 
urine testing will be standard for the protocol unless serum testing is required by local regulation or 
IRB/EC. 
The investigator must review the laboratory  report, do cument this review, and record an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 106Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.
d.Results in persistent or significant disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,
such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a Pfizer product of an infectious a gent, pathogenic 
or nonpathogenic  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a Pfizer product. The terms “suspected 
transmission” and “transmission ” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medical or scientific judgment should be ex ercised by the investigator in deciding 
whether SAE reporting is appropriate in other situations, such as significant
medical events that may jeopardize the participant or may  require medical or 
surgical intervention to prevent one of the other outcomes li sted in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or
convulsions that do not result in hospitalization, or development of drug 
dependency  or drug abuse.
Progression of the malignancy  under stud y (including signs and s ymptoms of 
progression) should not be reported as an SAE unless the outcome is fatal within 
the active collection period. Hospitalization due to signs and s ymptoms of disease 
progression should not be reported as an SAE. If the malignancy  has a fatal 
outcome during the study or within the active collection period, then the event 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 11210.4. Appendix 4: Contraceptive and Barrier Guidance 
10.4.1. Male Participant Reproductive Inclusion Criteria
No contraception methods are required for male participants in this study , as the calculated 
safet y margin is ≥100 fold between the estimated maternal exposure due to seminal transfer 
and the NOAEL for serious manifestations of developmental toxicity  in nonclinical studies.
10.4.2. Female Participant Reproductive Inclusion Criteria
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1) and specify  
the reproductive requir ements for including female participants. Refer to Section 10.4.4 for a 
complete list of contraceptive methods permitted in the study . 
A female participant is eligible to participate if she is not pregnant or breastfeeding 
and at least 1 of the following conditions applies:
Is not a WOCBP (see definition in Section 10.4.3).
OR
Is a WOCBP and agrees to use a highl y effective contraceptive method (failure 
rate of <1% per year) during the intervention period and for at least 
8weeks after 
the last dose of study  intervention, which corresponds to the time needed to 
eliminate any  reproductive safet y risk of the study  intervention(s). If a highly  
effective, user-dependent method is chosen, she agrees to concurrently  use an
effective barrier method of contraception. The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to t he first dose of study  
intervention.
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Poten tial
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first d ose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
1.Premenopausal female with 1 of the following: 
Documented h ysterectomy ;
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 113Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to a medical cause other than the above
(eg,mullerian agenesis, androgen insensitivity ), investigator discretion should be applied to 
determining stud y entr y.
Note: Documentation for a ny of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history  
interview. The method of documentation should be recorded in the participant’s medical 
record for the stud y.
2.Postmenopausal female:
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. In addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years of age and not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the highl y effective nonestrogen hormonal contraception methods 
if she wishes to continue her HRT during the study . Otherwise, she must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contraception Methods
Contracept ive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
The following contraceptive methods are appropriate for this study :
Highl y Effective Met hods That Have Low User Dependency  
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 1145.Vasectomized partner:
Vasectomized partne r is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The spermatogenesis cycle is approximately  90 day s.
Highl y Effective Methods That Are User Dependent 
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation:
Oral + barrier* ;
Intravaginal + barrier* ;
Transdermal + barrier *.
7.Progestogen -
only hormone contraception associated with inhibition of ovulation:
Oral + barrier* ;
Injectable + barrier* .
Sexual Abstinence
8.Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifest yle of the 
participant.
* Acceptable barrier methods to be used concomitantly  with options 6 or 7 for the study  
include an y of the following:
Male or female condom, with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male condom with either cervica l cap, diaphragm, or sponge 
with spermicide (double -barrier methods).
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 11510.5. Appendix 5: Genetics
Use/Analysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, susceptibility  
to, and severit y and progression of disease. Therefo re, where local regulations and 
IRBs/ECsallow, a blood sample will be collected for DNA anal ysis.
The scope of the g enetic research may  be narrow (eg , 1or more candidate genes )or 
broad (eg ,the entire genome ), as appropriate to the scientific question under 
investigation .
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to or study  interventions of this class to understand treatments 
for the disease(s) under study  or the disease(s) themselves.
The results of genetic analy ses may  be reported in the CSR or in a separate study  
summary , or may  be used for internal decision making without being included in a study  
report.
The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Retained samples will be stored indefinitely  or for another period as per local 
requirements.
Participant s may  withdraw their consent for the storag e and/or use of their Retained 
Research Samples at an y time by  making a request to the investigator; in this case, an y 
remaining material will be destro yed. Data alread y generated from the samples will be 
retained to protect the integrity  of existing anal yses.
Samples for genetic research will be labeled with a code. The key  between the code and 
the 
participant ’s personally  identify ing information (eg , name, address) will be held 
securel y at the study  site. 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 11610.6. Appendix 6: Liver Safety: Suggested Actions and Follow -Up Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury , commonl y referred to as DILI. 
Participant s who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/or ALT precede T bili elevations 
(>2×ULN) by  several day s or weeks. The increase in T bili ty pically  occurs wh ile 
AST/AL T is/are still elevated above 3 × ULN (ie, AST/AL T and T bili values will be 
elevated within the same lab oratory sample). In rare instances, by  the time T bili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy ’s law 
criteria) cases and should alway s be considered important me dical events, even before all 
other possible causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and T bili baseline values within the nor mal range who 
subsequently  present with AST OR AL T values ≥3 × ULN AND a T bili value 
≥
2 ×ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORT bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values 
≥2times the baseline value s AND ≥3 ×ULN; or ≥8 × ULN (whichever is 
smaller).
Preexisting values of T bili above the normal range: T bili level increased from 
baseline value b y an amount of 
≥1 × ULN or if the value reaches ≥3 × ULN 
(whichever is smaller).
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 117Rises in AST/AL T and T bili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results. This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurement
s of AST and AL T and T bilifor suspected Hy ’s law
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separa te tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  itself or as a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel his
tory, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
T bili elevation de fined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
invest igations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’
s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 11810.7. Appendix 7: Kidney Safety Monitoring Guidelines
10.7.1. Laboratory Assessment of Change in Kidney Function and Detection of Kidney 
Injury
Standard kidney  safety  monitoring requires assessment of baseline and postbaseline serum 
creatinine (Scr measurement to eGFR [Scr- based eG FR]or [eCrCl ]). Baseline and 
postbaseline Scy s makes it feasible to distinguish AKI from other causes of Scr increase. If 
Scr increase is confirmed after baseline, then reflex measurement of Scy s is indicated to 
estimate the combined Scr -Scys eGFR calcula tion (for adults onl y).
Regardless of whether kidney  function monitoring tests are required as a routine safet y 
monitoring procedure in the study , if the investigator or sponsor deems it necessary  to further 
assess kidney  safety  and quantify  kidney  functio n, then these test results should be managed 
and followed per standard of care.
10.7.2. Age-Specific Kidney Function Calculation Recommendations
10.7.2.1. Adults (18 Years and Above)-2021 CKD- EPI Equations
2021 
CKD -EPI 
Scr OnlyScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤0.7 N/A eGFR = 143 × (Scr/0.7)-0.241 × (0.9938)Age
Female if >0.7 N/A eGFR = 143 × (Scr/0.7)-1.200 × (0.9938)Age
Male if ≤0.9 N/A eGFR = 142 × (Scr/0.9)-0.302 × (0.9938)Age
Male if >0.9 N/A eGFR = 142 × (Scr/0.9)-1.200 × (0.9938)Age
2021 
CKD -EPI 
Scr-Scys 
CombinedScr
(mg/dL)Scys
(mg/L)Recommended eGFR Equation
Female if ≤0.7 if ≤0.8 eGFR = 130 × (Scr/0.7)-0.219 × (Scys/0.8)-0.323 × (0.9961)Age
Female if ≤0.7 if >0.8 eGFR = 130 × (Scr/0.7)-0.219 × (Scys/0.8)-0.778 ×(0.9961)Age
Female if >0.7 if ≤0.8 eGFR = 130 × (Scr/0.7)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age
Female if >0.7 if >0.8 eGFR = 130 × (Scr/0.7)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age
Male if ≤0.9 if ≤0.8 eGFR = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.323 ×(0.9961)Age
Male if ≤0.9 if >0.8 eGFR = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.778 × (0.9961)Age
Male if >0.9 if ≤0.8 eGFR = 135 × (Scr/0.9)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age
Male if >0.9 if >0.8 eGFR = 135 × (Scr/0.9)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age
Inker LA et al. N Engl J Med. 2021;385:1737 -49.18
10.7.3. Adverse Event Grading for Kidney Safety Lab oratory Abnormalities
AEgrading for decline in kidney  function (ie, eGFR or eCrCl) will be according to CTCAE
criteria.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 12110.9. Appendix 9: Comfort and Wearability Questionnaire
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 122
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 12410.11. Appendix 11: RECIST 1.1 Tumor Assessment Criteria RECIST (Response 
Evaluation Criteria In Solid Tumors) version 1.1 Guidelines
Adapted from Eisenhauer E.A., et al.19
*Since MRI s are not included in this study , the RECI ST criteria onl y applies to CT scans .
CATEGORIZING LESIONS AT BASELINE
Measurable Lesions 
Lesions that can be accurately  measured in at least one dimension.
Lesions with longest diameter twice the slice thickness and at least 10 mm or greater 
when assessed b y CT or MRI *(slice thic kness 5-8 mm).
Lesions with longest diameter at least 20 mm when assessed by  Chest X -ray. 
Superficial lesions with longest diameter 10 mm or greater when assessed by  caliper. 
Malignant l ymph nodes with the short axis 15 mm or greater when assessed by  CT.
NOTE: The shortest axis is used as the diameter for malignant lymph nodes, longest 
axis for all other measurable lesions. 
Non-measurable disease 
Non-measurable disease includes lesions too small to be considered measurable (including 
nodes with short ax is between 10 and 14.9 mm) and truly  non- measurable disease such as 
pleural or pericardial effusions, ascites, inflammatory breast disease, leptomeningeal disease, 
lymphangitic involvement of skin or lung, clinical lesions that cannot be accurately  measure d 
with calipers, abdominal masses identified b y physical exam that are not measurable b y 
reproducible imaging techniques.
Bone disease: Bone disease is non
-measurable with the exception of soft tissue 
components that can be evaluated b y CT or MRI *and meet the definition of 
measurability  at baseline.
Previous local treatment: A previously  irradiated lesion (or lesion subjected to other 
local treatment) is non -measurable unless it has progressed since completion of 
treatment.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 125Normal sites
Cystic lesions: Sim ple cysts should not be considered as malignant lesions and should 
not be recorded either as target or non -target disease. Cy stic lesions thought to 
represent cy stic metastases can be measurable lesions, if they  meet the specific 
definition above. If non -cystic lesions are also present, these are preferred as target 
lesions.
Normal nodes: Nodes with short axis <10 mm are considered normal and should not 
be recorded or followed either as measurable or non -measurable disease.
RECORDING TUMOR ASSESSMENTS
All sites of disease must be assessed at baseline. Baseline assessments should be done as 
close as possible prior to study  start. For an adequate baseline assessment, all required scans 
must be done within 28 days prior to treatment and all disease must be documented 
appropriatel y. If baseline assessment is inadequate, subsequent statuses generall y should be 
indeterminate.
Target lesions
All measurable lesions up to a maximum of 2 lesions per organ, 5 lesions in total, 
representative of all involved organs, shou ld be identified as target lesions at baseline. Target 
lesions should be selected on the basis of size (longest lesions) and suitability  for accurate 
repeated measurements. Record the longest diameter for each lesion, except in the case of 
pathological ly mph nodes for which the short axis should be recorded. The sum of the 
diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions at 
baseline will be the basis for comparison to assessments performed on study. 
If two targ et lesions coalesce the measurement of the coalesced mass is used. If a 
large target lesion splits, the sum of the parts is used.
Measurements for target lesions that become small should continue to be recorded. If 
a target lesion becomes too small to measure, 0 mm should be recorded if the lesion is 
considered to have disappeared; otherwise a default value of 5 mm should be 
recorded.
NOTE: When nodal lesions decrease to <10 mm (normal), the actual measurement 
should still be recorded.
Non-target disease 
All non-measurable disease is non- target. All measurable lesions not identified as target 
lesions are also included as non -target disease. Measurements are not required but rather 
assessments will be expressed as ABSENT, INDETERMI NATE, PRESENT/NOT 
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 126INCRE ASED, INCREASED. Multiple non -target lesions in one organ may be recorded as a 
single item on the CRF (eg, ‘multiple enlarged pelvic ly mph nodes’ or ‘multiple liver 
metastases’).
OBJECTIVE RESPONSE STATUS AT EACH EVALUATION.
Disease sites must be assessed using the same technique as baseline, including consistent 
administration of contrast and timing of scanning. If a change needs to be made the case must 
be discussed with the radiologist to determine if substitution is possible. I f not, subsequent 
objectiv e statuses are indeterminate.
Target disease
Complete response: Complete disappearance of all target lesions with the exception 
of nodal disease. All target nodes must decrease to normal size (short axis <10 mm). 
All target lesions must be assessed.
Partia l response: Greater than or equal to 30% decrease under baseline of the sum of 
diameters of all target measurable lesions. The short diameter is used in the sum for 
target nodes, while the longest diameter is used in the sum for all other target lesions. 
All target lesions must be assessed.
Stable: Does not qualify  for CR, PR, or progression. All target lesions must be 
assessed. Stable can follow PR only  in the rare case that the sum increases by  less 
than 20% from the nadir, but enough that a previously  documented 30% decrease no 
longer holds.
Objective progression: 20% increase in the sum of diameters of target measurable 
lesions above the smallest sum observed (over baseline if no decrease in the sum is 
observed during therap y), with a minimum absolute in crease of 5 mm.
Indeterminate: Progression has not been documented, and: 
1.
One or more target measurable lesions have not been assessed; or 
2.Assessment methods used were inconsistent with those used at baseline; or
3.One or more target lesions cannot be measu red accuratel y (eg, poorly visible 
unless due to being too small to measure); or
4. One or more target lesions were excised or irradiated and have not reappeared or 
increased.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 127Non-target disease
CR: Disappearance of all non- target lesions and normalization of tumor marker 
levels. All ly mph nodes must be ‘normal’ in size (<10 mm short axis).
Non-CR/Non -PD: Persistence of an y non -target lesions and/or tumor marker level 
above the normal limits.
PD: Unequivocal progression of pre- existing lesions. Generally  the overall tumor 
burden must increase sufficiently  to merit discontinuation of therapy . In the presence 
of SD or PR in target disease, progression due to unequivocal increase in non- target 
disease should be rare.
Indeterminate: Progression has not been determi
ned and one or more non- target sites 
were not assessed or assessment methods were inconsistent with those used at 
baseline.
New Lesions 
The appearance of an y new unequivocal malignant lesion indicates PD. If a new lesion is 
equivocal, for example due to i ts small size, continued assessment will clarify  the etiology . If 
repeat assessments confirm the lesion, then progression should be recorded on the date of the 
initial assessment. A lesion identified in an area not previously  scanned will be considered a 
new lesion.
Supplemental I nvestigations
If CR determination depends on a residual lesion that decreased in size but did not 
disappear completel y, it is recommended the residual lesion be investigated with 
biopsy  or fine needle aspirate. If no disease is ide ntified, objective status is CR.
If progression determination depends on a lesion with an increase possibly due to 
necrosis, the lesion may  be investigated with biopsy  or fine needle aspirate to clarify  
status.
Subjective progression
Patients requiring discontinuation of treatment without objective evidence of disease 
progression should not be reported as PD on tumor assessment CRFs. This should be 
indicated on the end of treatment CRF as off treatment due to Global Deterioration of Health 
Status. Every  effort should be made to document objective progression even after 
discontinuation of treatment.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 128Table 5. Objective Response Status at each Evaluation
Target Lesions Non-target Disease New 
LesionsObjective 
status
CR CR No CR
CR Non-CR/Non -PD No PR
CR Indeterminate or Missing No PR
PR Non-CR/Non -PD, 
Indeterminate, or MissingNo PR
SD Non-CR/Non -PD, 
Indeterminate, or MissingNo Stable
Indeterminate or Missing Non-PD No Indeterminate
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
If the protocol allows enrollment of patients with only  non-target disease, the following 
Table 6 will be used:
Table 6. Objective Response Status at each Evaluation for Patients with Non 
Target Disease Only
Non-target Disease New Lesions Objective status
CR No CR
Non-CR/Non -PD No Non-CR/Non -PD
Indeterminate No Indeterminate
Unequivocal progression Yes or No PD
Any Yes PD
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 12910.12. Appendix 1 2: List of Platinum -Based Chemotherapies
Platinum -based chemotherapies include the following:
Cisplatin
Oxaliplatin
Carboplatin
Nedaplatin
Lobaplatin
Heptaplatin
Miriplatin
Satraplatin
Picoplatin
Phenanthriplatin
The list above is non -exhaustive and please review list of chemotherapies carefully  with y our 
pharmacist and/or Pfizer study  team to determine if an y should be considered as platinum -
based. Please note agents are listed above using generic terms and trade names are not 
included.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 13010.13. Appendix 13: Abbreviations
The following is a list of abbreviations that may  be used in the protocol. 
Abbreviation Term
A1 to A3 albuminuria (KDIGO albuminuria severit y standardization)
Abs absolute
ACS anorexia and cachexia subscale
ADA anti-drug antibodies
ADE adverse device effect
ADL activit y/activit ies of daily living
AE adverse event
AESI adverse event of special interest
AIDS Acquired Immunodeficiency  Syndrome
AKI acute kidney  injury
ALT alanine aminotransferase
ANC absolute neutrophil count
aPTT activated partial thromboplastin time
ASCO American Societ y of Clinical Oncology
AST aspartate aminotransferase
AUC inf area under the serum concentration time profile from time zero
extrapolated to infinite time
AUC last area under the serum concentration time profile from time zero to
the time of the last quantifiable concentration
AUC tau area under the serum concentration -time curve over the dosing
interval tau
AV atrioventricular
AxMP auxiliary  medicinal product
BA bioavailability
BE bioequivalence
b-hCG b-human chorionic gonadotropin
BioMeT biometric monitoring technology
BMI Body Mass Index
BP blood pressure
bpm beats per minute
BSA body  surface area
Cavg average concentration
CFR Code of Federal Regulations
CL/F apparent clearance for oral dosing
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI chronic kidney  disease epidemiology  
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 131Abbreviation Term
CLIA clinical laboratory  improvement amendments
Cmax maximum observed concentration
CMC Chemistry , Manufacturing and Controls
CO 2 carbon dioxide (bicarbonate)
CONSORT Consolidated Standards of Reporting Trials
COPD chronic obstructive pulmonary  disease
COVID -19 coronavirus disease 2019
CRC colorectal cancer
CRCSD Cancer related cachexia sy mptom diary
CRF case report form
CRO contract research organization
CRU clinical research unit
CSF cerebrospinal fluid
CSR Clinical Study  Report
CT computed tomograph y/clinical trial
CTCAE Common Terminology  Criteria for Adverse Events
CTIS Clinical Trial I nformation Sy stem
CYP cytochrome P450
DCT data collection tool
DDI drug-drug interaction 
DHT digital health technology
DICI drug-induced creatinine increase
DIKI drug-induced kidney  injury
DILI drug-induced liver injury
DRE disease -related event
DU dispensable unit
EC ethics committee
eCOA electronic clinical outcome assessment
ECC emergency  contact card
ECG electrocardiogram or electrocardiography
ECOG PS Eastern Cooperative Oncology  Group Performance Status
eCrCl estimated creatinine clearance
eCRF electronic case report form
ED Early discontinuation
EDB exposure during breastfeeding
E-DMC External Data Monitoring Committee
EDP exposure during pregnancy
EDR extemporaneous dispensing record
eGFR estimated glomerular filtration rate
EGFR epidermal growth factor receptor
EMA European Medicines Agency
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 132Abbreviation Term
Emax maximal effect
EOT end of treatment
ePRO electronic Patient Reported Outcome
eSAE electronic serious adverse event
ESR erythrocy te sedimentation rate
EU European Union
EudraCT European Union Drug Regulating Authorities Clinical Trials 
(European Clinical Trials Database)
FAACT Functional Assessment of A norexia -Cachexia Therap y
FAACT -5IASS Functional Assessment of Anorexia/Cachexia Therap y 5-item 
Anorexia Sy mptom Scale
FAACT -ACS Functional Assessment of Anorexia- Cachexia Therap y-anorexia 
and cachexia subscale
FACIT Functional Assessment of Chronic Illness Therapy
FACT -G Functional Assessment of Cancer Therap y -General
FDA Food and Drug Administration
FSH follicle -stimulating hormone
F/U follow -up
G1 to G5 Grade (KDIGO eGFR category  standardization)
GCP Good Clinical Practice
GDF -15 growth differentiation factor 15
GGT gamma -glutamy l transferase
GI gastrointestinal
GLP-1 Glucagon -likepeptide -1
HBcAb hepatitis B core antibod y
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCP health care professional
HDL high-densit y lipoprotein
HIPAA Health Insurance Portability  and Accountability  Act
HIV human immunodeficiency virus
HLA human leukocy te antigen
HR heart rate
HRQ oL health -related quality  of life
HRT hormone replacement therap y
HRU healthcare resource utilization
hs-CRP high-sensitivity  C-reactive protein
Ht height
IB Investigator’s Brochure
ICD informed consent document
ICH International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 133Abbreviation Term
ID identification
IMP investigational medicinal product
IND Investigational New Drug
INR international normalized ratio
IP Investigational product
IPAL Investigational Product Accountability  Log
IPM investigational product manual
IRB Institutional Review Board
IRC internal review committee
IRT Interactive Response Technology
ISO International Organization for Standardization
IUO Investigational Use Onl y
IWR Interactive Web -based R esponse
K Proportionality  constant for Bedside and Modified Schwartz 
Equations (kidney  function)
KDIGO Kidney  Disease: I mproving Global Outcomes
LBBB left bundle branch block
LDH lactate deh ydrogenase
LDL low-density  lipoprotein
LFT liver function test
LLOQ lower limit of quantification
LPD local product document
LSmeans Least -Squares Means
LSMI Lumbar Skeletal Muscle Index
M6min Maximum daily  6 minutes of activity
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDR medical device regulation
MQI medically  qualified individual
MRI magnetic resonance imaging
NA not applicable
NAb neutralizing antibodies
NCI National Cancer Institute
NDCMC newly  diagnosed chronic medical condition
NIMP noninvestigational medicinal product
NOAEL no observed adverse effect level
NRS numerical rating scale
NSCL C non-small cell lung cancer
NT-pro-BNP N-terminal -pro hormone B -type natriuretic peptide
NYHA New York Heart Association
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 134Abbreviation Term
OLT Open -label treatment
PBMC peripheral blood mononuclear cell
PANC pancreatic cancer
PCD Primary  completion date
PCRU Pfizer Clinical Research Unit
PD pharmacod ynamic(s)
PFS prefilled s yringe
PGI-C Patient Global I mpression of Change
PGI-S Patient Global I mpression of Severity
PG-SGA Patient Generated -Subjective Global Assessment 
PI principal investigator
PK pharmacokinetic(s)
PR pulse rate
PRO Patient Reported Outcomes
PROACC -1 Patient Reported Outcomes and Activity  in CanCer
PROMI S Patient -Reported Outcomes Measurement Information Sy stem
PSSA Pfizer's Serious Adverse Event Submission Assistant
PT prothrombin time
PTH parathormone
PVC premature ventricular contraction
Q3W administered every  3 weeks
Q4W administered every  4 weeks
QTc corrected QT interval
QTcF QTc corrected using Fridericia’s formula
QTL quality  tolerance limit
qual qualitative
RBC red blood cell
RNA ribonucleic acid
SADE serious adverse device effect
SAE serious adverse event
SAP Statistical Analysis Plan
SARS -CoV -2 severe acute respiratory syndrome coronavirus 2
SC subcutaneous(l y)
Scr serum creatinine
Scys serum cy statin C
SD Standard deviation
SmPC Summary  of Product Characteristics
SoA schedule of activities
SOC standard of care
SOP standard operating procedure
SRSD Single Reference Safety  Document
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 135Abbreviation Term
SUSAR Suspected Unexpected Serious Adverse Reaction
t½ terminal elimination half -life
T3total triiodothy ronine
T4total thy roxine
TB tuberculosis 
T bili total bilirubin
TEAE treatment emergent adverse event
THC tetrah ydrocannabinol
Tmax time for Cmax
TOC table of contents
TSH thyroid-stimulating hormone
UACR urine albumin/creatinine ratio
UADE unanticipated adverse device effect
ULN upper limit of normal
US United States
USADE unanticipated serious adverse device effect
USPI United States Prescribing I nformation
UTI urinary  tract infection
VZV varicella zoster virus
WBC white blood cell
WOCBP woman/women of childbearing potential
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 13610.14. Appendix 14:Protocol Amendment History
Amendment 1 (27 October 2022)
Overall Rationale for the Amendment: The overall rationale for this amendment is to 
incorporate and clarify  various protocol elements related to stopping criteria of the study  
invention, assessment of weight change, CT scan regions and p atient reported outcomes. The 
details are described below.
Section # and 
NameDescription of Change Brief Rationale Substantial or 
Nonsubstantial
1.1. Sy nopsis; 3. 
Objectives, 
Endpoints, and 
Estimandsmoved CRCSD from 
tertiary  to secondary .To support 
validation of 
CRCSDSubstantial
1.3. Schedule of 
Activities  Added vital signs, ph ysical 
exams, chemistry  and 
hematology  assessments 
every  3 months in Part B; 
also expanded Part B visits 
such that all visits are 
visualized in the table rather 
than one column for visits 
16-60; added ECOG PS to 
Part B (visit 20 and ED).Additional 
timepoints for 
procedures added 
for evaluation of 
safet ySubstantial
1.3. Schedule of 
Activities; 8.3.1. 
Physical 
ExaminationUpdated ph ysical 
exam plan: 
updated SoA 
footnote ‘e’ to 
include evaluation of 
ascites and edema 
and reporting as an 
AE;
Added a separate 
line for abbreviated 
physical exam to 
clarify  which visits 
should be full 
physical exam added for 
evaluation of 
weight change and 
clarified which ty pe 
of type of phy sical 
exam would be 
required for 
specific visits Substantial
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 137Section # and 
NameDescription of Change Brief Rationale Substantial or 
Nonsubstantial
versus abbreviated 
physical exam; 
Updated Week 8 
physical exam from 
full phy sical exam to 
abbreviated ph ysical 
exam;
Added abbreviated 
physical exam at 
Week 4, 24, 36, 48, 
and 60;
Added text to 
include evaluation of 
ascites and edema 
and reporting as an 
AE.
1.3. Schedule of 
Activities; 3. 
Objectives, 
Endpoints and 
Estimands; 4.2 
Scientific 
Rationale for 
Study  Design; 
8.3.7. I maging 
Assessment -CT 
scan; 9.3.5 Other 
Analy sesClarified specific 
required bod y 
regions for CT scans 
in SoA footnote ‘o’; 
Clarified specific 
body  regions for CT 
scans and added text 
to clarify  that all CT 
scans will be 
collected centrall y to 
allow for a central 
review of bod y 
composition 
measures; 
Added an 
exploratory /tertiary  
objective for 
evaluation of LSMI 
and skeletal muscle Added for LSMI 
and skeletal muscle 
and adipose tissue 
measures 
evaluation and 
analysissubstantial
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 138Section # and 
NameDescription of Change Brief Rationale Substantial or 
Nonsubstantial
and adipose tissue 
measures derived 
from CT scans. 
1.3. Schedule of 
Activi ties; 8.2.2. 
Patient Reported 
OutcomesAdded an additional 
question related to ph ysical 
activity  to PGI -S and 
PGI-C.Added for 
anchoring of 
physical function 
assessmentsSubstantial
7.1. 
Discontinuation 
of Study  
Interventionadded stopping criteria for 
participants experiencing 
Grade 3 or 4 AEs.stopping rules 
added to assess 
toxicity  associated 
with PF -06946860 
leading to 
discontinuation or 
delay  in 
administration of 
anti-cancer therap ySubstantial
1.1. Sy nopsis; 
5.1. I nclusion 
Criteria 
(criterion #5)updated to reflect inclusion 
of ECOG PS ≤3and removal 
of sponsor discussion of 
ECOG PS of 4.updated to allow 
meaningful 
interpretation of 
resultsSubstantial
1.1. Sy nopsis; 
5.2. Exclusion 
Criteria 
(criterion # 11) Added specific criteria for 
exclusion due to liver 
enzy me lab abnormalities.Added specific 
values to quantify  
thresholdSubstantial
6.9. Prior and 
Concomitant 
Therap y Added text to clarify  that 
reasons for discontinuing 
and modify ing SOC 
therapies will be recorded 
on a CRF.Added for 
evaluat ion of SOC 
therapiesSubstantial
1.1 Sy nopsis and 
2.1 Study  
RationaleAdded study  name and 
description.Modification to 
incorporate stud y 
namenonsubstantial
1.1. Sy nopsis and 
3. Objectives, Updated objectives for 
FAACT.Modification nonsubstantial
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 139Section # and 
NameDescription of Change Brief Rationale Substantial or 
Nonsubstantial
Endpoints and 
Estimands
1.1 Sy nopsis and 
5.1 Inclusion 
CriteriaUpdated Inclusion Criterion 
#3 to clarify  the Fearon 
criteria of weight loss.Clarification nonsubstantial
Title page and 
Section 1.1 
synopsisUpdated Eudra CT number. Changed 
submission from 
CTR to National 
routenonsubstantial
1.1 Sy nopsis and 
3. Objectives, 
Endpoints and 
Estimands and 
9.1.1.1. Primary  
Estimand Updated Estimands to 
include prohibited 
medications.Clarification nonsubstantial
1.1. Sy nopsis; 3. 
Objectives, 
Endpoints, and 
EstimandsUpdated ph ysical function 
endpoints.Clarification nonsubstantial
1.3 Schedule of 
ActivitiesExpanded the visit windows 
for part B from ±1 to ±3.Updated to allow 
for additional 
flexibilitynonsubstantial
1.3 Schedule of 
Activities and 
8.3.6 Pregnancy  
TestingUpdated footnote f. to 
clarify  that following the 
Screening visit, a urine 
pregnancy  test may  be 
performed; removed 
duplicative text.Clarification nonsubstantial
1.3 Schedule of 
ActivitiesClarified that retained 
samples will not be 
collected for China.Clarification nonsubstantial
1.3. Schedule of 
Activities; 8.2.2. Modified SoA footnotes ‘k’ 
and ‘l’ to clarify  physical Clarification nonsubstantial
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 140Section # and 
NameDescription of Change Brief Rationale Substantial or 
Nonsubstantial
Patient Reported 
Outcomesactivity  collection period 
description;
Clarified in table and text 
for ph ysical acti vity 
collection period.
2.2.1.3 Summary  
of 
PharmacokineticsThe following sentence was 
corrected to describe 
information regarding 
ponsegromab rather than 
GDF -15: “The mean 
terminal t½ increased with 
increasing dose, ranging 
from 3.52~11.1 day s and 
20.1~30.9 days for the 
unbound and total 
ponsegromab, respectively , 
across the 10 to 300 mg 
dose groups.”Update nonsubstantial
2.2.1.5 
Immunogenicit yAdded immunogenicity  data 
based upon completion of 
the C3651009 CSR.Update nonsubstantial
2.3.1 Risk 
AssessmentCorrected text in the 
sentence related to injection 
site reactions in Phase 1 
studies in healthy  
participants and added use 
of ECG patches.Clarification nonsubstantial
3 Objectives, 
Endpoints, and 
EstimandsModified objectives table to 
include prohibited 
medications to estimands; 
modified phy sical activity  
endpoints.Clarification nonsubstantial
4.4 End of Study  
DefinitionUpdated the end of study 
definition and defined 
primary  completion date.Clarification nonsubst antial
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 141Section # and 
NameDescription of Change Brief Rationale Substantial or 
Nonsubstantial
6.9.2 Permitted 
During the StudyRemoved duplicative text 
regarding the collection of 
all concomitant therapies 
since alread y stated in 6.9 
Prior and Concomitant 
Therap y.Clarification nonsubstantial
8.1. 
Administrative 
Procedures; 8.5. 
Pharmacoki netics
;8.7.1. GDF -15Added text to collect PK 
and GDF -15 samples at any  
unplanned site visit when 
feasible.Clarification nonsubstantial
8.2.2 Patient 
Reported 
OutcomesClarified text for phy sical 
activity  collection period 
language in table.Clarification nonsubstantial
8.2.3 Phy sical 
Activity  Clarified description of 
physical activity  collection 
period.Clarification nonsubstantial
8.3.6 Pregnancy  
TestingClarified test is only  
required at Screening and 
will be sent to central lab.Clarifi cation nonsubstantial
8.5 
Pharmacokinetic; 
8.7.1 GDF -15To align with Section 8, 
clarified blood volume does 
not exceed 550 mL during 
any period of 
56consecutive day s.Clarification nonsubstantial
8.7.1 GDF -15 Added rationale for sample 
collection for potential 
companion diagnostic test 
for ponsegromab.Clarification nonsubstantial
9.1.1.1 Primary  
EstimandsAdded text to clarify  
the management of 
data collected after a 
participant has 
received prohibited 
medications that Clarification nonsubstantial
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 142Section # and 
NameDescription of Change Brief Rationale Substantial or 
Nonsubstantial
would modulate the 
primary  endp oint;
Updated text to 
provide clarit y on 
prohibited 
procedures and 
inadequate 
compliance.
9.1.1.2 Secondary  
Estimands and 
9.3.3 Secondary  
Endpoints 
Analy sis Modified text to correspond 
to the updates made to the 
FAACT, physical activity  
and CRCSD objectives and 
endpoints.Clarification nonsubstantial
9.2 Analy sis Sets Added “prohibited 
medications” to censored 
analysis set.Clarification Nonsubstantial
9.4 Interim 
Analy sisAdded text to describe end 
of study  data repor ting.Update Nonsubstantial
10.1.5.1. Data 
Monitoring 
Committee Included additional details 
related to the IRC data 
review.added to 
incorporate details 
of IRC review and 
timelinesNonsubstantial
10.2. Appendix 2. 
Clinical 
Laboratory  TestsClarified that 
glucose sample is 
collected 
non-fasting; 
Moved potential 
DILI lab tests under 
other; 
Added potential 
DICI/DIKI lab test 
under other.Update Nonsubstantial
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 143Section # and 
NameDescription of Change Brief Rationale Substantial or 
Nonsubstantial
10.3.3. 
Recording/Report
ing and 
Follow -up of AEs 
and/or SAEs 
During the Active 
Collection Per iodAdded severity grading 
table and descriptions to 
align with CTCAE v5.To align with safet y 
reporting of 
adverse eventsNonsubstantial
10.13. Appendix 
13. RECI ST 1.1 
Tumor 
Assessment 
Criteria RECI ST 
(Response 
Evaluation 
Criteria In Solid 
Tumors) version 
1.1 GuidelinesAdded note to specify  that 
the RECI ST criteria onl y 
applies to CT scans in this 
study .Clarification nonsubstantial
1.3. Schedule of 
ActivitiesThe PROMI S (fatigue 7A & 
physical function 8c) 
assessment corrected to be 
linked with footnote ‘j’ 
rather than ‘.Protocol 
Administrative 
Change Letter 
dated 28 July  2022Nonsubstantial
4.3. Justification 
for Dose The titles and corresponding 
footnotes for Table 1 and 2 
corrected to reflect that the 
predicted total and unbound 
Cmax, AUC tau, and C avgare 
steady -state exposures.Protocol 
Administrative 
Change Letter 
dated 28 July  2022 Nonsubstantial
6.1.1. 
Administration Specific instructions added 
to describe injection sites of 
administration of 
ponsegromab and placebo. Protocol 
Administrative
Change Letter 
dated 28 July  2022 Nonsubstantial
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 14411.REFERENCES
1Arends J, Strasser F, Gonella S, et al. Cancer cachexia in adult patients: ESMO Clinical 
Practice Guidelines. ESMO Open. 2021;6(3):100092.
2Roeland EJ, Bohlke K, Baracos VE, et al. Management of Cancer Cachexia: ASCO 
Guideline. J Clin Oncol. 2020;38(21):2438-2453.
3Ahmed DS, I snard S, Lin J, et al. GDF15/GFRAL Pathway as a Metabolic Signature for 
Cachexia in Patients with Cancer. J Cancer. 2021;12(4):1125 -1132.
4Tsai VW, Husain i Y, Manandhar R, et al . Anorexia/cachexia of chronic diseases: a role 
for the TGF-b family  cytokine MI C-1/GDF15. J Cachexia Sarcopenia Muscle. 
2012;3(4):239 -43.
5Lu ZH, Yang L, Yu JW, et al . Weight loss correlates with macrophage inhibitory  
cytokine -1 expression and might influence outcome in patients with advanced 
esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2014;15(15):6047 -
52.
6Lerner L, Hay es TG, Tao N, et al. Plasma growth differentiation factor 15 is associated 
with weight loss an d mortality  in cancer patients. J Cachexia Sarcopenia Muscle. 
2015;6(4):317 -324.
7Lerner L, Tao J, L iu Q, et al. MAP3K11/GDF15 axis is a critical driver of cancer 
cachexia. J Cachexia Sarcopenia Muscle. 2016;7(4):467 -482.
8Altena, R, Fehrmann RSN , Boer, H., et al. Growth differentiation factor 15 (GDF- 15) 
plasma levels increase during bleom ycin-and cisplatin -based treatment of testicular 
cancer patients and relate to endothelial damage. PLoS One . 2015;10(1) : e0115372.
9Von Haeling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in 
chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia 
Sarcopenia Muscle. 2016; 7(5): 507
–509. 
10Elecs ys®GDF -15 package insert (2017). Documentation Roche Diagnostics, Bâle.
11Jager -Wittenaara H
,Ottery F.Assessing nutritional status in cancer: role of the 
Patient- Generated Subjective Global Assessment. Clinical nutrition. 
2017; 20(5): 322-329.                                                
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)
Ponseg romab (PF -06946860)
Protocol C3651003
Final Protocol Amendment 2 24May 2023
PFIZER CONFIDENTIAL
CT02- GSOP Clinical Protocol Template Phase 1 2 3 4 (01 April 2022)
TMF Doc ID: 164.01
Page 14512Sampson HA, Muñoz- Furlong A, Campbell RL , et al. Second s ymposium on the 
definition and management of anaph ylaxis: summary  report—Second National I nstitute 
of Allergy  and Infectious Disease/Food Allergy  and Anaphy laxis Network sy mposium. 
JAllergy Clin Immunol 2006;117(2):391 -
7.
13Thomas, N., Sweeney , K., and Somay aji, V. (2014). Meta -analysis of clinical dose 
response in a large drug development portfolio . Stat Biopharm Res. 2014;6(4):302 -317.
14Thomas, N., and Ro y, D. (2016). Anal ysis of clinical dose -response in small -molecule 
drug development: 2009 -2014. Stat Biopharm Res. 2017;9(2):137-146.
15Wu J, Banerjee A, Jin B, et al. Clinical dose -
response for a broad set of biological 
products: A model -based meta -analysis. Stat Methods Med Res. 
2018 Sep;27(9):2694 -2721 .
16Neuenschwander B, Capkun -Niggli G, Branson M, et al. Summarizing historical
information on controls in clinical trials. Clinical Trials 2010;7(1):5 –18.
17Schmidli H, Gsteiger S, Roy choudhury  S, et al. Robust meta -analytic-predictive priors 
inclinical trials with historical control information. Biometrics 2014;70(4):10 23–32.
18Inker LA et al. N Engl J Med. 2021;385:1737
-49.
19Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECI ST guideline (version 1.1). Eur J of Cancer 2009; 45(2): 228 -47.
090177e19da07ca7\Approved\Approved On: 02-Jun-2023 06:15 (GMT)